Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription

Articles published in Schizophr Res

Retrieve available abstracts of 901 articles:
HTML format

Single Articles

    May 2024
  1. BOSE A, Agarwal SM, Nawani H, Shivakumar V, et al
    Effect of add-on tDCS therapy for auditory hallucinations on frequency and duration deviant mismatch negativity in schizophrenia.
    Schizophr Res. 2024;269:93-95.

  2. AVERSA S, Ghanem J, Grunfeld G, Lemonde AC, et al
    Sociodemographic and clinical correlates of hallucinations in patients entering an early intervention program for first episode psychosis.
    Schizophr Res. 2024;269:86-92.
    PubMed     Abstract available

  3. ALLIENDE LM, Strauss GP, Yang LH, Mittal VA, et al
    Perceptions of stigma in youth at clinical high risk for psychosis and depressive symptomatology.
    Schizophr Res. 2024;269:79-85.
    PubMed     Abstract available

  4. KIM E, Redwood S, Liu F, Roche DJO, et al
    Pilot study indicates that a gluten-free diet lowers oxidative stress for gluten-sensitive persons with schizophrenia.
    Schizophr Res. 2024;269:71-78.
    PubMed     Abstract available

  5. CHIAPPELLI J, Savransky A, Ma Y, Gao S, et al
    Impact of lifetime stressor exposure on neuroenergetics in schizophrenia spectrum disorders.
    Schizophr Res. 2024;269:58-63.
    PubMed     Abstract available

  6. JOSE BJ, Antonio GA, Reveca GF
    Cortisol response in individuals with genetic risk of schizophrenia. Some considerations.
    Schizophr Res. 2024;269:56-57.

  7. FENG S, Huang Y, Li H, Zhou S, et al
    Dynamic effective connectivity in the cerebellar dorsal dentate nucleus and the cerebrum, cognitive impairment, and clinical correlates in patients with schizophrenia.
    Schizophr Res. 2024 May 9:S0920-9964(24)00184.
    PubMed     Abstract available

  8. ZHU Q, Jiang G, Zheng Y, Fu Z, et al
    The effect of cognitive impairment based on Mini-Mental State Examination (MMSE) on suicidal tendency in patients with schizophrenia: A large cross-sectional study.
    Schizophr Res. 2024;269:48-55.
    PubMed     Abstract available

  9. LI N, Li Y, Yu T, Gou M, et al
    Immunosenescence-related T cell phenotypes and white matter in schizophrenia patients with tardive dyskinesia.
    Schizophr Res. 2024;269:36-47.
    PubMed     Abstract available

  10. WANG Y, Xu Y, Wu P, Zhou Y, et al
    Exploring the interplay between core and mood symptoms in schizophrenia: A network analysis.
    Schizophr Res. 2024;269:28-35.
    PubMed     Abstract available

  11. SHIMADA T, Morimoto T, Nagayama H, Nakamura N, et al
    Effect of individualized occupational therapy on cognition among patients with schizophrenia: A randomized controlled trial.
    Schizophr Res. 2024;269:18-27.
    PubMed     Abstract available

  12. ZHANG C, Liang J, Yan H, Li X, et al
    Fractional amplitude of low-frequency fluctuations in sensory-motor networks and limbic system as a potential predictor of treatment response in patients with schizophrenia.
    Schizophr Res. 2024 May 3:S0920-9964(24)00173.
    PubMed     Abstract available

    April 2024
  13. SASS L, Feyaerts J
    Schizophrenia, the very idea: On self-disorder, hyperreflexivity, and the diagnostic concept.
    Schizophr Res. 2024 Apr 30:S0920-9964(24)00122.
    PubMed     Abstract available

  14. ALBEELY AM, Williams OOF, Blight CR, Theriault RK, et al
    Sex differences in neuronal oscillatory activity and memory in the methylazoxymethanol acetate model of schizophrenia.
    Schizophr Res. 2024;267:451-461.
    PubMed     Abstract available

  15. LI H, Huang Y, Liang L, Li H, et al
    The relationship between the gut microbiota and oxidative stress in the cognitive function of schizophrenia: A pilot study in China.
    Schizophr Res. 2024;267:444-450.
    PubMed     Abstract available

  16. LE BARS T, Bulteau S, Bonnot O, Gollier-Briant F, et al
    Home-based transcranial direct current stimulation in schizophrenia: Systematic literature review, a teenager case report with cost-utility analysis.
    Schizophr Res. 2024;267:441-443.

  17. GOGOS A, Sbisa A, van den Buuse M
    Disruption of NMDA receptor-mediated regulation of PPI in the maternal immune activation model of schizophrenia is restored by 17beta-estradiol and raloxifene.
    Schizophr Res. 2024;267:432-440.
    PubMed     Abstract available

  18. AL-CHALABI N, Nader G, Gerretsen P, Fischer C, et al
    Assessing past suicidal behaviour in schizophrenia spectrum disorders using the Columbia-Suicide Severity Rating Scale and the Beck Scale for Suicide Ideation: Analysis across the life-span.
    Schizophr Res. 2024;267:415-421.
    PubMed     Abstract available

  19. MOURA BM, Madeira L, Bakker PR, van Harten P, et al
    The association between alterations in motor and cognitive dimensions of schizophrenia-spectrum disorders: A systematic review.
    Schizophr Res. 2024;267:398-414.
    PubMed     Abstract available

  20. HOLT DJ
    Personal space as a model neurobehavioral system for investigating schizophrenia.
    Schizophr Res. 2024;267:396-397.

  21. TOROUS J, Smith KA, Hardy A, Vinnikova A, et al
    Digital health interventions for schizophrenia: Setting standards for mental health.
    Schizophr Res. 2024;267:392-395.

  22. COHEN M, Roe D, Savir T, Baumel A, et al
    Blended care in psychosis - A systematic review.
    Schizophr Res. 2024;267:381-391.
    PubMed     Abstract available

  23. TAKAHASHI T, Katagiri N, Higuchi Y, Nishiyama S, et al
    Nomenclature for psychosis risk in Japan: Survey results from high-risk individuals, caregivers, and mental health professionals.
    Schizophr Res. 2024;267:373-380.
    PubMed     Abstract available

  24. CELLA M, Parri L, Wang K, Quinn R, et al
    Evaluating remote delivery of cognitive remediation in people with psychosis.
    Schizophr Res. 2024;267:367-372.
    PubMed     Abstract available

  25. MOREIRA-ALMEIDA A, Costa MA, Gattaz WF
    Spiritist anomalous experience is not associated with psychosis.
    Schizophr Res. 2024;267:356-358.

  26. LANDOLT A, Muller M, Ilg Y, Schulz PJ, et al
    Linguistic and (micro)cultural differences in the global debate about re-naming 'schizophrenia': A mixed-methods survey from Switzerland.
    Schizophr Res. 2024;267:341-348.
    PubMed     Abstract available

  27. ROCCA P, Brasso C, Montemagni C, Del Favero E, et al
    The relationship between the resting state functional connectivity and social cognition in schizophrenia: Results from the Italian Network for Research on Psychoses.
    Schizophr Res. 2024;267:330-340.
    PubMed     Abstract available

  28. SHEITMAN A, Bello I, Montague E, Scodes J, et al
    Observed Trajectories of Cannabis Use and Concurrent Longitudinal Outcomes in Youth and Young Adults Receiving Coordinated Specialty Care for Early Psychosis.
    Schizophr Res. 2024;267:313-321.
    PubMed     Abstract available

  29. GOUSE BM, Oblath R, Gibbs JS, Reagan EG, et al
    COVID-19 pandemic and emergency department visits for psychosis: Visit volume, restraint use, medication use, psychiatric hospitalization, and length of stay.
    Schizophr Res. 2024;267:301-307.
    PubMed     Abstract available

  30. DIAO H, Ma J, Jia Y, Jia H, et al
    Abnormalities in motor adaptation to different types of perturbations in schizophreniaperturbations in schizophrenia.
    Schizophr Res. 2024;267:291-300.
    PubMed     Abstract available

  31. CATTARINUSSI G, Di Giorgio A, Sambataro F
    Cerebellar dysconnectivity in schizophrenia and bipolar disorder is associated with cognitive and clinical variables.
    Schizophr Res. 2024 Apr 6:S0920-9964(24)00139.
    PubMed     Abstract available

  32. HO G, Pratt DN, Bridgwater MA, Schiffman J, et al
    Factors impacting intent to seek treatment within youth at clinical high risk for psychosis.
    Schizophr Res. 2024;267:273-281.
    PubMed     Abstract available

  33. KANG MJY, Eratne D, Wannan C, Santillo AF, et al
    Plasma neurofilament light chain is not elevated in people with first-episode psychosis or those at ultra-high risk for psychosis.
    Schizophr Res. 2024;267:269-272.
    PubMed     Abstract available

  34. SKLAR AL, Matinrazm S, Esseku A, Lopez-Caballero F, et al
    Intensity-dependent modulation of the early auditory gamma-band response in first-episode schizophrenia and its association with disease symptoms.
    Schizophr Res. 2024;267:261-268.
    PubMed     Abstract available

  35. MULLIGAN LD, Bojanic L, Hunt IM, Baird A, et al
    Substance use and self-poisoning in schizophrenia: 11-year findings from a national clinical survey of suicide in mental health patients in England.
    Schizophr Res. 2024;267:254-260.
    PubMed     Abstract available

  36. KISELY S, Arnautovska U, Siskind D, Warren N, et al
    Admissions for psychosis following agency-notified child maltreatment at 40-year-follow-up: Results from the Childhood Adversity and Lifetime Morbidity (CALM) cohort.
    Schizophr Res. 2024;267:247-253.
    PubMed     Abstract available

  37. OPLER M, Negash S, Tatsumi K, Liu C, et al
    Use of a novel study insight analytics (SIA) methodology to improve PANSS data quality and signal detection in a global clinical trial in schizophrenia.
    Schizophr Res. 2024;267:239-246.

  38. CEDERLOF E, Holm M, Taipale H, Tiihonen J, et al
    Antipsychotic medications and sleep problems in patients with schizophrenia.
    Schizophr Res. 2024;267:230-238.
    PubMed     Abstract available

  39. VARDEN GJERDE K, Bartz-Johannessen C, Steen VM, Andreassen OA, et al
    Cellular adhesion molecules in drug-naive and previously medicated patients with schizophrenia-spectrum disorders.
    Schizophr Res. 2024;267:223-229.
    PubMed     Abstract available

  40. BISMARK AW, Mikhael T, Mitchell K, Holden J, et al
    Pupillary responses as a biomarker of cognitive effort and the impact of task difficulty on reward processing in schizophrenia.
    Schizophr Res. 2024;267:216-222.
    PubMed     Abstract available

  41. FRANCO-RUBIO L, Puente-Martinez A, Ubillos-Landa S
    Factors associated with recovery during schizophrenia and related disorders: A review of meta-analysis.
    Schizophr Res. 2024;267:201-212.
    PubMed     Abstract available

  42. LI Y, Qiu D, Wu Q, Ni A, et al
    Affiliate stigma and its association with family burden among family members of people living with schizophrenia in China.
    Schizophr Res. 2024;267:193-200.
    PubMed     Abstract available

  43. FUJITA K, Mori Y, Kakumae Y, Takeuchi N, et al
    Pre-emptive ice pack cryotherapy for reducing pain caused by long-acting deltoid injectable antipsychotic treatment: A single-center open-label study.
    Schizophr Res. 2024;266:19-23.
    PubMed     Abstract available

    March 2024
  44. COHEN-LAROQUE J, Grangier I, Perez N, Kirschner M, et al
    Positive and negative symptoms in methamphetamine-induced psychosis compared to schizophrenia: A systematic review and meta-analysis.
    Schizophr Res. 2024;267:182-190.
    PubMed     Abstract available

  45. DODD K, Legget KT, Cornier MA, Novick AM, et al
    Relationship between functional connectivity and weight-gain risk of antipsychotics in schizophrenia.
    Schizophr Res. 2024;267:173-181.
    PubMed     Abstract available

  46. GAO YN, Wang R, Gu G, Chung R, et al
    Inpatient antipsychotic medication switching and rehospitalization risk among patients with schizophrenia-spectrum disorders.
    Schizophr Res. 2024;267:165-172.
    PubMed     Abstract available

  47. YU B, Sun Z, Li S, Chien IC, et al
    Social isolation and cognitive function in patients with schizophrenia: A two years follow-up study.
    Schizophr Res. 2024;267:150-155.
    PubMed     Abstract available

  48. BENNETT ME, Medoff D, Cowan T, Fang L, et al
    Tobacco smoking and nicotine vaping in persons with first episode psychosis.
    Schizophr Res. 2024;267:141-149.
    PubMed     Abstract available

  49. PELIZZA L, Leuci E, Leucci AC, Quattrone E, et al
    Diagnostic shift in first episode psychosis: Results from the 2-year follow-up of the "Parma Early Psychosis" program.
    Schizophr Res. 2024;267:99-106.
    PubMed     Abstract available

  50. MEHTA DD, Siddiqui S, Ward HB, Steele VR, et al
    Functional and structural effects of repetitive transcranial magnetic stimulation (rTMS) for the treatment of auditory verbal hallucinations in schizophrenia: A systematic review.
    Schizophr Res. 2024;267:86-98.
    PubMed     Abstract available

  51. LHO SK, Kim T, Moon SY, Kim M, et al
    Alteration in left frontoparietal connectivity correlates with impaired cognitive reappraisal in early psychosis.
    Schizophr Res. 2024;267:130-137.
    PubMed     Abstract available

  52. ZHOU R, Ye M, OuYang X, Zhang S, et al
    Insomnia and aggression in stable schizophrenic patients: The mediating role of quality of life.
    Schizophr Res. 2024;267:122-129.
    PubMed     Abstract available

  53. ELAM HB, Perez SM, Donegan JJ, Eassa NE, et al
    Knockdown of Lhx6 during embryonic development results in neurophysiological alterations and behavioral deficits analogous to schizophrenia in adult rats.
    Schizophr Res. 2024;267:113-121.
    PubMed     Abstract available

  54. EL HAJ M, Raffard S, Besche-Richard C
    Decoding schizophrenia: ChatGPT's role in clinical and neuropsychological assessment.
    Schizophr Res. 2024;267:84-85.

  55. NAIR N, Xavier S, Rabouin D, Mohan G, et al
    Patient-reported outcome measures in early psychosis: A cross-cultural, longitudinal examination of the self-reported health and self-reported mental health measures in Chennai, India and Montreal, Canada.
    Schizophr Res. 2024;267:75-83.
    PubMed     Abstract available

  56. ARSLAN B, Kizilay E, Verim B, Demirlek C, et al
    Automated linguistic analysis in speech samples of Turkish-speaking patients with schizophrenia-spectrum disorders.
    Schizophr Res. 2024;267:65-71.
    PubMed     Abstract available

  57. OZER D, Dissiz M
    The effect of online group based acceptance and commitment therapy on psychotic symptoms and functioning levels of individuals with early psychosis.
    Schizophr Res. 2024;267:55-64.
    PubMed     Abstract available

  58. MELVIN E, Green M, Keiller E, Parmar C, et al
    A systematic review of dramatherapy interventions used to support adults with psychosis.
    Schizophr Res. 2024;267:44-54.
    PubMed     Abstract available

  59. TZARTOS J, Karagiorgou K, Pechlivanidou M, Tzartos S, et al
    Absence of neuronal nicotinic acetylcholine receptor antibodies in sera and CSF from schizophrenia patients.
    Schizophr Res. 2024;267:39-41.

  60. KETCHAM E, Schooler NR, Severe JB, Buckley PF, et al
    Longitudinal study of insomnia, suicidal ideation, and psychopathology in schizophrenia.
    Schizophr Res. 2024;267:34-38.
    PubMed     Abstract available

  61. JOLLY AJ, Parmar A, Ghadigaonkar DS, Andrade C, et al
    Reflections on a study of electroconvulsive therapy for clozapine-refractory schizophrenia.
    Schizophr Res. 2024;267:32-33.

  62. LLORCA-BOFI V, Madero S, Amoretti S, Cuesta MJ, et al
    Inflammatory blood cells and ratios at remission for psychosis relapse prediction: A three-year follow-up of a cohort of first episodes of schizophrenia.
    Schizophr Res. 2024;267:24-31.
    PubMed     Abstract available

  63. DOLLFUS S, Letourneur F, Metivier L, Moulier V, et al
    Self-assessment scale of auditory verbal hallucinations (SAVH): A novel tool for patients with schizophrenia.
    Schizophr Res. 2024;267:19-23.
    PubMed     Abstract available

  64. DYKINS MM, Keedy SK, Sweeney JA, Hill SK, et al
    Characterizing cognitive heterogeneity in first-episode psychosis.
    Schizophr Res. 2024;267:16-18.

  65. MCLEAN RT, Buist E, St Clair D, Wei J, et al
    Autoantibodies against acetylcholine receptors are increased in archived serum samples from patients with schizophrenia.
    Schizophr Res. 2024;267:8-13.
    PubMed     Abstract available

  66. LI S, Liu W, Huang Z, Lin H, et al
    Sex-specific associations between sex hormones and clinical symptoms in late-life schizophrenia.
    Schizophr Res. 2024;267:1-7.
    PubMed     Abstract available

  67. LE TP, Ventura J, Subotnik KL, Nuechterlein KH, et al
    Intrinsic motivation predicts cognitive and functional gains during coordinated specialty care for first-episode schizophrenia.
    Schizophr Res. 2024;266:249-255.
    PubMed     Abstract available

  68. SLOT MIE, van Hell HH, Rossum IW, Dazzan P, et al
    A naturalistic cohort study of first-episode schizophrenia spectrum disorder: A description of the early phase of illness in the PSYSCAN cohort.
    Schizophr Res. 2024;266:237-248.
    PubMed     Abstract available

  69. KING B, Kempton MJ, Broberg BV, Merritt K, et al
    A letter to the editor: The effects of alcohol use on brain glutamate in first episode psychosis.
    Schizophr Res. 2024;266:234-236.

  70. STEPHANE M, Dzemidzic M, Yoon G
    Altered corollary discharge in the auditory cortex could reflect louder inner voice experience in patients with verbal hallucinations, a pilot fMRI study.
    Schizophr Res. 2024;265:14-19.
    PubMed     Abstract available

  71. LOPEZ-SILVA P, Harrow M, Jobe TH, Tufano M, et al
    'Are these my thoughts?': A 20-year prospective study of thought insertion, thought withdrawal, thought broadcasting, and their relationship to auditory verbal hallucinations.
    Schizophr Res. 2024;265:46-57.
    PubMed     Abstract available

    February 2024
  72. GARCIA-RIZO C, Crespo-Facorro B, Oliveira C, Gomez-Revuelta M, et al
    Anthropometry in antipsychotic-naive first-episode psychosis patients: An exploratory approach to the role of environmental early life events in two independent samples.
    Schizophr Res. 2024;266:216-226.
    PubMed     Abstract available

  73. ZAHER F, Diallo M, Achim AM, Joober R, et al
    Speech markers to predict and prevent recurrent episodes of psychosis: A narrative overview and emerging opportunities.
    Schizophr Res. 2024;266:205-215.
    PubMed     Abstract available

  74. ISAYEVA U, Manchia M, Collu R, Primavera D, et al
    Symptomatic remission and recovery in major psychosis: Is there a role for BDNF? A secondary analysis of the LABSP cohort data.
    Schizophr Res. 2024;266:197-204.
    PubMed     Abstract available

  75. SAVILL M, Loewy RL, Niendam TA, Porteus AJ, et al
    The diagnostic accuracy of screening for psychosis spectrum disorders in behavioral health clinics integrated into primary care.
    Schizophr Res. 2024;266:190-196.
    PubMed     Abstract available

  76. CABUK T, Sevim N, Mutlu E, Yagcioglu AEA, et al
    Natural language processing for defining linguistic features in schizophrenia: A sample from Turkish speakers.
    Schizophr Res. 2024;266:183-189.
    PubMed     Abstract available

  77. ZHAO W, Cannon TD
    Moral learning and positive schizotypy: Social cognitive mechanisms in psychosis- proneness.
    Schizophr Res. 2024;266:156-164.
    PubMed     Abstract available

  78. BAKER SC, Messer SJ, Girgis RR, Horga G, et al
    Prior overweighting relates to delusional ideation in individuals at clinical high-risk for psychosis.
    Schizophr Res. 2024;266:153-155.

  79. TIBIRICA L, Kohn J, Patapoff M, Williams AP, et al
    Acculturation and clinical symptoms of schizophrenia among Latine adults in the United States.
    Schizophr Res. 2024;266:145-152.
    PubMed     Abstract available

  80. PENG Z, Li Q, Liu X, Zhang H, et al
    A new schizophrenia screening instrument based on evaluating the patient's writing.
    Schizophr Res. 2024;266:127-135.
    PubMed     Abstract available

  81. MAKIPELTO V, Tuulio-Henriksson A, Hakulinen C, Niemela S, et al
    Association of antidepressant and benzodiazepine use, and anticholinergic burden with cognitive performance in schizophrenia.
    Schizophr Res. 2024;266:118-126.
    PubMed     Abstract available

  82. BALLERINI M, Magnani F, Amorosi S, Dell'Anna C, et al
    Anomalous Self-Experiences are predictive of social dysfunction in people with schizophrenia.
    Schizophr Res. 2024;266:116-117.

  83. TORREGROSSA LJ, Liu J, Armstrong K, Heckers S, et al
    Interplay between childhood trauma, bodily self-disturbances, and clinical phenomena in schizophrenia spectrum disorders: A network analysis.
    Schizophr Res. 2024;266:107-115.
    PubMed     Abstract available

  84. MILEY K, Bronstein MV, Ma S, Lee H, et al
    Trajectories and predictors of response to social cognition training in people with schizophrenia: A proof-of-concept machine learning study.
    Schizophr Res. 2024;266:92-99.
    PubMed     Abstract available

  85. IMAM I, Johnson KA, Saluja A, Mesholam-Gately RI, et al
    Advancing equity & access for psychosis care in Massachusetts: Proceedings from the 2023 Mass-STEP Conference.
    Schizophr Res. 2024;266:85-87.

  86. GURUSAMY J, Gandhi S, Damodharan D, Palaniappan M, et al
    Effect of lifestyle modification intervention (LMI) on metabolic syndrome in schizophrenia in a residential mental health care setting-A mixed method study.
    Schizophr Res. 2024;266:75-84.

  87. ZAKI JK, Lago SG, Spadaro B, Rustogi N, et al
    Exploring peripheral biomarkers of response to simvastatin supplementation in schizophrenia.
    Schizophr Res. 2024;266:66-74.
    PubMed     Abstract available

  88. BORA E, Eyuboglu MS, Cesim E, Demir M, et al
    Neurocognition and social cognition in youth and young adults at ultra-high-risk for psychosis and bipolar disorder.
    Schizophr Res. 2024;266:58-65.
    PubMed     Abstract available

  89. GARCIA-LEON MA, Fuentes-Claramonte P, Soler-Vidal J, Ramiro-Sousa N, et al
    Cortical volume abnormalities in schizophrenia: Correlations with symptoms and cognitive impairment.
    Schizophr Res. 2024;266:50-57.
    PubMed     Abstract available

  90. EKIN M, Akdal G, Bora E
    Antisaccade error rates in first-episode psychosis, ultra-high risk for psychosis and unaffected relatives of schizophrenia: A systematic review and meta-analysis.
    Schizophr Res. 2024;266:41-49.
    PubMed     Abstract available

  91. MAAS IL, Bohlken MM, Gangadin SS, Rosema BS, et al
    Personal recovery in first-episode psychosis: Beyond clinical and functional recovery.
    Schizophr Res. 2024;266:32-40.
    PubMed     Abstract available

  92. WARREN N, O'Gorman C, Horgan I, Weeratunga M, et al
    Inflammatory cerebrospinal fluid markers in schizophrenia spectrum disorders: A systematic review and meta-analysis of 69 studies with 5710 participants.
    Schizophr Res. 2024;266:24-31.
    PubMed     Abstract available

  93. CHANEN AM, Kerslake R, Berube FA, Nicol K, et al
    Psychopathology and psychosocial functioning among young people with first-episode psychosis and/or first-presentation borderline personality disorder.
    Schizophr Res. 2024;266:12-18.
    PubMed     Abstract available

  94. KRAUS J, Cavojska N, Harvanova S, Hajduk M, et al
    Interpersonal distance in schizophrenia: A systematic review.
    Schizophr Res. 2024;266:1-11.
    PubMed     Abstract available

  95. MCILWAINE SV, Mughal S, Ferrari M, Rosengard R, et al
    Pre-onset subthreshold psychotic symptoms are associated with differential treatment delays before a first episode of psychosis: Initial evidence and implications.
    Schizophr Res. 2024;264:549-556.
    PubMed     Abstract available

  96. JEYAPALAN J, Sassi P, Mittendorfer Rutz E, Tiihonen J, et al
    Characteristics of incident substance-induced psychosis compared to first-episode psychotic disorders: A nationwide register-linkage study from Sweden.
    Schizophr Res. 2024;264:526-533.

  97. PERALTA V, de Jalon EG, Moreno-Izco L, Peralta D, et al
    The effect of anticholinergic burden of psychiatric medications on major outcome domains of psychotic disorders: A 21-year prospective cohort study.
    Schizophr Res. 2024;264:386-393.
    PubMed     Abstract available

    January 2024
  98. WANG Y, Ding R, Luo Y, He P, et al
    Does college education reduce the risk of schizophrenia? Evidence from a college enrollment expansion policy in China.
    Schizophr Res. 2024;264:519-525.
    PubMed     Abstract available

  99. TORDAI C, Hathy E, Gyergyak H, Vincze K, et al
    Probing the biological consequences of a previously undescribed de novo mutation of ZMYND11 in a schizophrenia patient by CRISPR genome editing and induced pluripotent stem cell based in vitro disease-modeling.
    Schizophr Res. 2024 Jan 29:S0920-9964(24)00024.
    PubMed     Abstract available

  100. KANE JM, Schoretsanitis G, Rubio JM, Correll CU, et al
    Clozapine in treatment-resistant schizophrenia: Reflections from the Hallmark US clinical trial and beyond.
    Schizophr Res. 2024 Jan 29:S0920-9964(24)00035.

  101. FADEN J, Citrome L
    A systematic review of clozapine for aggression and violence in patients with schizophrenia or schizoaffective disorder.
    Schizophr Res. 2024 Jan 29:S0920-9964(23)00420.
    PubMed     Abstract available

  102. LOZANO-GOUPIL J, Marin L, Aubin L, Decombe A, et al
    Impaired perception of a partner's synchronizing behavior reduces positive attitude toward humanoid robot in schizophrenia patients.
    Schizophr Res. 2024;264:511-518.
    PubMed     Abstract available

  103. MACDOUGALL AG, Wiener JC, Puka K, Price E, et al
    Effectiveness of a mindfulness-based intervention for persons with early psychosis: A multi-site randomized controlled trial.
    Schizophr Res. 2024;264:502-510.
    PubMed     Abstract available

  104. MURPHY SM, Flores AT, Wojtalik JA, Keshavan MS, et al
    Symptom contributors to quality of life in schizophrenia: Exploratory factor and network analyses.
    Schizophr Res. 2024;264:494-501.
    PubMed     Abstract available

    Toward non-stigmatizing media and language in mental health: Addressing the social stigma of schizophrenia.
    Schizophr Res. 2024;264:491-493.

  106. ZEDAN SA, Zahid A, Best MW
    Examining the effects of diagnostic awareness, positive symptoms, and negative symptoms on stigmatizing attitudes and social exclusion towards schizophrenia.
    Schizophr Res. 2024;264:482-490.
    PubMed     Abstract available

  107. BHARGAV H, Keshavan M
    Why and how might yoga differ from other mind-body approaches in schizophrenia?
    Schizophr Res. 2024;264:479-481.

  108. VAN DER PLUIJM M, Alting M, Schrantee A, Edden RAE, et al
    Glutamate and GABA levels in the anterior cingulate cortex in treatment resistant first episode psychosis patients.
    Schizophr Res. 2024;264:471-478.
    PubMed     Abstract available

  109. LIU H, Tang E, Guan C, Li J, et al
    Not socially blind: Unimpaired perception of social interaction in schizophrenia.
    Schizophr Res. 2024;264:448-450.

  110. GRADY S, Twomey C, Cullen C, Gaynor K, et al
    Does affect mediate the relationship between interpersonal trauma and psychosis? A systematic review and meta-analysis.
    Schizophr Res. 2024;264:435-447.
    PubMed     Abstract available

  111. D'ARCEY JN, Zhao H, Wang W, Voineskos AN, et al
    An SMS text messaging intervention to improve clinical engagement in early psychosis: A pilot randomized-controlled trial.
    Schizophr Res. 2024;264:416-423.
    PubMed     Abstract available

  112. CHEN MY, Wang YY, Si TL, Liu YF, et al
    Poor sleep quality in schizophrenia patients: A systematic review and meta-analyses of epidemiological and case-control studies.
    Schizophr Res. 2024;264:407-415.
    PubMed     Abstract available

  113. CAI Y, Zhu ZH, Qi Q, Yin XY, et al
    The negative association of serum complement 3 and 4 levels with visuospatial/constructional function in first-episode patients with schizophrenia.
    Schizophr Res. 2024;264:404-406.

  114. SHANKAR A, Tripathi A
    Comments on "The effect on relapse rate and psychiatric symptomatology: Switching a combination of first- and second-generation antipsychotic polypharmacy to antipsychotic monotherapy in long-term inpatients with schizophrenia and related disorders. A
    Schizophr Res. 2024;264:402-403.

  115. NG BHM, Yu BCL, Leung JSY
    Investigation on the association between perceived family expressed emotion, self-stigma, and subjective quality of life in people with early psychosis in Hong Kong: A cross-sectional approach.
    Schizophr Res. 2024;264:394-401.

  116. GHIEH R, Krezolek M, Gaweda L
    Self-monitoring deficits in schizophrenia: A cross-sectional study of the underlying cognitive mechanisms.
    Schizophr Res. 2024;264:378-385.
    PubMed     Abstract available

  117. LAWRENCE RE, Appelbaum PS
    Ethics in placebo-controlled, acute treatment trials in schizophrenia: Two rival ethical frameworks.
    Schizophr Res. 2024;264:372-377.
    PubMed     Abstract available

  118. BOWERSOX NW, Smith CM, Austin K, Bradford DW, et al
    Mortality and suicidality in veterans health administration patients with newly-identified early episode psychosis.
    Schizophr Res. 2024;264:362-369.
    PubMed     Abstract available

  119. SONDERGAARD A, Gregersen M, Wilms M, Brandt JM, et al
    Exploring the relationship between attributional style measured in virtual reality and bullying among children at familial high risk of schizophrenia or bipolar disorder compared with controls.
    Schizophr Res. 2024;264:354-361.
    PubMed     Abstract available

  120. THAKKAR KN, Silverstein SM, Fattal J, Bao J, et al
    Stronger tilt aftereffects in individuals diagnosed with schizophrenia spectrum disorders but not bipolar disorder.
    Schizophr Res. 2024;264:345-353.
    PubMed     Abstract available

  121. PENTZ AB, O'Connel KS, van Jole O, Timpe CMF, et al
    Mismatch negativity and polygenic risk scores for schizophrenia and bipolar disorder.
    Schizophr Res. 2024;264:314-326.
    PubMed     Abstract available

  122. IBRAHIM K, Iturmendi-Sabater I, Vasishth M, Barron DS, et al
    Neural circuit disruptions of eye gaze processing in autism spectrum disorder and schizophrenia: An activation likelihood estimation meta-analysis.
    Schizophr Res. 2024;264:298-313.
    PubMed     Abstract available

  123. WANG P, Jiang Y, Biswal BB
    Aberrant interhemispheric structural and functional connectivity within whole brain in schizophrenia.
    Schizophr Res. 2024;264:336-344.
    PubMed     Abstract available

  124. OKADA H, Morimoto T, Ikeda N
    Exploratory; study on driving ability of people with schizophrenia: Relationships among cognitive function, symptoms, and brain activity.
    Schizophr Res. 2024;264:290-297.
    PubMed     Abstract available

  125. XIONG J, Ding Y, Wu X, Zhan J, et al
    Association between serum insulin-like growth factor 1 levels and the improvements of cognitive impairments in a subgroup of schizophrenia: Preliminary findings.
    Schizophr Res. 2024;264:282-289.
    PubMed     Abstract available

  126. DEAM MM, Gupta T, Bridgwater MA, Haas GL, et al
    Associations between interpersonal trauma and social impairments in adolescents with and without a family history of psychosis.
    Schizophr Res. 2024;264:280-281.

  127. CHEN YL, Chen PY, Pan CH, Chen PH, et al
    Prevalence and 3-year incidence of physical illnesses after schizophrenia diagnosis: Comparison with general population.
    Schizophr Res. 2024;264:272-279.
    PubMed     Abstract available

  128. DONMEZLER S, Sonmez D, Yilbas B, Ozturk HI, et al
    Thalamic nuclei volume differences in schizophrenia patients and healthy controls using probabilistic mapping: A comparative analysis.
    Schizophr Res. 2024;264:266-271.
    PubMed     Abstract available

  129. SU Y, Pan X, Li H, Zhang G, et al
    Effects of mind-body therapies on schizophrenia: A systematic review and network meta-analysis.
    Schizophr Res. 2024;264:236-247.
    PubMed     Abstract available

  130. MILLER M, Braun A, Cadenhead KS, Cornblatt BA, et al
    Self-perceptions and depression in youth at risk of psychosis.
    Schizophr Res. 2024;264:231-232.

  131. CHANG Y, Wang X, Liao J, Chen S, et al
    Temporal hyper-connectivity and frontal hypo-connectivity within gamma band in schizophrenia: A resting state EEG study.
    Schizophr Res. 2024;264:220-230.
    PubMed     Abstract available

  132. LEGRAND A, Moyal M, Deschamps C, Louveau C, et al
    Catatonia and genetic variant in GABA receptor: A case report involving GABRB2.
    Schizophr Res. 2024;263:191-193.

  133. KARL S, Sartorius A, Aksay SS
    Catatonia and ECT across the lifespan.
    Schizophr Res. 2024;263:246-251.
    PubMed     Abstract available

  134. HIRJAK D, Brandt GA, Fritze S, Kubera KM, et al
    Distribution and frequency of clinical criteria and rating scales for diagnosis and assessment of catatonia in different study types.
    Schizophr Res. 2024;263:93-98.
    PubMed     Abstract available

    From operational diagnostic to dimensional-continuum concepts of psychotic and non-psychotic illness: Embracing catatonia across psychopathology and intrinsic movement disorder in neural network dysfunction.
    Schizophr Res. 2024;263:99-108.
    PubMed     Abstract available

  136. SAINI A, Begum N, Matti J, Ghanem DA, et al
    Clozapine as a treatment for catatonia: A systematic review.
    Schizophr Res. 2024;263:275-281.
    PubMed     Abstract available

    December 2023
  137. KLAASSEN AL, Michel C, Stuble M, Kaess M, et al
    Reduced anterior callosal white matter in risk for psychosis associated with processing speed as a fundamental cognitive impairment.
    Schizophr Res. 2023;264:211-219.
    PubMed     Abstract available

    Anomalies of imagination and development of psychosis: A phenomenological account.
    Schizophr Res. 2023;264:204-210.
    PubMed     Abstract available

  139. SABE M, Kohler R, Perez N, Sauvain-Sabe M, et al
    Mindfulness-based interventions for patients with schizophrenia spectrum disorders: A systematic review of the literature.
    Schizophr Res. 2023;264:191-203.
    PubMed     Abstract available

  140. DOLLFUS S, Letourneur F, Metivier L, Moulier V, et al
    A digital tool for self-assessment of auditory verbal hallucinations in schizophrenia.
    Schizophr Res. 2023;264:188-190.
    PubMed     Abstract available

  141. MYERS EJ, Abel DB, Mickens JL, Russell MT, et al
    Meta-analysis of the relationship between metacognition and disorganized symptoms in psychosis.
    Schizophr Res. 2023;264:178-187.
    PubMed     Abstract available

  142. MELZER-RIBEIRO DL, Napolitano IC, Leite SA, Alencar de Souza JA, et al
    Randomized, double-blind, sham-controlled trial to evaluate the efficacy and tolerability of electroconvulsive therapy in patients with clozapine-resistant schizophrenia.
    Schizophr Res. 2023 Dec 26:S0920-9964(23)00421.
    PubMed     Abstract available

  143. BAHLINGER K, Lincoln TM, Clamor A
    Do deficits in subjective stress recovery predict subsequent stress sensitivity and symptoms in schizophrenia spectrum disorders?
    Schizophr Res. 2023;264:170-177.
    PubMed     Abstract available

  144. ZINELLU A, Mangoni AA
    The pathophysiological role of circulating adhesion molecules in schizophrenia: A systematic review and meta-analysis.
    Schizophr Res. 2023;264:157-169.
    PubMed     Abstract available

  145. BARBALAT G, Marechal L, Plasse J, Chereau-Boudet I, et al
    Functioning, clinical severity, education and sex moderate the inverse relationship between insight and quality of life in patients with schizophrenia.
    Schizophr Res. 2023;264:149-156.
    PubMed     Abstract available

  146. TROISI A, Brune M
    The ethological method for studying facial behavior in schizophrenia.
    Schizophr Res. 2023;264:147-148.

  147. HYATT A, Mullin B, Hasler V, Madore D, et al
    Predictors of relapse and engagement in care one year after ending services in an urban safety net coordinated specialty care program for first episode psychosis.
    Schizophr Res. 2023;264:140-146.
    PubMed     Abstract available

  148. JI Y, Pearlson G, Bustillo J, Kochunov P, et al
    Identifying psychosis subtypes use individualized covariance structural differential networks and multi-site clustering.
    Schizophr Res. 2023;264:130-139.
    PubMed     Abstract available

  149. HUANG TY, Chen LC, Li XP, Li WH, et al
    Elevated triglycerides and low triiodothyronine: Key risk factors for coronary artery calcification in patients with schizophrenia.
    Schizophr Res. 2023;264:113-121.
    PubMed     Abstract available

  150. DONDE C, Coulon N, Turbe H, Andre M, et al
    Clinical and cognitive characteristics of subjects with schizophrenia and childhood attention-deficit/hyperactivity disorder: Results from the multicentric FACE-SZ cross-sectional dataset.
    Schizophr Res. 2023;264:105-112.
    PubMed     Abstract available

  151. MORERA D, Miller BJ
    Meta-analysis of a family history of diabetes in schizophrenia.
    Schizophr Res. 2023;264:90-94.
    PubMed     Abstract available

  152. GUAN X, Chen Y, Wang X, Xiu M, et al
    Total antioxidant capacity, obesity and clinical correlates in first-episode and drug-naive patients with schizophrenia.
    Schizophr Res. 2023;264:81-86.
    PubMed     Abstract available

  153. SAPIENZA J, Agostoni G, Dall'Acqua S, Sut S, et al
    The kynurenine pathway in treatment-resistant schizophrenia at the crossroads between pathophysiology and pharmacotherapy.
    Schizophr Res. 2023;264:71-80.
    PubMed     Abstract available

  154. BOIKO DI, Chopra H, Bilal M, Kydon PV, et al
    Schizophrenia and disruption of circadian rhythms: An overview of genetic, metabolic and clinical signs.
    Schizophr Res. 2023;264:58-70.
    PubMed     Abstract available

  155. LIEBRAND M, Katsarakis A, Josi J, Diezig S, et al
    EEG microstate D as psychosis-specific correlate in adolescents and young adults with clinical high risk for psychosis and first-episode psychosis.
    Schizophr Res. 2023;264:49-57.
    PubMed     Abstract available

  156. CADENHEAD KS, Mirzakhanian H, Achim C, Reyes-Madrigal F, et al
    Peripheral and central biomarkers associated with inflammation in antipsychotic naive first episode psychosis: Pilot studies.
    Schizophr Res. 2023;264:39-48.
    PubMed     Abstract available

  157. LIU S, Zhang L, Fan X, Wang G, et al
    Lactate levels in the brain and blood of schizophrenia patients: A systematic review and meta-analysis.
    Schizophr Res. 2023;264:29-38.
    PubMed     Abstract available

  158. TANDON R, Nasrallah H, Akbarian S, Carpenter WT Jr, et al
    The schizophrenia syndrome, circa 2024: What we know and how that informs its nature.
    Schizophr Res. 2023;264:1-28.
    PubMed     Abstract available

  159. GARCIA-MARTI G, Escarti MJ, Nacher J, Perez-Rando M, et al
    Progressive loss of cortical gray matter in first episode psychosis patients with auditory hallucinations.
    Schizophr Res. 2023 Dec 2:S0920-9964(23)00423.
    PubMed     Abstract available

  160. LE TP, Green MF, Wynn JK, Iglesias JE, et al
    Effort-based decision-making as a determinant of supported employment outcomes in psychotic disorders.
    Schizophr Res. 2023;262:149-155.
    PubMed     Abstract available

  161. VIROLLE J, Redon M, Montastruc F, Taib S, et al
    What clinical analysis of antipsychotic-induced catatonia and neuroleptic malignant syndrome tells us about the links between these two syndromes: A systematic review.
    Schizophr Res. 2023;262:184-200.
    PubMed     Abstract available

    November 2023
  162. YU S, Qu Y, Du Z, Ou M, et al
    The expression of immune related genes and potential regulatory mechanisms in schizophrenia.
    Schizophr Res. 2023 Nov 21:S0920-9964(23)00419.
    PubMed     Abstract available

  163. SCHAUG JP, Storebo OJ, Pedersen MB, Haahr UH, et al
    How first-episode psychosis patients' subjective beliefs about their childhood trauma's causal effect provide support for potential schizophrenia subtypes.
    Schizophr Res. 2023;262:175-183.
    PubMed     Abstract available

  164. FU X, Baranova A, Cao H, Liu Y, et al
    miR-9-5p deficiency contributes to schizophrenia.
    Schizophr Res. 2023;262:168-174.
    PubMed     Abstract available

  165. TANG W, Zhou LJ, Zhang WQ, Jia YJ, et al
    Adverse perinatal pregnancy outcomes in women with schizophrenia: A systematic review and meta-analysis.
    Schizophr Res. 2023;262:156-167.
    PubMed     Abstract available

  166. DEL RE EC, Keshavan MS
    Childhood trauma and psychosis-Searching for causes and mechanisms.
    Schizophr Res. 2023;262:146-148.

  167. VAN HOOIJDONK CFM, van der Pluijm M, de Vries BM, Cysouw M, et al
    The association between clinical, sociodemographic, familial, and environmental factors and treatment resistance in schizophrenia: A machine-learning-based approach.
    Schizophr Res. 2023;262:132-141.
    PubMed     Abstract available

  168. MOE AM, Kilicoglu MFV, Angers K, Huang K, et al
    Coordinated specialty care for first-episode psychosis: Effects on social motivation and social pleasure.
    Schizophr Res. 2023;262:130-131.

  169. EL KIRAT H, Khattabi A, Khalis M, Belrhiti Z, et al
    Effects of physical activity and nutrient supplementation on symptoms and well-being of schizophrenia patients: An umbrella review.
    Schizophr Res. 2023;262:112-120.
    PubMed     Abstract available

  170. TIEN YT, Wang LJ, Lee Y, Lin PY, et al
    Comparative predictive efficacy of atherogenic indices on metabolic syndrome in patients with schizophrenia.
    Schizophr Res. 2023;262:95-101.
    PubMed     Abstract available

  171. BURKE T, Holleran L, Mothersill D, Lyons J, et al
    Bilateral anterior corona radiata microstructure organisation relates to impaired social cognition in schizophrenia.
    Schizophr Res. 2023;262:87-94.
    PubMed     Abstract available

  172. XU S, Xu L
    Childhood emotional maltreatment increases the "wear-and-tear" of physiological systems, especially neuroendocrine changes in schizophrenia.
    Schizophr Res. 2023;262:84-86.

  173. STEENHUIS LA, Harms T, Nauta MH, Bartels-Velthuis AA, et al
    The dynamics of social activation and suspiciousness in individuals at ultra-high risk for psychosis.
    Schizophr Res. 2023;262:67-75.
    PubMed     Abstract available

  174. BARUTH JM, Bateman DR, Kovacs RJ, Bateman PV, et al
    Cardiac healthcare disparities and electrocardiography (ECG) differences in schizophrenia at end of life.
    Schizophr Res. 2023;262:60-66.
    PubMed     Abstract available

  175. OH H, Karcher NR, Schiffman J, Anglin DM, et al
    A broader conceptualization of premorbid risk in psychoses can motivate primordial prevention.
    Schizophr Res. 2023;262:53-54.

  176. PANIKRATOVA YR, Lebedeva IS, Akhutina TV, Tikhonov DV, et al
    Executive control of language in schizophrenia patients with history of auditory verbal hallucinations: A neuropsychological and resting-state fMRI study.
    Schizophr Res. 2023 Nov 1:S0920-9964(23)00388.
    PubMed     Abstract available

  177. HAHN B, Holzel ES
    Nicotine insensitivity and cue-controlled smoking behavior in people with schizophrenia.
    Schizophr Res. 2023;262:51-52.

  178. EACK SM, Wojtalik JA, Keshavan MS
    Anticholinergic medications in the treatment of psychoses: Pharmacological subtraction is better than addition.
    Schizophr Res. 2023;262:40-41.

  179. RINCON-CORTES M, Grace AA
    Sex-dependent emergence of prepubertal social dysfunction and augmented dopamine activity in a neurodevelopmental rodent model relevant for schizophrenia.
    Schizophr Res. 2023;262:32-39.
    PubMed     Abstract available

  180. VAZIRI N, Marques D, Greenway SC, Bousman CA, et al
    The cellular mechanism of antipsychotic-induced myocarditis: A systematic review.
    Schizophr Res. 2023;261:206-215.
    PubMed     Abstract available

    October 2023
  181. WU X, Ao H, Wu X, Cao Y, et al
    Sulfur-containing amino acids and risk of schizophrenia.
    Schizophr Res. 2023;262:8-17.
    PubMed     Abstract available

  182. CLAUSS-KOBAYASHI JME, Bonah C, Danion-Grilliat A, Scarfone M, et al
    Reshaping the diagnostic borders: Historical analysis of the diagnostic changes following the introduction of the schizophrenia concept.
    Schizophr Res. 2023;262:21-29.
    PubMed     Abstract available

  183. STAINTON A, Cheng N, Bryce S, Dalton A, et al
    Cognition is a treatment priority for young people with psychosis: Findings from the Your Mind, Your Choice survey.
    Schizophr Res. 2023;262:30-31.

  184. ROGERS E, Gresswell M, Durrant S
    The relationship between sleep and suicidality in schizophrenia spectrum and other psychotic disorders: A systematic review.
    Schizophr Res. 2023;261:291-303.
    PubMed     Abstract available

  185. HUO L, Qu D, Pei C, Wu W, et al
    Alexithymia in chronic schizophrenia and its mediating effect between cognitive deficits and negative symptoms.
    Schizophr Res. 2023;261:275-280.
    PubMed     Abstract available

  186. WILSON M, Harris M, Pereira M, Buckle J, et al
    Predictors of hospitalisation and recovery following full antipsychotic discontinuation in first episode psychosis. A naturalistic retrospective cohort study.
    Schizophr Res. 2023;261:269-274.
    PubMed     Abstract available

  187. FERNANDEZ-ABASCAL B, Suarez-Pinilla M, Cobo-Corrales C, Crespo-Facorro B, et al
    Lifestyle intervention based on exercise and behavioural counselling and its effect on physical and psychological health in outpatients with schizophrenia spectrum disorders. An exploratory, pragmatic randomized clinical trial.
    Schizophr Res. 2023;261:256-268.
    PubMed     Abstract available

  188. POORGANJI M, Goeke K, Zomorrodi R, Voineskos D, et al
    The use of theta burst stimulation in patients with schizophrenia - A systematic review.
    Schizophr Res. 2023;261:245-255.
    PubMed     Abstract available

    A genetics-guided approach to the clinical management of schizophrenia.
    Schizophr Res. 2023 Oct 7:S0920-9964(23)00353.
    PubMed     Abstract available

  190. STONE WS, Phillips MR, Yang LH, Kegeles LS, et al
    Is schizophrenia neurodevelopmental, neurodegenerative or something else: A reply to Murray et al. (2022).
    Schizophr Res. 2023;261:234-235.

  191. OLOGUNDUDU OM, Palaniyappan L, Cipriano LE, Wijnen BFM, et al
    Risk stratification for treating people at ultra-high risk for psychosis: A cost-effectiveness analysis.
    Schizophr Res. 2023;261:225-233.
    PubMed     Abstract available

  192. LUTHER L, Westbrook A, Ayawvi G, Ruiz I, et al
    The role of defeatist performance beliefs on cognitive effort-cost decision-making in schizophrenia.
    Schizophr Res. 2023;261:216-224.
    PubMed     Abstract available

  193. CHEUK NKW, Tse W, Tsui HKH, Ma CF, et al
    A systematic review and meta-analysis of the effect of clozapine on cognitive functions in patients with treatment-resistant schizophrenia.
    Schizophr Res. 2023 Oct 1:S0920-9964(23)00338.
    PubMed     Abstract available

    September 2023
  194. KERKOVA B, Knizkova K, Vecerova M, Sustova P, et al
    Inflammation and cognitive performance in first-episode schizophrenia spectrum disorders: The moderating effects of childhood trauma.
    Schizophr Res. 2023;261:185-193.
    PubMed     Abstract available

  195. PESA J, Liu Z, Fu AZ, Campbell AK, et al
    Racial disparities in utilization of first-generation versus second-generation long-acting injectable antipsychotics in Medicaid beneficiaries with schizophrenia.
    Schizophr Res. 2023;261:170-177.
    PubMed     Abstract available

  196. HUANG LY, Parker DA, Ethridge LE, Hamm JP, et al
    Double dissociation between P300 components and task switch error type in healthy but not psychosis participants.
    Schizophr Res. 2023;261:161-169.
    PubMed     Abstract available

  197. STEPHAN NM, van Sprang ED, Wiebenga JXM, Dickhoff J, et al
    Risk factors for suicidality across psychosis vulnerability spectrum.
    Schizophr Res. 2023;261:152-160.
    PubMed     Abstract available

  198. KANG N, Kim SH, Kim J, Kim S, et al
    Association between initial clozapine titration and pneumonia risk among patients with schizophrenia in a Korean tertiary hospital.
    Schizophr Res. 2023 Sep 26:S0920-9964(23)00340.
    PubMed     Abstract available

  199. OU M, Du Z, Jiang Y, Zhou Q, et al
    Causal relationship between schizophrenia and sex hormone binding globulin: A Mendelian randomization study.
    Schizophr Res. 2023 Sep 19:S0920-9964(23)00341.
    PubMed     Abstract available

  200. GURCAN G, Senol SH, Yagcioglu AEA, Ertugrul A, et al
    Effect of clozapine on suicidality in patients with schizophrenia at a university hospital in Turkey.
    Schizophr Res. 2023 Sep 19:S0920-9964(23)00297.

  201. LI X, Lafit G, van Aubel E, Vaessen T, et al
    Emotion regulation in daily life in early psychosis: The role of contextual appraisals.
    Schizophr Res. 2023;261:130-138.
    PubMed     Abstract available

  202. CHEN Q, Li X, Weng K, Zhang Y, et al
    Inflammatory mediators and the effect of electroconvulsive therapy in patients with schizophrenia.
    Schizophr Res. 2023;261:125-127.

  203. DAMIANI S, Zarbo C, Stolarski M, Zamparini M, et al
    Time will tell: Associations between unbalanced time perspectives and symptom severity in individuals with schizophrenia spectrum disorders.
    Schizophr Res. 2023;261:116-124.
    PubMed     Abstract available

  204. HEGDE S, Keshavan MS
    The brain on the beat: How music may heal schizophrenia.
    Schizophr Res. 2023;261:113-115.

  205. ZHANG L, James SH, Strauss GP
    Environmental resource reductions predict greater severity of negative symptoms in schizophrenia.
    Schizophr Res. 2023;261:94-99.
    PubMed     Abstract available

  206. PENTZ AB, Timpe CMF, Normann EM, Slapo NB, et al
    Mismatch negativity in schizophrenia spectrum and bipolar disorders: Group and sex differences and associations with symptom severity.
    Schizophr Res. 2023;261:80-93.
    PubMed     Abstract available

  207. GAUDIANO BA, Ellenberg S, Johnson JE, Mueser KT, et al
    Effectiveness of acceptance and commitment therapy for inpatients with psychosis: Implementation feasibility and acceptability from a pilot randomized controlled trial.
    Schizophr Res. 2023;261:72-79.
    PubMed     Abstract available

  208. QI W, Wen Z, Chen J, Capichioni G, et al
    Aberrant resting-state functional connectivity of the globus pallidus interna in first-episode schizophrenia.
    Schizophr Res. 2023;261:100-106.
    PubMed     Abstract available

  209. SAUER A, Grent-'t-Jong T, Zeev-Wolf M, Singer W, et al
    Spectral and phase-coherence correlates of impaired auditory mismatch negativity (MMN) in schizophrenia: A MEG study.
    Schizophr Res. 2023;261:60-71.
    PubMed     Abstract available

  210. GOVANI V, Shastry AM, Iosifescu DV, Govil P, et al
    Augmentation of learning in schizophrenia by d-serine and auditory remediation is related to auditory and frontally-generated biomarkers: A randomized, double-blind, placebo-controlled study.
    Schizophr Res. 2023;260:205-208.

  211. SORIA BRETONES C, Roncero Parra C, Cascon J, Borja AL, et al
    Automatic identification of schizophrenia employing EEG records analyzed with deep learning algorithms.
    Schizophr Res. 2023;261:36-46.
    PubMed     Abstract available

  212. MATSUI K, Kuriyama K, Yoshiike T, Kawamura A, et al
    Relapse of schizophrenia associated with comorbid delayed sleep-wake phase disorder but not with evening chronotype.
    Schizophr Res. 2023;261:34-35.

  213. PANCHAL Y, Gannon JM, Tatar JM, Balasubramani GK, et al
    COVID-19 vaccination among patients with schizophrenia prescribed clozapine.
    Schizophr Res. 2023;261:31-33.

  214. FERRARA M, Guloksuz S, Hazan H, Li F, et al
    The effect of duration of untreated psychosis (DUP) on the risk for hospitalization after admission to a first episode service.
    Schizophr Res. 2023;260:198-204.
    PubMed     Abstract available

  215. GOLAY P, Abrahamyan Empson L, Mebdouhi N, Conus P, et al
    A better understanding of the impact of childhood trauma on depression in early psychosis: A differential item functioning approach.
    Schizophr Res. 2023;261:18-23.
    PubMed     Abstract available

  216. PATEL R, Chan KMY, Palmer EOC, Valko M, et al
    Associations of comorbid substance use disorders with clinical outcomes in schizophrenia using electronic health record data.
    Schizophr Res. 2023;260:191-197.
    PubMed     Abstract available

  217. SCHOTTLE D, Wiedemann K, Correll CU, Janetzky W, et al
    Response prediction in treatment of patients with schizophrenia after switching from oral aripiprazole to aripiprazole once-monthly.
    Schizophr Res. 2023;260:183-190.

  218. GANGADIN SS, Germann M, de Witte LD, Gelderman KA, et al
    Complement component 4A protein levels are negatively related to frontal volumes in patients with schizophrenia spectrum disorders.
    Schizophr Res. 2023;261:6-14.
    PubMed     Abstract available

  219. HINKLEY LBN, Haas SS, Cheung SW, Nagarajan SS, et al
    Reduced neural connectivity in the caudate anterior head predicts hallucination severity in schizophrenia.
    Schizophr Res. 2023;261:1-5.
    PubMed     Abstract available

  220. POLETTI M, Raballo A
    Subjective self-experiences at the mirror in patients with schizophrenia.
    Schizophr Res. 2023;260:180-182.

  221. WANG T, Codling D, Bhugra D, Msosa Y, et al
    Unraveling ethnic disparities in antipsychotic prescribing among patients with psychosis: A retrospective cohort study based on electronic clinical records.
    Schizophr Res. 2023;260:168-179.
    PubMed     Abstract available

  222. ROBINSON N, Ploner A, Muller-Eberstein R, Lichtenstein P, et al
    Migration and risk of schizophrenia and bipolar disorder: A Swedish national study.
    Schizophr Res. 2023;260:160-167.
    PubMed     Abstract available

  223. GRANRUD OE, Rodriguez Z, Cowan T, Masucci MD, et al
    Alogia and pressured speech do not fall on a continuum of speech production using objective speech technologies.
    Schizophr Res. 2023;259:121-126.
    PubMed     Abstract available

    August 2023
    Clozapine in treatment-resistant schizophrenia: Who designed that famous US clinical trial?
    Schizophr Res. 2023 Aug 31:S0920-9964(23)00287.

  225. GRIFFITHS K, Smart SE, Barker GJ, Deakin B, et al
    Treatment resistance NMDA receptor pathway polygenic score is associated with brain glutamate in schizophrenia.
    Schizophr Res. 2023;260:152-159.
    PubMed     Abstract available

  226. CLEMENTZ BA, Chattopadhyay I, Trotti RL, Parker DA, et al
    Clinical characterization and differentiation of B-SNIP psychosis Biotypes: Algorithmic Diagnostics for Efficient Prescription of Treatments (ADEPT)-1.
    Schizophr Res. 2023;260:143-151.
    PubMed     Abstract available

  227. GOFF DC, Santacatterina M, Capichioni G, Ando F, et al
    Levetiracetam effects on hippocampal blood flow and symptoms in medication-free individuals with nonaffective first episode psychosis (letter).
    Schizophr Res. 2023;260:140-142.

  228. MUESER KT, Sussman RF, DeTore NR, Eberlin ES, et al
    The impact of early intervention for first episode psychosis on cognitive functioning.
    Schizophr Res. 2023;260:132-139.
    PubMed     Abstract available

  229. SMYTH E, Steel C, Ellett L
    The prevalence of non-affective psychosis in refugee populations: A systematic review.
    Schizophr Res. 2023;260:99-112.
    PubMed     Abstract available

  230. TORGALSBOEN AK, Mohn C, Laroi F, Fu S, et al
    A ten-year longitudinal repeated assessment study of cognitive improvement in patients with first-episode schizophrenia and healthy controls: The Oslo Schizophrenia Recovery (OSR) study.
    Schizophr Res. 2023;260:92-98.
    PubMed     Abstract available

  231. KANG N, Kim SH, Kim J, Kim S, et al
    Association between initial pattern of clozapine titration, concentration-to-dose ratio, and incidence of fever in patients with schizophrenia spectrum disorders in a Korean tertiary hospital.
    Schizophr Res. 2023 Aug 24:S0920-9964(23)00259.
    PubMed     Abstract available

  232. SELVAGGI P, Fazio L, Toro VD, Mucci A, et al
    Effect of anticholinergic burden on brain activity during Working Memory and real-world functioning in patients with schizophrenia.
    Schizophr Res. 2023;260:76-84.
    PubMed     Abstract available

  233. NYGARD M, Brobakken MF, Lydersen S, Guzey IC, et al
    Strength training integrated in long term collaborative care of patients with schizophrenia.
    Schizophr Res. 2023;260:67-75.
    PubMed     Abstract available

  234. ABEL DB, Minor KS
    Social pleasure in daily life: A meta-analysis of experience sampling studies in schizophrenia.
    Schizophr Res. 2023;260:56-64.
    PubMed     Abstract available

  235. REN W, Han M, Zhang Z
    Duration estimation abnormalities in unaffected first-degree relatives and individuals of schizophrenia.
    Schizophr Res. 2023;260:39-40.

  236. CECCHI GA, Corcoran CM
    Exploring language and cognition in schizophrenia: Insights from computational analysis.
    Schizophr Res. 2023 Aug 6:S0920-9964(23)00256.

  237. TAKAHASHI T, Sasabayashi D, Takayanagi Y, Furuichi A, et al
    Gross anatomical variations of the insular cortex in first-episode schizophrenia.
    Schizophr Res. 2023;260:23-29.
    PubMed     Abstract available

  238. VOCKEL J, Thiemann U, Weisbrod M, Schroder J, et al
    Movement initiation and preparation in subjects with schizophrenia - The amplitude of the readiness potential as a biological marker for negative symptom severity.
    Schizophr Res. 2023;260:3-11.
    PubMed     Abstract available

  239. CAO T, Zhang S, Chen Q, Zeng C, et al
    Long non-coding RNAs in schizophrenia: Genetic variations, treatment markers and potential targeted signaling pathways.
    Schizophr Res. 2023;260:12-22.
    PubMed     Abstract available

  240. WILLIAMS TF, Pratt DN, Pinkham AE, Mittal VA, et al
    Advances in online data gathering and personalized advertisement complicate assessment of some symptoms.
    Schizophr Res. 2023;258:69-70.

    July 2023
  241. GANNON L, Pearson N, Tsiglopoulos J, Mifsud N, et al
    Longitudinal study of the prevalence of sleep disorders in first episode psychosis and its clinical correlates.
    Schizophr Res. 2023;258:81-83.

  242. ZHANG Z, Lin H, Feng Z, Xie H, et al
    Impaired calcium channel function and pronounced hippocampal atrophy in a schizophrenia patient with cognitive impairment carrying Presenilin-2 Ser130Leu mutation: A case report and literature review.
    Schizophr Res. 2023;258:78-80.

  243. MARDER SR, Umbricht D
    Negative symptoms in schizophrenia: Newly emerging measurements, pathways, and treatments.
    Schizophr Res. 2023;258:71-77.
    PubMed     Abstract available

  244. MORO L, Orri M, Sicotte R, Thibaudeau E, et al
    Sociodemographic and clinical risk factors associated with suicidal ideation and attempt during a 2-year early intervention program for first-episode psychosis.
    Schizophr Res. 2023;258:61-68.
    PubMed     Abstract available

  245. LEWANDOWSKI KE, Ongur D, Cohen BM
    Recall of treatment information by patients in a first episode psychosis outpatient clinic.
    Schizophr Res. 2023;258:58-60.

  246. ZAVLIS O, Elahi A, Alba C, Valiente CM, et al
    Increased network connectivity among paranoid beliefs characterizes the clinical end of the schizophrenia-spectrum: A Conversian systems perspective.
    Schizophr Res. 2023;258:55-57.

  247. CHEN WY, Chen PH, Pan CH, Su SS, et al
    Clozapine and its protective effect on all-cause, natural, and suicide mortality in patients with schizophrenia: A nationwide cohort study in Taiwan.
    Schizophr Res. 2023 Jul 19:S0920-9964(23)00240.
    PubMed     Abstract available

    Use and abuse of causal language in non-experimental studies on cannabis use and the development of psychosis.
    Schizophr Res. 2023;258:53-54.

  249. LOCH AA, Gondim JM, Argolo FC, Lopes-Rocha AC, et al
    Detecting at-risk mental states for psychosis (ARMS) using machine learning ensembles and facial features.
    Schizophr Res. 2023;258:45-52.
    PubMed     Abstract available

  250. HASAN SM, Huq MS, Chowdury AZ, Baajour S, et al
    Learning without contingencies: A loss of synergy between memory and reward circuits in schizophrenia.
    Schizophr Res. 2023;258:21-35.
    PubMed     Abstract available

    June 2023
  251. PEREZ SM, Elam HB, McCoy AM, Boley AM, et al
    Congenital blindness does not protect against a schizophrenia-related phenotype in rodents.
    Schizophr Res. 2023;258:1-8.
    PubMed     Abstract available

  252. SALISBURY DF, Seebold D, Longenecker JM, Coffman BA, et al
    White matter tracts differentially associated with auditory hallucinations in first-episode psychosis: A correlational tractography diffusion spectrum imaging study.
    Schizophr Res. 2023 Jun 14:S0920-9964(23)00208.
    PubMed     Abstract available

  253. YIN Y, Li S, Tong J, Huang J, et al
    Short-term antipsychotic treatment response in early-onset, typical-onset, and late-onset first episode schizophrenia.
    Schizophr Res. 2023;257:58-63.
    PubMed     Abstract available

  254. MUSTAFA S, Malla A, Mohan G, Padmavati R, et al
    Subjective quality of life among first-episode psychosis patients in Chennai, India and Montreal, Canada.
    Schizophr Res. 2023;257:41-49.
    PubMed     Abstract available

  255. ORHAN F, Goiny M, Becklen M, Mathe L, et al
    CSF dopamine is elevated in first-episode psychosis and associates to symptom severity and cognitive performance.
    Schizophr Res. 2023;257:34-40.
    PubMed     Abstract available

  256. RAUGH IM, Luther L, Bartolomeo LA, Gupta T, et al
    Negative Symptom Inventory-Self-Report (NSI-SR): Initial development and validation.
    Schizophr Res. 2023;256:79-87.
    PubMed     Abstract available

  257. ABALO-RODRIGUEZ I, Santos-Mayo A, Moratti S
    Pavlovian conditioning-induced hallucinations reduce MMN amplitudes for duration but not frequency deviants.
    Schizophr Res. 2023;256:63-71.
    PubMed     Abstract available

  258. VAN DE MEENT I, Maat A, Boute M, van Dellen E, et al
    The Laban/Bartenieff Movement System in gait-analysis reveals upper-lower body movement dysconnectivity in psychotic disorders.
    Schizophr Res. 2023;256:47-49.

    May 2023
  259. KRUCKOW L, Basit S, Nordentoft M, Banner J, et al
    The influence of comorbid disease on premature death due to natural and unnatural causes in persons with schizophrenia.
    Schizophr Res. 2023;257:27-33.
    PubMed     Abstract available

  260. LIN CH, Lane HY
    Sodium benzoate: A novel multi-target pharmaceutical approach to rescue clozapine-resistant schizophrenia.
    Schizophr Res. 2023 May 23:S0920-9964(23)00171.

  261. SERPA M, Doshi J, Joaquim HPG, Vieira ELM, et al
    Inflammatory cytokines and white matter microstructure in the acute phase of first-episode psychosis: A longitudinal study.
    Schizophr Res. 2023;257:5-18.
    PubMed     Abstract available

  262. RICHARDS SE, Sumner PJ, Tan EJ, Meyer D, et al
    A detailed examination of pitch discrimination deficits associated with auditory verbal hallucinations in schizophrenia.
    Schizophr Res. 2023;257:19-24.
    PubMed     Abstract available

  263. SAPERSTEIN AM, Meyler S, Golub JS, Medalia A, et al
    Correlates of hearing loss among adults with schizophrenia.
    Schizophr Res. 2023;257:1-4.
    PubMed     Abstract available

  264. KORMAN N, Stanton R, Vecchio A, Chapman J, et al
    The effect of exercise on global, social, daily living and occupational functioning in people living with schizophrenia: A systematic review and meta-analysis.
    Schizophr Res. 2023;256:98-111.
    PubMed     Abstract available

  265. PRASAD KM, Muldoon B, Theis N, Iyengar S, et al
    Multipronged investigation of morphometry and connectivity of hippocampal network in relation to risk for psychosis using ultrahigh field MRI.
    Schizophr Res. 2023;256:88-97.
    PubMed     Abstract available

  266. OKRUSZEK L, Piejka A, Chrustowicz M, Krawczyk M, et al
    Social cognitive bias increases loneliness both directly and by decreasing social connection in patients with schizophrenia.
    Schizophr Res. 2023;256:72-78.
    PubMed     Abstract available

  267. DANIELS EC, Eaton WW, Cihakova D, Talor MV, et al
    The relationship of peripheral inflammation with antibodies to gliadin (AGA IgG) in persons with schizophrenia.
    Schizophr Res. 2023;256:50-51.

  268. ALTMAN RAE, Tan EJ, Rossell SL
    Access to cognitive remediation in Australia for people with schizophrenia.
    Schizophr Res. 2023;256:44-46.

  269. SURTI TS, Ranganathan M, Johannesen JK, Gueorguieva R, et al
    Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia.
    Schizophr Res. 2023;256:36-43.
    PubMed     Abstract available

  270. BENITO RA, Gatusky MH, Panoussi MW, McCall KL, et al
    Thirteen-fold variation between states in clozapine prescriptions to United States Medicaid patients.
    Schizophr Res. 2023;255:79-81.

  271. ZHANG L, Lizano P, Xu Y, Rubin LH, et al
    Peripheral inflammation is associated with impairments of inhibitory behavioral control and visual sensorimotor function in psychotic disorders.
    Schizophr Res. 2023;255:69-78.
    PubMed     Abstract available

  272. RAMSEY A, Govind T, Lam JA, Palmer BW, et al
    Self-compassion, but not compassion toward others, is associated with better physical health: A cross-sectional study.
    Schizophr Res. 2023;255:17-23.
    PubMed     Abstract available

    April 2023
  273. LUNDIN NB, Cowan HR, Singh DK, Moe AM, et al
    Lower cohesion and altered first-person pronoun usage in the spoken life narratives of individuals with schizophrenia.
    Schizophr Res. 2023 Apr 29:S0920-9964(23)00143.
    PubMed     Abstract available

  274. MORCH-JOHNSEN L, Jorgensen KN, Barth C, Nerland S, et al
    Thalamic nuclei volumes in schizophrenia and bipolar spectrum disorders - Associations with diagnosis and clinical characteristics.
    Schizophr Res. 2023;256:26-35.
    PubMed     Abstract available

  275. BRASSO C, Bellino S, Bozzatello P, Del Favero E, et al
    Inter-relationships among psychopathology, cognition, and real-life functioning in early and late phase schizophrenia: A network analysis approach.
    Schizophr Res. 2023;256:8-16.
    PubMed     Abstract available

  276. MARTINEZ-ALES G, Bello I, Basaraba C, Van der Ven E, et al
    Incidence, prevalence, and trajectories of suicidal ideation among clients enrolled in early intervention services for first episode psychosis in New York State.
    Schizophr Res. 2023;256:17-25.
    PubMed     Abstract available

  277. ZHAO J, Chen DY, Li XB, Xi YJ, et al
    EMDR versus waiting list in individuals at clinical high risk for psychosis with post-traumatic stress symptoms: A randomized controlled trial.
    Schizophr Res. 2023;256:1-7.
    PubMed     Abstract available

  278. DEAN B, Haroutunian V, Scarr E
    Lower levels of cortical [(3)H]pirenzepine binding to postmortem tissue defines a sub-group of older people with schizophrenia with less severe cognitive deficits.
    Schizophr Res. 2023;255:274-282.
    PubMed     Abstract available

  279. MULLER K, Schuster F, Rodolico A, Siafis S, et al
    How should patient decision aids for schizophrenia treatment be designed? - A scoping review.
    Schizophr Res. 2023;255:261-273.
    PubMed     Abstract available

  280. ZHANG G, Ye X, Wang X, Lin Y, et al
    Serum total cholesterol levels associated with immediate memory performance in patients with chronic schizophrenia.
    Schizophr Res. 2023;255:256-260.
    PubMed     Abstract available

  281. FOUCHER JR, Hirjak D, Walther S, Dormegny-Jeanjean LC, et al
    From one to many: Hypertonia in schizophrenia spectrum psychosis an integrative review and adversarial collaboration report.
    Schizophr Res. 2023 Apr 12:S0920-9964(23)00125.
    PubMed     Abstract available

  282. BASAVARAJU R, France J, Sigmon HC, Girgis RR, et al
    Increased parietal and occipital lobe gyrification predicts conversion to syndromal psychosis in a clinical high-risk cohort.
    Schizophr Res. 2023;255:246-255.
    PubMed     Abstract available

  283. HAGLER MA, Ferrara M, Yoviene Sykes LA, Li F, et al
    Sampling from different populations: Sociodemographic, clinical, and functional differences between samples of first episode psychosis individuals and clinical high-risk individuals who progressed to psychosis.
    Schizophr Res. 2023;255:239-245.
    PubMed     Abstract available

  284. PARNAS J, Yttri JE, Urfer-Parnas A
    Phenomenology of auditory verbal hallucination in schizophrenia: An erroneous perception or something else?
    Schizophr Res. 2023 Apr 4:S0920-9964(23)00139.
    PubMed     Abstract available

  285. KUBERA KM, Rashidi M, Schmitgen MM, Barth A, et al
    Functional network interactions in patients with schizophrenia with persistent auditory verbal hallucinations: A multimodal MRI fusion approach using three-way pICA.
    Schizophr Res. 2023 Apr 4:S0920-9964(23)00094.
    PubMed     Abstract available

  286. WANG C, Tishler TA, Oughourlian T, Nuechterlein KH, et al
    Prospective, randomized, multicenter clinical trial evaluating longitudinal changes in brain function and microstructure in first-episode schizophrenia patients treated with long-acting injectable paliperidone palmitate versus oral antipsychotics.
    Schizophr Res. 2023;255:222-232.
    PubMed     Abstract available

  287. SHI JY, Cao YM, Luo HY, Liu S, et al
    Effect of a group-based acceptance and commitment therapy (ACT) intervention on self-esteem and psychological flexibility in patients with schizophrenia in remission.
    Schizophr Res. 2023;255:213-221.
    PubMed     Abstract available

    March 2023
  288. GLEESON JFM, Koval P, Zyphur M, Lederman R, et al
    A randomized controlled trial of moderated online social therapy for family carers of first-episode psychosis patients in a specialist treatment setting.
    Schizophr Res. 2023;255:203-212.
    PubMed     Abstract available

  289. TISHLER TA, Ellingson BM, Salvadore G, Baker P, et al
    Effect of treatment with paliperidone palmitate versus oral antipsychotics on frontal lobe intracortical myelin volume in participants with recent-onset schizophrenia: Magnetic resonance imaging results from the DREaM study.
    Schizophr Res. 2023;255:195-202.
    PubMed     Abstract available

  290. MILLGATE E, Smart SE, Pardinas AF, Kravariti E, et al
    Cognitive performance at first episode of psychosis and the relationship with future treatment resistance: Evidence from an international prospective cohort study.
    Schizophr Res. 2023;255:173-181.
    PubMed     Abstract available

  291. ALMSTRUP FB, Nordentoft M, Jensen MA, Kristiansen J, et al
    Associations between saliva alpha-amylase, heart rate variability, saliva cortisol and cognitive performance in individuals at ultra high-risk for psychosis.
    Schizophr Res. 2023;255:165-172.
    PubMed     Abstract available

  292. NORDHOLM D, Jensen MA, Kristiansen J, Glenthoj LB, et al
    A longitudinal study on physiological stress in individuals at ultra high-risk of psychosis.
    Schizophr Res. 2023;254:218-226.
    PubMed     Abstract available

  293. VAESSEN T, Reininghaus U, van Aubel E, Beijer-Klippel A, et al
    Neural correlates of daily-life affective stress reactivity in early psychosis: A study combining functional MRI and experience sampling methodology.
    Schizophr Res. 2023;255:93-101.
    PubMed     Abstract available

  294. HOGOBOOM A, Rouch M, Lauerman D, Pauselli L, et al
    Initial evidence of vowel space reduction in a subset of individuals with schizophrenia.
    Schizophr Res. 2023;255:158-164.
    PubMed     Abstract available

  295. KULAGA SS, Wehring HJ, Demyanovoich HJ, Rubin L, et al
    The hormonal effects of childhood trauma in adult women with and without schizophrenia.
    Schizophr Res. 2023;255:155-157.

  296. KRUIPER C, Sommer IEC, Koster M, Bakker PR, et al
    Clonidine augmentation in patients with schizophrenia: A double-blind, randomized placebo-controlled trial.
    Schizophr Res. 2023;255:148-154.
    PubMed     Abstract available

  297. ZHANG W, Wang D, Zhou H, Chen D, et al
    Sex difference in association between tardive dyskinesia and cognitive deficits in patients with chronic schizophrenia.
    Schizophr Res. 2023;255:140-147.
    PubMed     Abstract available

  298. IYO M, Akiyoshi H, Sekine D, Shibasaki Y, et al
    An exploratory database study of factors influencing the continuation of brexpiprazole treatment (prescription) in patients with schizophrenia using information from psychiatric electronic medical records processed with natural language processing.
    Schizophr Res. 2023;255:122-131.
    PubMed     Abstract available

  299. HUA JPY, Cummings J, Roach BJ, Fryer SL, et al
    Rich-club connectivity and structural connectome organization in youth at clinical high-risk for psychosis and individuals with early illness schizophrenia.
    Schizophr Res. 2023;255:110-121.
    PubMed     Abstract available

  300. DEL RE EC, Yassin W, Zeng V, Keedy S, et al
    Characterization of childhood trauma, hippocampal mediation and Cannabis use in a large dataset of psychosis and non-psychosis individuals.
    Schizophr Res. 2023;255:102-109.
    PubMed     Abstract available

  301. SAMPEDRO A, Ibarretxe-Bilbao N, Pena J, Cabrera-Zubizarreta A, et al
    Analyzing structural and functional brain changes related to an integrative cognitive remediation program for schizophrenia: A randomized controlled trial.
    Schizophr Res. 2023;255:82-92.
    PubMed     Abstract available

  302. PRASAD K, Rubin J, Iyengar S, Cape J, et al
    Global network disorganization underlying psychosis high risk states.
    Schizophr Res. 2023;255:67-68.

  303. LI Z, Qing Y, Cui G, Li M, et al
    Shotgun metagenomics reveals abnormal short-chain fatty acid-producing bacteria and glucose and lipid metabolism of the gut microbiota in patients with schizophrenia.
    Schizophr Res. 2023;255:59-66.
    PubMed     Abstract available

  304. BUCHANAN A, Stefanovics E, Rosenheck R
    Victimization in schizophrenia and its relation to violence.
    Schizophr Res. 2023;255:52-58.
    PubMed     Abstract available

  305. MARTINHO FP, Magalhaes D, Felicio R, Ferreira TF, et al
    Obsessive-compulsive symptoms in first episode psychosis and risk states: Systematic review with meta-analysis.
    Schizophr Res. 2023;255:41-51.
    PubMed     Abstract available

  306. VAN ECK RM, van Velden J, Vellinga A, van der Krieke L, et al
    Personal recovery suits us all: A study in patients with non-affective psychosis, unaffected siblings and healthy controls.
    Schizophr Res. 2023;255:24-32.
    PubMed     Abstract available

  307. DOBBS MF, McGowan A, Selloni A, Bilgrami Z, et al
    Linguistic correlates of suicidal ideation in youth at clinical high-risk for psychosis.
    Schizophr Res. 2023 Mar 16:S0920-9964(23)00108.
    PubMed     Abstract available

  308. PFARR JK, Meller T, Evermann U, Sahakyan L, et al
    Trait schizotypy and the psychosis prodrome: Current standard assessment of extended psychosis spectrum phenotypes.
    Schizophr Res. 2023;254:208-217.
    PubMed     Abstract available

  309. RABINOWITZ J, Staner C, Saoud J, Weiser M, et al
    Long-term effects of Roluperidone on negative symptoms of schizophrenia.
    Schizophr Res. 2023;255:9-13.
    PubMed     Abstract available

  310. PRATT SI, Ferron JC, Wolfe R, Xie H, et al
    Healthy choices, healthy changes: A randomized trial of incentives to promote healthy eating and exercise in people with schizophrenia and other serious mental illnesses.
    Schizophr Res. 2023;255:1-8.
    PubMed     Abstract available

  311. SANTARRIAGA S, Gerlovin K, Layadi Y, Karmacharya R, et al
    Human stem cell-based models to study synaptic dysfunction and cognition in schizophrenia: A narrative review.
    Schizophr Res. 2023 Mar 14:S0920-9964(23)00084.
    PubMed     Abstract available

  312. TANTCHIK W, Green MJ, Quide Y, Erk S, et al
    Investigating the neural correlates of affective mentalizing and their association with general intelligence in patients with schizophrenia.
    Schizophr Res. 2023;254:190-198.
    PubMed     Abstract available

  313. CECCHI M, Adachi M, Basile A, Buhl DL, et al
    Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers.
    Schizophr Res. 2023;254:178-189.
    PubMed     Abstract available

  314. TAKEUCHI H, Lee J, Fervaha G, Agid O, et al
    Second version of Brief Evaluation of Psychosis Symptom Domains (BE-PSD-V2.0).
    Schizophr Res. 2023;254:176-177.

  315. HOPTMAN MJ, Tural U, Arnold MS, Collins KA, et al
    Suicidal ideation and behavior in schizophrenia: The role of negative urgency and psychiatric symptoms.
    Schizophr Res. 2023;254:173-175.

  316. MURILLO-GARCIA N, Ortiz-Garcia de la Foz V, Miguel-Corredera M, Vazquez-Bourgon J, et al
    Intelligence quotient changes over 10 years: Diversity of cognitive profiles in first episode of psychosis and healthy controls.
    Schizophr Res. 2023;254:163-172.
    PubMed     Abstract available

  317. SIAO WH, Chang FY, Chen YC
    Memantine treats psychosis and agitation associated with Moderna COVID-19 vaccine.
    Schizophr Res. 2023;255:14-16.

  318. LIANG S, Cao B, Deng W, Kong X, et al
    Functional dysconnectivity of anterior cingulate subregions in schizophrenia and psychotic and nonpsychotic bipolar disorder.
    Schizophr Res. 2023;254:155-162.
    PubMed     Abstract available

  319. DEMIRLEK C, Bora E
    Sleep-dependent memory consolidation in schizophrenia: A systematic review and meta-analysis.
    Schizophr Res. 2023;254:146-154.
    PubMed     Abstract available

  320. TANDON R
    Computational psychiatry and the psychopathology of psychosis: Promising leads and blind alleys.
    Schizophr Res. 2023;254:143-145.

  321. DETORE NR, Balogun-Mwangi O, Mueser KT, McGurk SR, et al
    Comparison of Black and White participants with severe mental illness in response to cognitive remediation as an augmentation of vocational rehabilitation.
    Schizophr Res. 2023;253:60-67.
    PubMed     Abstract available

    February 2023
  322. VAN DEE V, Schnack HG, Cahn W
    Systematic review and meta-analysis on predictors of prognosis in patients with schizophrenia spectrum disorders: An overview of current evidence and a call for prospective research and open access to datasets.
    Schizophr Res. 2023;254:133-142.
    PubMed     Abstract available

  323. MICHAELS TI, Carrion RE, Addington J, Bearden CE, et al
    Ethnoracial discrimination and the development of suspiciousness symptoms in individuals at clinical high-risk for psychosis.
    Schizophr Res. 2023;254:125-132.
    PubMed     Abstract available

  324. KUMAZAKI H, Muramatsu T, Yoshikawa Y, Matsumoto Y, et al
    Android robot was beneficial for communication rehabilitation in a patient with schizophrenia comorbid with autism spectrum disorders.
    Schizophr Res. 2023;254:116-117.

  325. DE MICHELI A, Provenzani U, Solmi M, Van Pabst AVL, et al
    Prevalence of tobacco smoking in people at clinical high-risk for psychosis: Systematic review and meta-analysis.
    Schizophr Res. 2023;254:109-115.
    PubMed     Abstract available

  326. STEVENS KL, Teich CD, Longenecker JM, Sponheim SR, et al
    Relational memory function in schizophrenia: Electrophysiological evidence for early perceptual and late associative abnormalities.
    Schizophr Res. 2023;254:99-108.
    PubMed     Abstract available

  327. KARBALAEE M, Jameie M, Amanollahi M, TaghaviZanjani F, et al
    Efficacy and safety of adjunctive therapy with fingolimod in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial.
    Schizophr Res. 2023;254:92-98.
    PubMed     Abstract available

  328. MAO Z, Bo Q, Sun Y, Li W, et al
    Prepulse inhibition and attentional modulation in individuals with attenuated psychotic syndrome and at genetically high risk of schizophrenia.
    Schizophr Res. 2023;254:90-91.

  329. SHOHAM N, Lewis G, Hayes JF, Silverstein SM, et al
    Association between visual impairment and psychosis: A longitudinal study and nested case-control study of adults.
    Schizophr Res. 2023;254:81-89.
    PubMed     Abstract available

  330. CABUK T, Mutlu E, Toulopoulou T
    Thought and language disorder as a possible endophenotype in schizophrenia: Evidence from patients and their unaffected siblings.
    Schizophr Res. 2023;254:78-80.

  331. DONDE C, Pouchon A, Polosan M
    Recovery effect: Cigarette smoking acts on the neural dynamics of early auditory processing in schizophrenia.
    Schizophr Res. 2023;254:76-77.

  332. RAMAIN J, Conus P, Golay P
    Interactions between mood and paranoid symptoms affect suicidality in first-episode affective psychoses.
    Schizophr Res. 2023;254:62-67.
    PubMed     Abstract available

  333. COOPER SM, Fusar-Poli P, Uhlhaas PJ
    Characteristics and clinical correlates of risk symptoms in individuals at clinical high-risk for psychosis: A systematic review and meta-analysis.
    Schizophr Res. 2023;254:54-61.
    PubMed     Abstract available

  334. CASTRO MN, Bocaccio H, De Pino G, Sanchez SM, et al
    Abnormal brain network community structure related to psychological stress in schizophrenia.
    Schizophr Res. 2023;254:42-53.
    PubMed     Abstract available

  335. TAKAHASHI Y, Fujii S, Osakabe Y, Hoshino H, et al
    Impaired mismatch negativity reflects the inability to perceive beat interval in patients with schizophrenia.
    Schizophr Res. 2023;254:40-41.

  336. LIN Y, Li C, Wang X, Song Y, et al
    Channel- and category-specific emotion recognition deficits and their associations with symptomatology and cognition in individuals with schizophrenia.
    Schizophr Res. 2023;254:37-39.

    Schizophrenia and COVID-19: A bibliometric analysis of trends and themes.
    Schizophr Res. 2023;254:35-36.

  338. PANULA JM, Lindgren M, Kieseppa T, Suvisaari J, et al
    Associations between acceptance of the implausible bias, theory of mind and delusions in first-episode psychosis patients; A longitudinal study.
    Schizophr Res. 2023;254:27-34.
    PubMed     Abstract available

  339. TANDON R, Keshavan M, Nasrallah H
    "Reinventing schizophrenia: Updating the construct". Project update and next steps.
    Schizophr Res. 2023;252:345-347.

  340. KULKARNI J, Gurvich C, Gilbert H, Worsley R, et al
    The use of first and second-generation antipsychotic drugs and the potential to develop gestational diabetes mellitus among perinatal patients with psychosis.
    Schizophr Res. 2023;254:22-26.
    PubMed     Abstract available

  341. SCHNEIDER BC, Rahmede M, Pillny M, Karow A, et al
    In the eyes of the beholders: Subjective experiences of positive symptoms among patients with symptoms of psychosis seeking psychotherapy.
    Schizophr Res. 2023;254:14-21.
    PubMed     Abstract available

  342. PADEE A, Missonnier P, Prevot A, Favre G, et al
    Anticipatory deficits in psychosis during social cognition task analysed by task-based EEG dynamic functional connectivity.
    Schizophr Res. 2023;254:11-13.

  343. LIMA MF, Sarudiansky M, Oddo S, Giagante B, et al
    Comorbid psychosis in temporal lobe epilepsy is associated with auditory emotion recognition impairments.
    Schizophr Res. 2023;254:8-10.

    January 2023
  344. MANDAL MK, Habel U, Gur RC
    Facial expression-based indicators of schizophrenia: Evidence from recent research.
    Schizophr Res. 2023;252:335-344.
    PubMed     Abstract available

  345. WOOTTON O, Dalvie S, Susser E, Gur RC, et al
    Within-individual variability in cognitive performance in schizophrenia: A narrative review of the key literature and proposed research agenda.
    Schizophr Res. 2023;252:329-334.
    PubMed     Abstract available

    Is preventing the second psychotic episode a disease-modifying strategy for schizophrenia?
    Schizophr Res. 2023;252:326-328.

  347. IHLER HM, Lyngstad SH, Gardsjord ES, Widing LH, et al
    The trajectory of two negative symptom dimensions in first-episode psychosis and the role of cannabis use: A 10-year follow-up study.
    Schizophr Res. 2023;252:317-325.
    PubMed     Abstract available

  348. OKADA Y, Inada K, Akazawa M
    Comparative effectiveness of long-acting injectable antipsychotics in patients with schizophrenia in Japan.
    Schizophr Res. 2023;252:300-308.
    PubMed     Abstract available

  349. GAUR V, Singh S
    Psychopathology, clinical insight and cognitive insight in patients with treatment resistant schizophrenia.
    Schizophr Res. 2023;252:294-295.

  350. ALBERT N, Hansen HG, Starzer M, Nordentoft M, et al
    Functioning pre- and post-treatment in schizophrenia; further investigations into lead time bias and duration of untreated psychosis.
    Schizophr Res. 2023;252:287-293.
    PubMed     Abstract available

  351. STEENKAMP LR, Parrish EM, Chalker SA, Badal VD, et al
    Childhood trauma and real-world social experiences in psychosis.
    Schizophr Res. 2023;252:279-286.
    PubMed     Abstract available

  352. CUESTA MJ, Sanchez-Torres AM, Garcia de Jalon E, Moreno-Izco L, et al
    Empirical validity of Leonhard's psychoses: A long-term follow-up study of first-episode psychosis patients.
    Schizophr Res. 2023 Jan 20:S0920-9964(22)00469.
    PubMed     Abstract available

  353. BENNETT ME, Brown CH, Fang LJ, Blanchard JJ, et al
    Increasing social and community participation in veterans living with schizophrenia: A treatment outcome study.
    Schizophr Res. 2023;252:262-270.
    PubMed     Abstract available

  354. SUN H, Lui S, Huang X, Sweeney J, et al
    Effects of randomness in the development of machine learning models in neuroimaging studies of schizophrenia.
    Schizophr Res. 2023;252:253-261.
    PubMed     Abstract available

  355. COURY SM, Lombroso A, Avila-Quintero VJ, Taylor JH, et al
    Systematic review and meta-analysis: Season of birth and schizophrenia risk.
    Schizophr Res. 2023;252:244-252.
    PubMed     Abstract available

  356. AMADOR X
    Denial of anosognosia in schizophrenia.
    Schizophr Res. 2023;252:242-243.

  357. BARENDSE MEA, Lara GA, Guyer AE, Swartz JR, et al
    Sex and pubertal influences on the neurodevelopmental underpinnings of schizophrenia: A case for longitudinal research on adolescents.
    Schizophr Res. 2023;252:231-241.
    PubMed     Abstract available

  358. MIRALLES C, Alonso Y, Algora MJ, Lopez-Sanchez L, et al
    Maladaptive personality traits in patients with recent-onset psychosis: A case-control study using the Personality Inventory for the DSM-5 (PID-5).
    Schizophr Res. 2023;252:216-224.
    PubMed     Abstract available

  359. MILLER BJ, McEvoy JP, McCall WV
    Meta-analysis of clozapine and insomnia in schizophrenia.
    Schizophr Res. 2023;252:208-215.
    PubMed     Abstract available

  360. LI SB, Liu C, Zhang JB, Wang LL, et al
    Corrigendum to "Revisiting the latent structure of negative symptoms in schizophrenia: Evidence from two second-generation clinical assessments" [Schizophr. Res. 248 (2022) 131-139].
    Schizophr Res. 2023;252:206-207.

  361. PATRONO E, Hruzova K, Svoboda J, Stuchlik A, et al
    The role of optogenetic stimulations of parvalbumin-positive interneurons in the prefrontal cortex and the ventral hippocampus on an acute MK-801 model of schizophrenia-like cognitive inflexibility.
    Schizophr Res. 2023;252:198-205.
    PubMed     Abstract available

  362. FACAL F, Costas J
    Polygenic risk scores for schizophrenia and treatment resistance: New data, systematic review and meta-analysis.
    Schizophr Res. 2023;252:189-197.

  363. CHAN SKW, Liao Y, Hui CLM, Wong TY, et al
    Longitudinal changes of cognitive function and its relationship with subdomains of negative symptoms in patients with adult-onset first-episode schizophrenia: A 4-year follow up study.
    Schizophr Res. 2023;252:181-188.
    PubMed     Abstract available

  364. SASTRE-BUADES A, Caro-Canizares I, Ochoa S, Lorente-Rovira E, et al
    Relationship between cognition and suicidal behavior in recent-onset psychosis.
    Schizophr Res. 2023;252:172-180.
    PubMed     Abstract available

  365. DAVID FS, Stein F, Andlauer TFM, Streit F, et al
    Genetic contributions to transdiagnostic symptom dimensions in patients with major depressive disorder, bipolar disorder, and schizophrenia spectrum disorders.
    Schizophr Res. 2023;252:161-171.
    PubMed     Abstract available

  366. HERRERA SN, Sarac C, Phili A, Gorman J, et al
    Psychoeducation for individuals at clinical high risk for psychosis: A scoping review.
    Schizophr Res. 2023;252:148-158.
    PubMed     Abstract available

  367. PALMER-COOPER EC, Wright AC, Maguire N, Montagnese M, et al
    Metacognition and psychosis-spectrum experiences: A study of objective and subjective measures.
    Schizophr Res. 2023 Jan 14:S0920-9964(22)00461.
    PubMed     Abstract available

  368. ALKELAI A, Greenbaum L, Shohat S, Povysil G, et al
    Genetic insights into childhood-onset schizophrenia: The yield of clinical exome sequencing.
    Schizophr Res. 2023;252:138-145.
    PubMed     Abstract available

  369. OGYU K, Matsushita K, Honda S, Wada M, et al
    Decrease in gamma-band auditory steady-state response in patients with treatment-resistant schizophrenia.
    Schizophr Res. 2023;252:129-137.
    PubMed     Abstract available

  370. OH J, Lee E, Cha EJ, Seo HJ, et al
    Community-based multi-site randomized controlled trial of behavioral activation for patients with negative symptoms of schizophrenia.
    Schizophr Res. 2023;252:118-126.
    PubMed     Abstract available

  371. FLORENTIN S, Reuveni I, Rosca P, Zwi-Ran SR, et al
    Schizophrenia or schizoaffective disorder? A 50-year assessment of diagnostic stability based on a national case registry.
    Schizophr Res. 2023;252:110-117.
    PubMed     Abstract available

  372. HOLTTINEN T, Pirkola S, Kaltiala R
    Schizophrenia among young people first admitted to psychiatric inpatient care during early and middle adolescence.
    Schizophr Res. 2023;252:103-109.
    PubMed     Abstract available

  373. MILLER BJ, Lemos H, Schooler NR, Goff DC, et al
    Longitudinal study of inflammation and relapse in schizophrenia.
    Schizophr Res. 2023;252:88-95.
    PubMed     Abstract available

  374. HOPREKSTAD GE, Kjelby E, Gjestad R, Fathian F, et al
    Depression trajectories and cytokines in schizophrenia spectrum disorders - A longitudinal observational study.
    Schizophr Res. 2023;252:77-87.
    PubMed     Abstract available

  375. HONDA S, Matsushita K, Noda Y, Tarumi R, et al
    Music rhythm perception and production relate to treatment response in schizophrenia.
    Schizophr Res. 2023;252:69-76.
    PubMed     Abstract available

  376. MISIAK B, Bielawski T, Samochowiec J, Samochowiec A, et al
    Activation of the endocannabinoid system in schizophrenia: A compensatory mechanism of subclinical inflammation?
    Schizophr Res. 2023;252:67-68.

  377. GOUSE BM, Kline ER
    Clinical insights: Preventing psychosis treatment disengagement.
    Schizophr Res. 2023;252:64-66.
    PubMed     Abstract available

  378. CHOI SY, Ha M, Choi S, Moon SY, et al
    Altered intrinsic cerebellar-cerebral functional connectivity is related to negative symptoms in patients with first-episode psychosis.
    Schizophr Res. 2023;252:56-63.
    PubMed     Abstract available

  379. ROUX P, Faivre N, Urbach M, Aouizerate B, et al
    Relationships between neuropsychological performance, insight, medication adherence, and social metacognition in schizophrenia.
    Schizophr Res. 2023;252:48-55.
    PubMed     Abstract available

  380. SIMMONITE M, Yao B, Welsh RC, Taylor SF, et al
    Increased rostral medial frontal GABA+ in early psychosis is obscured by levels of negative affect.
    Schizophr Res. 2023;252:46-47.

  381. TAKAHASHI T, Sasabayashi D, Wood SJ, McGorry PD, et al
    Increased prevalence of the Heschl's gyrus duplication pattern common to various first-episode psychoses.
    Schizophr Res. 2023;252:36-38.

  382. ULUDAG K, Wang DM, Mohamoud Y, Wu HE, et al
    Antipsychotic-based machine learning models may help prediction of tardive dyskinesia in patients with schizophrenia.
    Schizophr Res. 2023;252:33-35.

  383. GIL-BERROZPE GJ, Peralta V, Sanchez-Torres AM, Moreno-Izco L, et al
    Psychopathological networks in psychosis: Changes over time and clinical relevance. A long-term cohort study of first-episode psychosis.
    Schizophr Res. 2023;252:23-32.
    PubMed     Abstract available

  384. BUCCI P, Giordano GM, Mucci A, Rocca P, et al
    Sex and gender differences in clinical and functional indices in subjects with schizophrenia and healthy controls: Data from the baseline and 4-year follow-up studies of the Italian Network for Research on Psychoses.
    Schizophr Res. 2023;251:94-107.
    PubMed     Abstract available

  385. COSTA ALL, Costa DL, Pessoa VF, Caixeta FV, et al
    Systematic review of visual illusions in schizophrenia.
    Schizophr Res. 2023;252:13-22.
    PubMed     Abstract available

  386. LI K, Long J, Cao M, Xue R, et al
    Thyroid hormone optimize management in electroconvulsive therapy treatment of schizophrenia.
    Schizophr Res. 2023;252:10-12.

  387. MOSCARELLI M, Min JY, Kopelowicz A, Torous J, et al
    The scale for the assessment of the passively received experiences (PRE) in schizophrenia and digital mental health.
    Schizophr Res. 2023;251:91-93.

  388. DALKNER N, Moore RC, Depp CA, Ackerman RA, et al
    Negative mood states as a correlate of cognitive performance and self-assessment of cognitive performance in bipolar disorder versus schizophrenia.
    Schizophr Res. 2023;252:1-9.
    PubMed     Abstract available

    December 2022
  389. BAREIS N, Olfson M, Gerhard T, Rolin S, et al
    Means of suicide among adults with schizophrenia across the life span.
    Schizophr Res. 2022;251:82-90.
    PubMed     Abstract available

  390. SHYMKO G, Dobson L, Acacio MC, Grace T, et al
    Weight changes in people with early psychosis treated with oral or long-acting injectable aripiprazole.
    Schizophr Res. 2022;251:74-81.
    PubMed     Abstract available

  391. MALETTA RM, Vass V
    A 20-year review comparing the use of 'schizophrenia' and 'psychosis' in UK newspapers from 2000 to 2019: Implications for stigma reduction.
    Schizophr Res. 2022;251:66-73.
    PubMed     Abstract available

  392. GANGADIN SS, Mandl RCW, de Witte LD, van Haren NEM, et al
    Lower fractional anisotropy without evidence for neuro-inflammation in patients with early-phase schizophrenia spectrum disorders.
    Schizophr Res. 2022 Dec 26:S0920-9964(22)00456.
    PubMed     Abstract available

  393. LE TP, Ventura J, Ruiz-Yu B, McEwen SC, et al
    Treatment engagement in first-episode schizophrenia: Associations between intrinsic motivation and attendance during cognitive training and an aerobic exercise program.
    Schizophr Res. 2022;251:59-65.
    PubMed     Abstract available

  394. WANG D, Russel WA, Sun Y, Belanger KD, et al
    Machine learning and network analysis of the gut microbiome from patients with schizophrenia and non-psychiatric subject controls reveal behavioral risk factors and bacterial interactions.
    Schizophr Res. 2022;251:49-58.
    PubMed     Abstract available

  395. CUNILL R, Vives L, Pla M, Usall J, et al
    Relationship between obsessive compulsive symptomatology and severity of psychotic symptoms in schizophrenia: Meta-analysis and meta-regression analysis.
    Schizophr Res. 2022;251:37-45.
    PubMed     Abstract available

    What social determinants can tell us about schizophrenia.
    Schizophr Res. 2022 Dec 15:S0920-9964(22)00400.

  397. JENKINS AK, Lewis DA, Volk DW
    Altered expression of microglial markers of phagocytosis in schizophrenia.
    Schizophr Res. 2022;251:22-29.
    PubMed     Abstract available

  398. MCEWEN SC, Jarrahi B, Ventura J, Subotnik KL, et al
    A combined exercise and cognitive training intervention induces fronto-cingulate cortical plasticity in first-episode psychosis patients.
    Schizophr Res. 2022;251:12-21.
    PubMed     Abstract available

  399. MORORO LG, Guimaraes AL, Costa AC, Genaro L, et al
    Association between motivation and engagement with changes in cognition and symptoms after digital cognitive training in schizophrenia.
    Schizophr Res. 2022;251:1-9.
    PubMed     Abstract available

  400. BUCK B, Munson J, Chander A, Wang W, et al
    The relationship between appraisals of auditory verbal hallucinations and real-time affect and social functioning.
    Schizophr Res. 2022;250:112-119.
    PubMed     Abstract available

    November 2022
  401. CHOUDHARY A, Peles D, Nayak R, Mizrahi L, et al
    Current progress in understanding schizophrenia using genomics and pluripotent stem cells: A meta-analytical overview.
    Schizophr Res. 2022 Nov 25:S0920-9964(22)00406.
    PubMed     Abstract available

  402. KILIAN S, Du Plessis S, Fouche JP, Luckhoff H, et al
    Differences in white matter microstructure in first-episode schizophrenia spectrum disorders vs healthy volunteers and their association with cognition.
    Schizophr Res. 2022;250:196-202.
    PubMed     Abstract available

  403. MARTINUZZI LJ, Strassnig MT, Depp CA, Moore RC, et al
    A closer look at avolition in schizophrenia and bipolar disorder: Persistence of different types of activities over time.
    Schizophr Res. 2022;250:188-195.
    PubMed     Abstract available

  404. KHAN A, Lindenmayer JP, Insel B, Seddo M, et al
    Computerized cognitive and social cognition training in schizophrenia for impulsive aggression.
    Schizophr Res. 2022 Nov 21:S0920-9964(22)00418.
    PubMed     Abstract available

  405. ZHAO Q, Wang WQ, Fan HZ, Li D, et al
    Vocal acoustic features may be objective biomarkers of negative symptoms in schizophrenia: A cross-sectional study.
    Schizophr Res. 2022;250:180-185.
    PubMed     Abstract available

  406. RASMUSSEN AR, Zandersen M, Nordgaard J, Sandsten KE, et al
    Pseudoneurotic symptoms in the schizophrenia spectrum: An empirical study.
    Schizophr Res. 2022;250:164-171.
    PubMed     Abstract available

  407. MOLSTROM IM, Nordgaard J, Urfer-Parnas A, Handest R, et al
    The prognosis of schizophrenia: A systematic review and meta-analysis with meta-regression of 20-year follow-up studies.
    Schizophr Res. 2022;250:152-163.
    PubMed     Abstract available

  408. SCHORR B, Clauss JME, de Billy CC, Dassing R, et al
    Subtyping chronic catatonia: Clinical and neuropsychological characteristics of progressive periodic catatonia and chronic system catatonias vs. non-catatonic schizophrenia.
    Schizophr Res. 2022 Nov 18:S0920-9964(22)00392.
    PubMed     Abstract available

  409. DJORDJEVIC M, Brink V, Wardenaar KJ, Scholte-Stalenhoef AN, et al
    Personality traits and coping strategies in recent-onset psychosis: Associations with symptom severity and psychosocial functioning.
    Schizophr Res. 2022;250:143-151.
    PubMed     Abstract available

  410. MILLER BJ, McEvoy JP, McCall WV, Lu XY, et al
    Lower adiponectin levels as a predictor of depressive symptoms in African-American males with schizophrenia.
    Schizophr Res. 2022;250:134-136.

  411. CAROFF SN, Ungvari GS, Gazdag G
    Treatment of schizophrenia with catatonic symptoms: A narrative review.
    Schizophr Res. 2022 Nov 17:S0920-9964(22)00431.
    PubMed     Abstract available

  412. BECKER WRIGHT ML, Ahmed AO, Barchard KA, Benning SD, et al
    Latent structure of cognitive tests is invariant in men and women with schizophrenia.
    Schizophr Res. 2022;250:127-133.
    PubMed     Abstract available

  413. ZHANG W, Perivoliotis D
    Promoting recovery among persons with schizophrenia using Recovery-Oriented Cognitive Therapy (CT-R).
    Schizophr Res. 2022;250:125-126.

  414. BROWN H, Ongur D, Smurawska L, Valcourt S, et al
    Inpatient - Outpatient transitions in first episode psychosis care.
    Schizophr Res. 2022;250:123-124.

  415. KIRIHARA K, Fujioka M, Suga M, Kondo S, et al
    Betaine supplementation improves positive symptoms in schizophrenia.
    Schizophr Res. 2022;250:120-122.

  416. COHEN BM, Singh T, Ongur D, Konstantin GE, et al
    Clinical phenotypes of five patients with psychotic disorders carrying rare schizophrenia-associated loss-of-function variants.
    Schizophr Res. 2022;250:100-103.
    PubMed     Abstract available

  417. NAGENDRA A, Black C, Penn DL
    Black Americans and Schizophrenia: Racism as a Driver of Inequities in Psychosis Diagnosis, Assessment, and Treatment.
    Schizophr Res. 2022 Nov 14. pii: S0920-9964(22)00390.

  418. CONLEY AC, Albert KM, Armstrong K, Johnson JV, et al
    A pilot study of transdermal nicotine effects on facial emotion responding in non-smoking healthy controls and individuals with schizophrenia: Feasibility and effect size estimates.
    Schizophr Res. 2022;250:89-91.

  419. YUAN X, Li X, Kang Y, Pang L, et al
    Gut mycobiota dysbiosis in drug-naive, first-episode schizophrenia.
    Schizophr Res. 2022;250:76-86.
    PubMed     Abstract available

  420. CORRELL CU, Bitter I, Hoti F, Mehtala J, et al
    Factors and their weight in reducing life expectancy in schizophrenia.
    Schizophr Res. 2022;250:67-75.
    PubMed     Abstract available

  421. ZHAI D, Bing J, Shan X, Luo H, et al
    Higher central set point of thyroid homeostasis in drug-naive patients affected by first episode schizophrenia.
    Schizophr Res. 2022;250:62-66.
    PubMed     Abstract available

    A commentary on the interpretability of computational linguistic findings in schizophrenia research.
    Schizophr Res. 2022;250:60-61.

  423. FREEMAN D, Lambe S, Galal U, Yu LM, et al
    Agoraphobic avoidance in patients with psychosis: Severity and response to automated VR therapy in a secondary analysis of a randomised controlled clinical trial.
    Schizophr Res. 2022;250:50-59.
    PubMed     Abstract available

  424. INTSON K, Geissah S, McCullumsmith RE, Ramsey AJ, et al
    A role for endothelial NMDA receptors in the pathophysiology of schizophrenia.
    Schizophr Res. 2022;249:63-73.
    PubMed     Abstract available

  425. CHAUMETTE B, Sengupta SM, Lepage M, Malla A, et al
    A polymorphism in the glutamate metabotropic receptor 7 is associated with cognitive deficits in the early phases of psychosis.
    Schizophr Res. 2022;249:56-62.
    PubMed     Abstract available

  426. LEON-ORTIZ P, Reyes-Madrigal F, Kochunov P, Gomez-Cruz G, et al
    White matter alterations and the conversion to psychosis: A combined diffusion tensor imaging and glutamate (1)H MRS study.
    Schizophr Res. 2022;249:85-92.
    PubMed     Abstract available

  427. ZEPPILLO T, Schulmann A, Macciardi F, Hjelm BE, et al
    Functional impairment of cortical AMPA receptors in schizophrenia.
    Schizophr Res. 2022;249:25-37.
    PubMed     Abstract available

  428. QIAN N, Lipkin RM, Kaszowska A, Silipo G, et al
    Computational modeling of excitatory/inhibitory balance impairments in schizophrenia.
    Schizophr Res. 2022;249:47-55.
    PubMed     Abstract available

  429. ASAH S, Alganem K, McCullumsmith RE, O'Donovan SM, et al
    A bioinformatic inquiry of the EAAT2 interactome in postmortem and neuropsychiatric datasets.
    Schizophr Res. 2022;249:38-46.
    PubMed     Abstract available

  430. REDDY-THOOTKUR M, Kraguljac NV, Lahti AC
    The role of glutamate and GABA in cognitive dysfunction in schizophrenia and mood disorders - A systematic review of magnetic resonance spectroscopy studies.
    Schizophr Res. 2022;249:74-84.
    PubMed     Abstract available

  431. BENESH JL, Mueller TM, Meador-Woodruff JH
    AMPA receptor subunit localization in schizophrenia anterior cingulate cortex.
    Schizophr Res. 2022;249:16-24.
    PubMed     Abstract available

  432. ROBERTS RC, McCollum LA, Schoonover KE, Mabry SJ, et al
    Ultrastructural evidence for glutamatergic dysregulation in schizophrenia.
    Schizophr Res. 2022;249:4-15.
    PubMed     Abstract available

    October 2022
  433. KLINE ER, Thibeau H, Davis BJ, Fenley A, et al
    Motivational interviewing for loved ones: Randomized controlled trial of brief training for first episode psychosis caregivers.
    Schizophr Res. 2022;250:43-49.
    PubMed     Abstract available

  434. WALTHER S, Nadesalingam N, Nuoffer M, Kyrou A, et al
    Structural alterations of the motor cortex and higher order cortical areas suggest early neurodevelopmental origin of catatonia in schizophrenia.
    Schizophr Res. 2022 Oct 20. pii: S0920-9964(22)00374.
    PubMed     Abstract available

  435. VARNUM PV
    The what, why, and so what of psychosis.
    Schizophr Res. 2022;250:41-42.

  436. DEL RE EC
    Emerging themes in schizophrenia research at SIRS 2022: Inclusivity, equality and Cannabis impact on mental health.
    Schizophr Res. 2022;250:39-40.

  437. BARLATI S, Nibbio G, Calzavara-Pinton I, Invernizzi E, et al
    Primary and secondary negative symptoms severity and the use of psychiatric care resources in schizophrenia spectrum disorders: A 3-year follow-up longitudinal retrospective study.
    Schizophr Res. 2022;250:31-38.
    PubMed     Abstract available

  438. CHIEN WT, Ho LK, Gray R, Bressington D, et al
    A randomized controlled trial of a peer-facilitated self-management program for people with recent-onset psychosis.
    Schizophr Res. 2022;250:22-30.
    PubMed     Abstract available

  439. MOW JL, Gard DE, Mueser KT, Mote J, et al
    Smartphone-based mobility metrics capture daily social motivation and behavior in schizophrenia.
    Schizophr Res. 2022;250:13-21.
    PubMed     Abstract available

  440. NAGENDRA A, Orleans-Pobee M, Vincent C, Padgett J, et al
    The representation of authors of color in schizophrenia research articles published in high-impact psychiatric journals.
    Schizophr Res. 2022 Oct 7. pii: S0920-9964(22)00323.
    PubMed     Abstract available

  441. BRUHN D, Hwang S, Howarth A, Dube S, et al
    The burden of illness for patients with schizophrenia and primary negative symptoms: A systematic literature review.
    Schizophr Res. 2022;248:341-344.

  442. GAO YN, Olfson M
    National trends in metabolic risk of psychiatric inpatients in the United States during the atypical antipsychotic era.
    Schizophr Res. 2022;248:320-328.
    PubMed     Abstract available

  443. BENAROUS X, Lahaye H, Cottin G, Garny de la Riviere S, et al
    Trends in the use of long-acting injectable antipsychotics in children and adolescents in France between 2014 and 2018.
    Schizophr Res. 2022;248:231-232.

  444. KESHAVAN MS, Bishop DL, Coconcea C, Bishop JR, et al
    Clozapine, an update.
    Schizophr Res. 2022;248:168-170.

    September 2022
  445. CUESTA MJ, Ballesteros A, Sanchez-Torres AM, Amoretti S, et al
    Relapse of first-episode schizophrenia patients and neurocognitive impairment: The role of dopaminergic and anticholinergic burden.
    Schizophr Res. 2022;248:331-340.
    PubMed     Abstract available

  446. AUERBACH JG, Hans SL, Zhang Y
    Neurocognitive functioning in adult and adolescent offspring of parents with schizophrenia.
    Schizophr Res. 2022;248:300-308.
    PubMed     Abstract available

  447. HINOTSU K, Miyaji C, Yada Y, Kawai H, et al
    The validity of atypical psychosis diagnostic criteria to detect anti-NMDA receptor encephalitis with psychiatric symptoms.
    Schizophr Res. 2022;248:292-299.
    PubMed     Abstract available

  448. HOSGELEN EI, Akgul O, Akdede BB, Alptekin K, et al
    Relation between processing speed and social media use in schizophrenia patients.
    Schizophr Res. 2022;248:290-291.

  449. SCHILLING TM, Andelfinger V, Bossert M, Konig M, et al
    No clinically relevant effects of 12 sessions of 2 mA of anodal transcranial Direct Current Stimulation over the left DLPFC in combination with concurrent cognitive training compared to cognitive training only on executive functions in patients with s
    Schizophr Res. 2022;248:287-289.

  450. MONTELEONE P, Cascino G, Rossi A, Rocca P, et al
    Evolution of antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia in the real-life: A 4-year follow-up naturalistic study.
    Schizophr Res. 2022;248:279-286.
    PubMed     Abstract available

  451. KANE JM, Kinon BJ, Forray C, Such P, et al
    Efficacy and safety of Lu AF35700 in treatment-resistant schizophrenia: A randomized, active-controlled trial with open-label extension.
    Schizophr Res. 2022;248:271-278.
    PubMed     Abstract available

  452. YANG KC, Chen YY, Liu MN, Yang BH, et al
    Interactions between dopamine transporter and N-methyl-d-aspartate receptor-related amino acids on cognitive impairments in schizophrenia.
    Schizophr Res. 2022;248:263-270.
    PubMed     Abstract available

  453. FATTAL J, Brascamp JW, Slate RE, Lehet M, et al
    Blunted pupil light reflex is associated with negative symptoms and working memory in individuals with schizophrenia.
    Schizophr Res. 2022;248:254-262.
    PubMed     Abstract available

  454. KUHNEY FS, Damme KSF, Ellman LM, Schiffman J, et al
    Evaluating the Social Functioning Scale modified for use in individuals at clinical high-risk for psychosis.
    Schizophr Res. 2022;248:246-253.
    PubMed     Abstract available

  455. KOMULAINEN K, Elovainio M, Tormalehto S, Ruuhela R, et al
    Climatic exposures in childhood and the risk of schizophrenia from childhood to early adulthood.
    Schizophr Res. 2022;248:233-239.
    PubMed     Abstract available

  456. SINGH SM, Win PW, Castellani CA
    Complementary approaches involving monozygotic twins and single neuron genomics support postzygotic somatic mutations in schizophrenia.
    Schizophr Res. 2022;248:228-230.

  457. UNRAU J, Percie du Sert O, Joober R, Malla A, et al
    Subtyping negative symptoms in first-episode psychosis: Contrasting persistent negative symptoms with a data-driven approach.
    Schizophr Res. 2022;248:219-227.
    PubMed     Abstract available

  458. NORTH HF, Weissleder C, Fullerton JM, Webster MJ, et al
    Increased immune cell and altered microglia and neurogenesis transcripts in an Australian schizophrenia subgroup with elevated inflammation.
    Schizophr Res. 2022;248:208-218.
    PubMed     Abstract available

  459. KLINE CL, Suzuki T, Simmonite M, Taylor SF, et al
    Catatonia is associated with higher rates of negative affect amongst patients with schizophrenia and schizoaffective disorder.
    Schizophr Res. 2022 Sep 13. pii: S0920-9964(22)00334.
    PubMed     Abstract available

  460. TOUSKOVA TP, Bob P, Pec O, Lysaker P, et al
    Dissociative symptoms in schizophrenia spectrum disorders: Historical links and future research perspectives.
    Schizophr Res. 2022;248:206-207.

  461. PAINO M, Gonzalez-Menendez AM, Vallina-Fernandez O, Rus-Calafell M, et al
    A novel algorithm to detect early risk of psychosis: Results from the Prevention Program for Psychosis (P3).
    Schizophr Res. 2022;248:196-197.

    Postmortem, in silico, and clinical studies focused on perturbations of glutamate neurobiology in schizophrenia.
    Schizophr Res. 2022 Sep 8. pii: S0920-9964(22)00292.

  463. TAKEUCHI H, Sanches M, Borlido C, Remington G, et al
    Consistency of adherence to antipsychotics between two bottles in patients with schizophrenia.
    Schizophr Res. 2022;248:194-195.

  464. KHACHADOURIAN V, Zaks N, Lin E, Reichenberg A, et al
    Reprint of: Advanced paternal age and risk of schizophrenia in offspring - Review of epidemiological findings and potential mechanisms.
    Schizophr Res. 2022 Sep 6. pii: S0920-9964(22)00329.
    PubMed     Abstract available

  465. LEON-ORTIZ P, Reyes-Madrigal F, Mondragon-Maya A, Mora-Duran R, et al
    Social cognition and its association with the duration and severity of psychosis in antipsychotic-naive individuals at different stages of the schizophrenia spectrum disorders.
    Schizophr Res. 2022;248:180-182.

  466. ZHAO W, Zhang Q, Su Y, Chen X, et al
    Effect of schizophrenia risk gene polymorphisms on cognitive and neural plasticity.
    Schizophr Res. 2022;248:173-179.
    PubMed     Abstract available

  467. BOBERG M, Felding S, Jansson L, Nordgaard J, et al
    Differential diagnosis: Schizophrenia and personality disorder.
    Schizophr Res. 2022;248:171-172.

  468. POUSA E, Brebion G, Lopez-Carrilero R, Ruiz AI, et al
    Clinical insight in first-episode psychosis: Clinical, neurocognitive and metacognitive predictors.
    Schizophr Res. 2022;248:158-167.
    PubMed     Abstract available

  469. REAVIS EA, Wynn JK, Green MF
    The flickering spotlight of visual attention: Characterizing abnormal object-based attention in schizophrenia.
    Schizophr Res. 2022;248:151-157.
    PubMed     Abstract available

  470. WASTLER HM, Moe AM, Breitborde NJK
    Emotion regulation strategies and suicidal ideation among individuals with first-episode psychosis.
    Schizophr Res. 2022;248:149-150.

  471. ROSENFIELD PJ, Jiang D, Pauselli L
    Childhood adversity and psychotic disorders: Epidemiological evidence, theoretical models and clinical considerations.
    Schizophr Res. 2022;247:55-66.
    PubMed     Abstract available

    August 2022
  472. CHENG N, Lin A, Bowden S, Gao C, et al
    Intelligence trajectories in individuals at ultra-high risk for psychosis: An 8-year longitudinal analysis.
    Schizophr Res. 2022;248:140-148.
    PubMed     Abstract available

  473. LI SB, Liu C, Zhang JB, Wang LL, et al
    Revisiting the latent structure of negative symptoms in schizophrenia: Evidence from two second-generation clinical assessments.
    Schizophr Res. 2022;248:131-139.
    PubMed     Abstract available

  474. NKIRE N, Kingston T, Kinsella A, Russell V, et al
    Mixed-effects models reveal prediction of long-term outcome by duration of untreated psychosis (DUP) and illness (DUI) varies with quantile gradation but is invariant with time across 7 years in the Cavan-Monaghan First Episode Psychosis Study (CAMFEP
    Schizophr Res. 2022;248:124-130.
    PubMed     Abstract available

  475. MILLMAN ZB, Guvenek-Cokol PE, Kim HJ, Ongur D, et al
    The support, treatment, and resilience (STAR) program for youth at clinical high-risk of psychosis.
    Schizophr Res. 2022;248:122-123.

  476. SANTESTEBAN-ECHARRI O, Liu L, Miller M, Bearden CE, et al
    Cannabis use and attenuated positive and negative symptoms in youth at clinical high risk for psychosis.
    Schizophr Res. 2022;248:114-121.
    PubMed     Abstract available

  477. CHEW QH, Prakash KNB, Koh LY, Chilla G, et al
    Neuroanatomical subtypes of schizophrenia and relationship with illness duration and deficit status.
    Schizophr Res. 2022;248:107-113.
    PubMed     Abstract available

  478. SONNENSCHEIN SF, Mayeli A, Yushmanov VE, Blazer A, et al
    A longitudinal investigation of GABA, glutamate, and glutamine across the insula during antipsychotic treatment of first-episode schizophrenia.
    Schizophr Res. 2022;248:98-106.
    PubMed     Abstract available

  479. DUNCAN E, Roach BJ, Massa N, Hamilton HK, et al
    Auditory N100 amplitude deficits predict conversion to psychosis in the North American Prodrome Longitudinal Study (NAPLS-2) cohort.
    Schizophr Res. 2022;248:89-97.
    PubMed     Abstract available

  480. KARPOUZIAN-ROGERS T, Sweeney JA, Rubin LH, McDowell J, et al
    Reduced task-evoked pupillary response in preparation for an executive cognitive control response among individuals across the psychosis spectrum.
    Schizophr Res. 2022;248:79-88.
    PubMed     Abstract available

  481. SARRAF L, Lepage M, Sauve G
    The clinical and psychosocial correlates of self-stigma among people with schizophrenia spectrum disorders across cultures: A systematic review and meta-analysis.
    Schizophr Res. 2022;248:64-78.
    PubMed     Abstract available

  482. ALPHS L, Baker P, Brown B, Fu DJ, et al
    Evaluation of major treatment failure in patients with recent-onset schizophrenia or schizophreniform disorder: A post hoc analysis from the Disease Recovery Evaluation and Modification (DREaM) study.
    Schizophr Res. 2022;248:58-63.
    PubMed     Abstract available

  483. CELLA M, Tomlin P, Robotham D, Green P, et al
    Virtual Reality Therapy for the Negative Symptoms of Schizophrenia (V-NeST): A pilot randomised feasibility trial.
    Schizophr Res. 2022;248:50-57.
    PubMed     Abstract available

  484. STROMME MF, Bartz-Johannesen C, Kroken RA, Mehlum L, et al
    Overactive, aggressive, disruptive and agitated behavior associated with the use of psychotropic medications in schizophrenia.
    Schizophr Res. 2022;248:35-41.
    PubMed     Abstract available

  485. PAROLA A, Lin JM, Simonsen A, Bliksted V, et al
    Speech disturbances in schizophrenia: Assessing cross-linguistic generalizability of NLP automated measures of coherence.
    Schizophr Res. 2022 Aug 1. pii: S0920-9964(22)00274.
    PubMed     Abstract available

  486. LAUNDERS N, Scolamiero L, Osborn DPJ, Hayes JF, et al
    Cancer rates and mortality in people with severe mental illness: Further evidence of lack of parity.
    Schizophr Res. 2022;246:260-267.
    PubMed     Abstract available

  487. PAUL NB, Strauss GP, Woodyatt JJ, Paul MG, et al
    Cluster analysis of negative symptoms identifies distinct negative symptom subgroups.
    Schizophr Res. 2022;246:207-215.
    PubMed     Abstract available

  488. CHEUNG JP, Tubbs JD, Sham PC
    Extended gene set analysis of human neuro-psychiatric traits shows enrichment in brain-expressed human accelerated regions across development.
    Schizophr Res. 2022;246:148-155.
    PubMed     Abstract available

    July 2022
  489. GALLUCCI J, Tan T, Schifani C, Dickie EW, et al
    Greater individual variability in functional brain activity during working memory performance in Schizophrenia Spectrum Disorders (SSD).
    Schizophr Res. 2022;248:21-31.
    PubMed     Abstract available

  490. AKER S, Kahve AC
    What do psychiatrists think about renaming schizophrenia in Turkey?
    Schizophr Res. 2022;248:8-13.
    PubMed     Abstract available

  491. TRAN T, Spilka MJ, Ruiz I, Strauss GP, et al
    Implicit cognitive effort monitoring impairments are associated with expressive negative symptoms in schizophrenia.
    Schizophr Res. 2022;248:14-20.
    PubMed     Abstract available

  492. ACHIM AM, Roy MA, Fossard M
    The other side of the social interaction: Theory of mind impairments in people with schizophrenia are linked to other people's difficulties in understanding them.
    Schizophr Res. 2022 Jul 26. pii: S0920-9964(22)00273.
    PubMed     Abstract available

  493. GARRIDO-TORRES N, Ruiz-Veguilla M, Alameda L, Canal-Rivero M, et al
    Prevalence of metabolic syndrome and related factors in a large sample of antipsychotic naive patients with first-episode psychosis: Baseline results from the PAFIP cohort.
    Schizophr Res. 2022;246:277-285.
    PubMed     Abstract available

  494. COKAL D, Palominos-Flores C, Yalincetin B, Ture-Abaci O, et al
    Referential noun phrases distribute differently in Turkish speakers with schizophrenia.
    Schizophr Res. 2022 Jul 21. pii: S0920-9964(22)00259.
    PubMed     Abstract available

  495. ROHDE C, Hojlund M, Gasse C, Hauser AS, et al
    Psychopharmacological treatment patterns prior to a schizophrenia diagnosis: A Danish nationwide study.
    Schizophr Res. 2022;246:268-276.
    PubMed     Abstract available

  496. FILTS Y, Litman RE, Martinez J, Anta L, et al
    Corrigendum to "Long-term efficacy and safety of once-monthly Risperidone ISM(R) in the treatment of schizophrenia: Results from a 12-month open-label extension study" [Schizophr. Res. 239 (2022) 83-91].
    Schizophr Res. 2022;246:258-259.

  497. SULLIVAN SA, Kounali D, Morris R, Kessler D, et al
    Developing and internally validating a prognostic model (P Risk) to improve the prediction of psychosis in a primary care population using electronic health records: The MAPPED study.
    Schizophr Res. 2022;246:241-249.
    PubMed     Abstract available

  498. WALTA M, Laurikainen H, Armio RL, From T, et al
    Selection bias in clinical studies of first-episode psychosis: A follow-up study.
    Schizophr Res. 2022;246:235-240.
    PubMed     Abstract available

  499. TANG SX, Cong Y, Nikzad AH, Mehta A, et al
    Clinical and computational speech measures are associated with social cognition in schizophrenia spectrum disorders.
    Schizophr Res. 2022 Jul 11. pii: S0920-9964(22)00247.
    PubMed     Abstract available

  500. SEBASTIAN R, Song Y, Pak C
    Probing the molecular and cellular pathological mechanisms of schizophrenia using human induced pluripotent stem cell models.
    Schizophr Res. 2022 Jul 11. pii: S0920-9964(22)00263.
    PubMed     Abstract available

  501. MOTA NB, Ribeiro M, Malcorra BLC, Atidio JP, et al
    Happy thoughts: What computational assessment of connectedness and emotional words can inform about early stages of psychosis.
    Schizophr Res. 2022 Jul 7. pii: S0920-9964(22)00260.
    PubMed     Abstract available

  502. LEE J, Song S, Lee J, Kang J, et al
    Impaired migration of autologous induced neural stem cells from patients with schizophrenia and implications for genetic risk for psychosis.
    Schizophr Res. 2022;246:225-234.
    PubMed     Abstract available

  503. KANTOR JR, Gur RC, Calkins ME, Moore TM, et al
    Comparison of two cognitive screening measures in a longitudinal sample of youth at-risk for psychosis.
    Schizophr Res. 2022;246:216-224.
    PubMed     Abstract available

  504. GARCIA-RIZO C, Ortiz Garcia de la Foz V, Mayoral-van Son J, Gomez-Revuelta M, et al
    Reduced glomerular filter rate in antipsychotic-naive patients with first-episode psychosis.
    Schizophr Res. 2022;246:202-204.

  505. GREVE AN, Jepsen JRM, Mortensen EL, Uher R, et al
    Transmission of intelligence, working memory, and processing speed from parents to their seven-year-old offspring is function specific in families with schizophrenia or bipolar disorder.
    Schizophr Res. 2022;246:195-201.

  506. VER LOREN VAN THEMAAT AH, Oranje B, Larsen KM, Tomasevic L, et al
    Mismatch negativity and P3a amplitude in children with familial high risk of schizophrenia or bipolar disorder - A Danish register-based EEG study.
    Schizophr Res. 2022;246:187-194.
    PubMed     Abstract available

  507. ADAMS RA, Vincent P, Benrimoh D, Friston KJ, et al
    Everything is connected: Inference and attractors in delusions.
    Schizophr Res. 2022;245:5-22.
    PubMed     Abstract available

  508. BOUTTIER V, Duttagupta S, Deneve S, Jardri R, et al
    Circular inference predicts nonuniform overactivation and dysconnectivity in brain-wide connectomes.
    Schizophr Res. 2022;245:59-67.
    PubMed     Abstract available

  509. RAJJI TK, Mamo DC, Holden J, Granholm E, et al
    Corrigendum to "Cognitive-behavioral social skills training for patients with late-life schizophrenia and the moderating effect of executive dysfunction" [Schizophr. Res. 239 (2022) 160-167].
    Schizophr Res. 2022 Jul 1. pii: S0920-9964(22)00271.

  510. LESTRA V, Romeo B, Martelli C, Benyamina A, et al
    Could CRP be a differential biomarker of illness stages in schizophrenia? A systematic review and meta-analysis.
    Schizophr Res. 2022;246:175-186.
    PubMed     Abstract available

    June 2022
  511. CHRUSCIEL JH, Orso R, de Mattos BP, Fries GR, et al
    A systematic review and meta-analysis of epigenetic clocks in schizophrenia.
    Schizophr Res. 2022;246:172-174.
    PubMed     Abstract available

  512. BRACHER-SMITH M, Rees E, Menzies G, Walters JTR, et al
    Machine learning for prediction of schizophrenia using genetic and demographic factors in the UK biobank.
    Schizophr Res. 2022;246:156-164.
    PubMed     Abstract available

  513. CORONA-HERNANDEZ H, de Boer JN, Brederoo SG, Voppel AE, et al
    Assessing coherence through linguistic connectives: Analysis of speech in patients with schizophrenia-spectrum disorders.
    Schizophr Res. 2022 Jun 28. pii: S0920-9964(22)00248.
    PubMed     Abstract available

  514. ISAACS AN, Brooks H, Lawn S, Mohammadi L, et al
    Effectiveness of personal recovery facilitators in adults with schizophrenia and other psychoses: A systematic review of reviews and narrative synthesis.
    Schizophr Res. 2022;246:132-147.
    PubMed     Abstract available

  515. GOLAY P, Ramain J, Abrahamyan Empson L, Mebdouhi N, et al
    Symptom dimensions stability over time in recent onset psychosis: A prospective study.
    Schizophr Res. 2022;246:126-131.
    PubMed     Abstract available

  516. RIEDL L, Nagels A, Sammer G, Choudhury M, et al
    Multimodal speech-gesture training in patients with schizophrenia spectrum disorder: Effects on quality of life and neural processing.
    Schizophr Res. 2022;246:112-125.
    PubMed     Abstract available

  517. SCHIWY LC, Forlim CG, Fischer DJ, Kuhn S, et al
    Aberrant functional connectivity within the salience network is related to cognitive deficits and disorganization in psychosis.
    Schizophr Res. 2022;246:103-111.
    PubMed     Abstract available

  518. SILVA AM, Limongi R, MacKinley M, Ford SD, et al
    Syntactic complexity of spoken language in the diagnosis of schizophrenia: A probabilistic Bayes network model.
    Schizophr Res. 2022 Jun 22. pii: S0920-9964(22)00245.
    PubMed     Abstract available

  519. BEGUE I, Brakowski J, Seifritz E, Dagher A, et al
    Cerebellar and cortico-striatal-midbrain contributions to reward-cognition processes and apathy within the psychosis continuum.
    Schizophr Res. 2022;246:85-94.
    PubMed     Abstract available

  520. RAUCHER-CHENE D, Pochiet G, Lavigne KM, Heinrichs RW, et al
    Normal-range verbal memory in the first-episode of psychosis: Clinical and functional outcomes across 24 months and impact of estimated verbal memory decrement.
    Schizophr Res. 2022;246:75-84.
    PubMed     Abstract available

  521. NIZNIKIEWICZ MA, Brady RO, Whitfield-Gabrieli S, Keshavan MS, et al
    Dynamic intervention-based biomarkers may reduce heterogeneity and motivate targeted interventions in clinical high risk for psychosis.
    Schizophr Res. 2022;246:60-62.

  522. MORKVED N, Johnsen E, Kroken RA, Winje D, et al
    Impact of childhood trauma on antipsychotic effectiveness in schizophrenia spectrum disorders: A prospective, pragmatic, semi-randomized trial.
    Schizophr Res. 2022;246:49-59.
    PubMed     Abstract available

  523. KUO SS, Musket CW, Rupert PE, Almasy L, et al
    Age-dependent patterns of schizophrenia genetic risk affect cognition.
    Schizophr Res. 2022;246:39-48.
    PubMed     Abstract available

  524. POWERS AR
    Mathematical nosology: Computational approaches to understanding psychosis.
    Schizophr Res. 2022 Jun 10. pii: S0920-9964(22)00202.

  525. SCHOFIELD P, Thisted Horsdal H, Das-Munshi J, Thygesen M, et al
    A comparison of neighbourhood level variation and risk factors for affective versus non-affective psychosis.
    Schizophr Res. 2022 Jun 10. pii: S0920-9964(22)00192.
    PubMed     Abstract available

  526. CATALANO LT, Wynn JK, Green MF, Gold JM, et al
    Reduced neural activity when anticipating social versus nonsocial rewards in schizophrenia: Preliminary evidence from an ERP study.
    Schizophr Res. 2022;246:7-16.
    PubMed     Abstract available

  527. GALIANO RUS S, Ortiz Garcia de la Foz V, Arias-Loste MT, Iruzubieta P, et al
    Elevated risk of liver steatosis in first-episode psychosis patients: Results from a 3-year prospective study.
    Schizophr Res. 2022;246:30-38.
    PubMed     Abstract available

  528. LALLY J, Ajnakina O, Stubbs B, Gardner-Sood P, et al
    Vitamin D and cardiometabolic outcomes in first episode psychosis (FEP): A prospective cohort study.
    Schizophr Res. 2022;246:26-29.

  529. SCHOR SH, Gibbs JS, Gouse BM, Brown HE, et al
    A call to action: Increased mortality from COVID-19 among individuals with schizophrenia calls for coordinated vaccination efforts.
    Schizophr Res. 2022;246:63-64.

  530. ORTIZ BB, Gadelha A, Bressan RA
    Should we rethink how we introduce schizophrenia?
    Schizophr Res. 2022;244:134.

  531. PHELAN S, Sigala N
    The effect of treatment on insight in psychotic disorders - A systematic review and meta-analysis.
    Schizophr Res. 2022;244:126-133.
    PubMed     Abstract available

    May 2022
  532. SEGURA AG, Martinez-Pinteno A, Gasso P, Rodriguez N, et al
    Metabolic polygenic risk scores effect on antipsychotic-induced metabolic dysregulation: A longitudinal study in a first episode psychosis cohort.
    Schizophr Res. 2022;244:101-110.
    PubMed     Abstract available

  533. LIANG L, Heinrichs RW, Liddle PF, Jeon P, et al
    Cortical impoverishment in a stable subgroup of schizophrenia: Validation across various stages of psychosis.
    Schizophr Res. 2022 May 26. pii: S0920-9964(22)00188.
    PubMed     Abstract available

  534. PALOMAR-CIRIA N, Cegla-Schvartzman F, Bello HJ, Martinez-Ales G, et al
    Diagnostic stability of schizophrenia in clinical settings: An observational study of 198,289 patient/years.
    Schizophr Res. 2022;244:81-83.

  535. SETIEN-SUERO E, Ayesa-Arriola R, Pena J, Crespo-Facorro B, et al
    Longitudinal effects of cannabis use on attentional processes in patients with first episode of psychosis.
    Schizophr Res. 2022;244:71-80.
    PubMed     Abstract available

  536. KURTZ MM
    Kraepelin, schizophrenia and the first biological era in psychiatry.
    Schizophr Res. 2022;244:69-70.

  537. WILLIAMS TF, Powers AR, Ellman LM, Corlett PR, et al
    Three prominent self-report risk measures show unique and overlapping utility in characterizing those at clinical high-risk for psychosis.
    Schizophr Res. 2022;244:58-65.
    PubMed     Abstract available

  538. SCHIFFMAN J, Horton LE, Landa Y, Woods SW, et al
    Considerations for providing feedback to patients and families regarding clinical high-risk for psychosis status.
    Schizophr Res. 2022;244:55-57.

  539. SANCHEZ-TORRES AM, Peralta V, Gil-Berrozpe GJ, Mezquida G, et al
    The network structure of cognitive deficits in first episode psychosis patients.
    Schizophr Res. 2022;244:46-54.
    PubMed     Abstract available

  540. ALONSO-SANCHEZ MF, Limongi R, Gati J, Palaniyappan L, et al
    Language network self-inhibition and semantic similarity in first-episode schizophrenia: A computational-linguistic and effective connectivity approach.
    Schizophr Res. 2022 May 11. pii: S0920-9964(22)00160.
    PubMed     Abstract available

  541. CARRA G, Crocamo C, Bartoli F, Angermeyer M, et al
    Influence of positive and negative symptoms on hedonic and eudaemonic well-being in people with schizophrenia: A longitudinal analysis from the EuroSc study.
    Schizophr Res. 2022;244:21-28.
    PubMed     Abstract available

  542. DELISI LE
    Commentary on whether progressive brain change underlies the pathology of schizophrenia: Should this even be debated?
    Schizophr Res. 2022;244:18-20.

  543. CAVALIERE VS, Glassman M, DiPaula BA, Mackowick M, et al
    Anti-aggressive effects of clozapine in involuntarily committed black patients with severe mental illness.
    Schizophr Res. 2022;243:163-169.
    PubMed     Abstract available

  544. STEPHANE M, Dzemidzic M, Yoon G
    Altered corollary discharge in the auditory cortex could reflect louder inner voice experience in patients with verbal hallucinations, a pilot fMRI study.
    Schizophr Res. 2022;243:475-480.
    PubMed     Abstract available

  545. NARITA Z, Koyanagi A, Oh H, DeVylder J, et al
    Association between incarceration and psychotic experiences in a general population sample.
    Schizophr Res. 2022;243:112-117.
    PubMed     Abstract available

  546. CEREDA G, Boscutti A, Lazzaretti M, Enrico P, et al
    Amitriptyline for clozapine-induced hypersalivation: A case series.
    Schizophr Res. 2022;243:110-111.

  547. JIMENO N, Gomez-Pilar J, Poza J, Hornero R, et al
    (Attenuated) hallucinations join basic symptoms in a transdiagnostic network cluster analysis.
    Schizophr Res. 2022;243:43-54.
    PubMed     Abstract available

  548. RUIZ DE PELLON-SANTAMARIA A, Sarasqueta-Eizaguirre C, Basterrechea-Pena FJ
    An overall protective effect of antipsychotic drugs against COVID-19 seems implausible.
    Schizophr Res. 2022;243:486-488.

  549. ZHANG L, Zhang R, Han S, Womer FY, et al
    Three major psychiatric disorders share specific dynamic alterations of intrinsic brain activity.
    Schizophr Res. 2022;243:322-329.
    PubMed     Abstract available

  550. HJELSENG IV, Vaskinn A, Ueland T, Lunding SH, et al
    Childhood trauma is associated with poorer social functioning in severe mental disorders both during an active illness phase and in remission.
    Schizophr Res. 2022;243:241-246.
    PubMed     Abstract available

  551. JEREMIAN R, Bani-Fatemi A, Strauss JS, Tasmim S, et al
    Investigation of accelerated epigenetic aging in individuals suffering from schizophrenia in the context of lifetime suicide attempt.
    Schizophr Res. 2022;243:222-224.

  552. TASMIM S, Bani-Fatemi A, Dada OD, Wang KZ, et al
    Recent health-related stressful life events predictive of emergent suicidal ideation in schizophrenia.
    Schizophr Res. 2022;243:220-221.

    April 2022
  553. MALHI GS, Bell E
    Reframing schizophrenia: Altering our perceptions?
    Schizophr Res. 2022;244:8-9.

  554. TAKAHASHI T, Wood SJ, Yung AR, Nelson B, et al
    Pineal morphology of the clinical high-risk state for psychosis and different psychotic disorders.
    Schizophr Res. 2022;244:1-7.
    PubMed     Abstract available

  555. HAINING K, Grent-'t-Jong T, Chetcuti B, Gajwani R, et al
    Computerised cognitive training during early-stage psychosis improves cognitive deficits and gamma-band oscillations: A pilot study.
    Schizophr Res. 2022;243:217-219.

  556. GAWDE U, Hegde P, Desai K, Barai RS, et al
    Multimorbidity landscape of schizophrenia: Insights from meta-analysis of genome wide association studies.
    Schizophr Res. 2022;243:214-216.

  557. WEINREB S, Li F, Kurtz MM
    A meta-analysis of social cognitive deficits in schizophrenia: Does world region matter?
    Schizophr Res. 2022;243:206-213.
    PubMed     Abstract available

  558. MAMTANI H, Pathak H, Sakhardande KA, Gowda GS, et al
    Can peripheral brain-derived neurotrophic factor (BDNF) be a potential biomarker of suicide risk in schizophrenia?
    Schizophr Res. 2022;243:203-205.

  559. GUPTA T, Horton WS, Haase CM, Carol EE, et al
    Clues from caregiver emotional language usage highlight the link between putative social environment and the psychosis-risk syndrome.
    Schizophr Res. 2022 Apr 7. pii: S0920-9964(22)00151.
    PubMed     Abstract available

  560. AMSALEM D, Valeri L, Jankowski SE, Yang LH, et al
    Reducing public stigma toward individuals with psychosis across race and gender: A randomized controlled trial of young adults.
    Schizophr Res. 2022;243:195-202.
    PubMed     Abstract available

  561. SHAKIR M, Willems AE, van Harten PN, van Lutterveld R, et al
    The effect on relapse rate and psychiatric symptomatology: Switching a combination of first- and second-generation antipsychotic polypharmacy to antipsychotic monotherapy in long-term inpatients with schizophrenia and related disorders. A pragmatic ra
    Schizophr Res. 2022;243:187-194.
    PubMed     Abstract available

    Editorial for Special Issue: From cytokines to climate and C-sections and from micronutrients to the microbiome: Neurodevelopment and the risk for psychosis.
    Schizophr Res. 2022 Apr 5. pii: S0920-9964(22)00077.

  563. MURRAY RM, Bora E, Modinos G, Vernon A, et al
    Schizophrenia: A developmental disorder with a risk of non-specific but avoidable decline.
    Schizophr Res. 2022;243:181-186.
    PubMed     Abstract available

  564. SARPAL DK, Blazer A, Wilson JD, Calabro FJ, et al
    Relationship between plasma clozapine/N-desmethylclozapine and changes in basal forebrain-dorsolateral prefrontal cortex coupling in treatment-resistant schizophrenia.
    Schizophr Res. 2022;243:170-177.
    PubMed     Abstract available

    March 2022
  565. STONE WS, Phillips MR, Yang LH, Kegeles LS, et al
    Neurodegenerative model of schizophrenia: Growing evidence to support a revisit.
    Schizophr Res. 2022;243:154-162.
    PubMed     Abstract available

  566. KHAU M, Tabbane K, Bloom D, Abadi S, et al
    Pragmatic implementation of the Clinical Global Impression Scale of Severity as a tool for measurement-based care in a first-episode psychosis program.
    Schizophr Res. 2022;243:147-153.
    PubMed     Abstract available

  567. TANG CH, Ramcharran D, Qiu H, Chung KH, et al
    Attaching importance to the risk of all-cause, sudden death, and cardiovascular mortality among antipsychotic-treated patients with schizophrenia.
    Schizophr Res. 2022 Mar 22. pii: S0920-9964(22)00129.

  568. SUHAS S, Mehta UM
    A redux of schizophrenia research in 2021.
    Schizophr Res. 2022 Mar 14. pii: S0920-9964(22)00130.

  569. ASKEVIS-LEHERPEUX F, Hazo JB, Agoub M, Baleige A, et al
    Accessibility of psychiatric vocabulary: An international study about schizophrenia essential features.
    Schizophr Res. 2022 Mar 13. pii: S0920-9964(22)00119.

  570. SHARPE V, Schoot L, Lewandowski KE, Ongur D, et al
    We both say tomato: Intact lexical alignment in schizophrenia and bipolar disorder.
    Schizophr Res. 2022;243:138-146.
    PubMed     Abstract available

  571. LOPEZ-DIAZ A, Ayesa-Arriola R, Garrido-Torres N, Otiz-Garcia de la Foz V, et al
    A proxy measure of premorbid adjustment in psychosis for large-scale epidemiological studies and electronic health record-based research.
    Schizophr Res. 2022 Mar 11. pii: S0920-9964(22)00112.

  572. PENCE AY, Pries LK, Ferrara M, Rutten BPF, et al
    Gender differences in the association between environment and psychosis.
    Schizophr Res. 2022;243:120-137.
    PubMed     Abstract available

  573. COSTARDI CG, Malinowski F, Fonseca L, Redondo L, et al
    COVID-19 contamination and severity among patients with schizophrenia: Results from a specialized outpatient clinic survey.
    Schizophr Res. 2022 Mar 4. pii: S0920-9964(22)00118.

  574. YONEZAWA K, Tani H, Nakajima S, Nagai N, et al
    AMPA receptors in schizophrenia: A systematic review of postmortem studies on receptor subunit expression and binding.
    Schizophr Res. 2022;243:98-109.
    PubMed     Abstract available

  575. SAKS ER
    Holding onto the center: Lived experience and the construct of schizophrenia.
    Schizophr Res. 2022 Mar 2. pii: S0920-9964(22)00094.

  576. ALPHS L, Brown B, Turkoz I, Baker P, et al
    The Disease Recovery Evaluation and Modification (DREaM) study: Effectiveness of paliperidone palmitate versus oral antipsychotics in patients with recent-onset schizophrenia or schizophreniform disorder.
    Schizophr Res. 2022;243:86-97.
    PubMed     Abstract available

  577. LUCKHOFF HK, Asmal L, Scheffler F, du Plessis S, et al
    Sex and gender associations with indicators of neurodevelopmental compromise in schizophrenia spectrum disorders.
    Schizophr Res. 2022;243:70-77.
    PubMed     Abstract available

  578. RANJAN T, Melcher J, Keshavan M, Smith M, et al
    Longitudinal symptom changes and association with home time in people with schizophrenia: An observational digital phenotyping study.
    Schizophr Res. 2022;243:64-69.
    PubMed     Abstract available

  579. MCGURK SR, Xie H, Bond GR, Mueser KT, et al
    Impact of cognitive remediation on the prediction of employment outcomes in severe mental illness.
    Schizophr Res. 2022;241:149-155.
    PubMed     Abstract available

  580. STEENKAMP L, Weijers J, Gerrmann J, Eurelings-Bontekoe E, et al
    The relationship between childhood abuse and severity of psychosis is mediated by loneliness: an experience sampling study.
    Schizophr Res. 2022;241:306-311.
    PubMed     Abstract available

    February 2022
  581. FIRST MB, Lieberman JA
    How should we diagnose schizophrenia: Don't throw the baby out with the bath water.
    Schizophr Res. 2022 Feb 28. pii: S0920-9964(22)00034.

  582. TANDON R, Keshavan M, Nasrallah H
    Reinventing schizophrenia. Updating the construct.
    Schizophr Res. 2022 Feb 28. pii: S0920-9964(22)00093.

    The construct of schizophrenia as a human-specific condition.
    Schizophr Res. 2022 Feb 28. pii: S0920-9964(22)00092.

  584. BIOQUE M, Mezquida G, Amoretti S, Garcia-Rizo C, et al
    Clinical and treatment predictors of relapse during a three-year follow-up of a cohort of first episodes of schizophrenia.
    Schizophr Res. 2022;243:32-42.
    PubMed     Abstract available

  585. PHAHLADIRA L, Asmal L, Luckhoff HK, du Plessis S, et al
    The trajectories and correlates of two negative symptom subdomains in first-episode schizophrenia.
    Schizophr Res. 2022;243:17-23.
    PubMed     Abstract available

  586. WANG Z, Fu Y, Jiang F, Chen L, et al
    Further evidence and meta-analysis support association of a single nucleotide polymorphism rs4765905 in CACNA1C with schizophrenia.
    Schizophr Res. 2022 Feb 24. pii: S0920-9964(22)00062.

  587. AKOURI-SHAN L, DeLuca JS, Pitts SC, Jay SY, et al
    Internalized stigma mediates the relation between psychosis-risk symptoms and subjective quality of life in a help-seeking sample.
    Schizophr Res. 2022;241:298-305.
    PubMed     Abstract available

  588. RASMUSSEN AR, Parnas J
    What is obsession? Differentiating obsessive-compulsive disorder and the schizophrenia spectrum.
    Schizophr Res. 2022;243:1-8.
    PubMed     Abstract available

  589. HUANG BJ, Pu CC, Miao Q, Ma K, et al
    Neurocognitive trajectories and their clinical implications in first-episode schizophrenia after one year of antipsychotic treatment.
    Schizophr Res. 2022;241:292-297.
    PubMed     Abstract available

  590. LONG M, Stansfeld JL, Davies N, Crellin NE, et al
    A systematic review of social functioning outcome measures in schizophrenia with a focus on suitability for intervention research.
    Schizophr Res. 2022;241:275-291.
    PubMed     Abstract available

    Schizophrenia: Transcending old world shadows.
    Schizophr Res. 2022 Feb 18. pii: S0920-9964(22)00074.

  592. GORDON JA, Morris SE, Avenevoli S
    A framework for integration of dimensional and diagnostic approaches to the diagnosis of schizophrenia.
    Schizophr Res. 2022 Feb 18. pii: S0920-9964(22)00066.

  593. ZHANG L, Strauss GP
    Adaptive and maladaptive consequences of increased social media and internet use during the COVID-19 pandemic in schizophrenia.
    Schizophr Res. 2022 Feb 17. pii: S0920-9964(22)00085.

  594. SCORIELS L, Genaro LT, Keffer S, Guimaraes AL, et al
    Changes in emotion processing and social cognition with auditory versus visual neuroscience-informed cognitive training in individuals with schizophrenia.
    Schizophr Res. 2022;241:267-274.
    PubMed     Abstract available

  595. MCHUGO M, Rogers BP, Avery SN, Armstrong K, et al
    Increased amplitude of hippocampal low frequency fluctuations in early psychosis: A two-year follow-up study.
    Schizophr Res. 2022;241:260-266.
    PubMed     Abstract available

  596. WEBER S, Scott JG, Chatterton ML
    Healthcare costs and resource use associated with negative symptoms of schizophrenia: A systematic literature review.
    Schizophr Res. 2022;241:251-259.
    PubMed     Abstract available

  597. ZHAO Y, Guan Q, Shi J, Sun J, et al
    Impaired central set point of thyroid homeostasis during quetiapine treatment in the acute phase of schizophrenia.
    Schizophr Res. 2022;241:244-250.
    PubMed     Abstract available

  598. KESHAVAN MS, Yassin W, Stone WS
    Conceptualizing psychosis as an information processing disorder: Signal, bandwidth, noise, and bias.
    Schizophr Res. 2022 Feb 14. pii: S0920-9964(22)00027.

  599. APPAJI A, Harish V, Korann V, Devi P, et al
    Deep learning model using retinal vascular images for classifying schizophrenia.
    Schizophr Res. 2022;241:238-243.
    PubMed     Abstract available

  600. OOMEN PP, Gangadin SS, Begemann MJH, Visser E, et al
    The neurobiological characterization of distinct cognitive subtypes in early-phase schizophrenia-spectrum disorders.
    Schizophr Res. 2022;241:228-237.
    PubMed     Abstract available

  601. TANDON R, Greden JF
    Reconstructing schizophrenia: Lessons from major mood disorders.
    Schizophr Res. 2022 Feb 12. pii: S0920-9964(22)00070.

  602. ADANTY C, Qian J, Wang Y, Remington G, et al
    Childhood trauma exposure and personality traits in schizophrenia patients.
    Schizophr Res. 2022;241:221-227.
    PubMed     Abstract available

  603. MOSCARELLI M, Min JY, Kopelowicz A, Chavez O, et al
    The "PRE" scale: The assessment of the elementary passively received experiences of schizophrenia.
    Schizophr Res. 2022;241:218-220.

  604. GUREJE O, Ojagbemi A
    Applicability and future status of schizophrenia as a construct in Africa.
    Schizophr Res. 2022 Feb 9. pii: S0920-9964(22)00033.
    PubMed     Abstract available

  605. STEINER J, Dobrowolny H, Guest PC, Bernstein HG, et al
    Gender-specific elevation of plasma anthranilic acid in schizophrenia: Protection against glutamatergic hypofunction?
    Schizophr Res. 2022 Feb 9. pii: S0920-9964(22)00058.

  606. KOTOV R, Jonas KG, Lian W, Docherty AR, et al
    Reconceptualizing schizophrenia in the Hierarchical Taxonomy Of Psychopathology (HiTOP).
    Schizophr Res. 2022 Feb 7. pii: S0920-9964(22)00064.
    PubMed     Abstract available

  607. MAMAH D, Mutiso VN, Ndetei DM
    Longitudinal and cross-sectional validation of the WERCAP screen for assessing psychosis risk and conversion.
    Schizophr Res. 2022;241:201-209.
    PubMed     Abstract available

  608. ZHANG Y, Zhang CY, Yuan J, Zeng XZ, et al
    Epistatic interactions of NRG1 and ERBB4 on antipsychotic treatment response in first-episode schizophrenia patients.
    Schizophr Res. 2022;241:197-200.

  609. BASSETT D, Boyce P, Lyndon B, Mulder R, et al
    Guidelines for the management of psychosis in the context of mood disorders.
    Schizophr Res. 2022;241:187-196.
    PubMed     Abstract available

  610. LO KYH, Hopman HJ, Chan SC, Chau WHS, et al
    Concurrent anodal transcranial direct current stimulation (tDCS) with cognitive training to improve cognition in schizophrenia.
    Schizophr Res. 2022;241:184-186.

  611. FATHIAN F, Gjestad R, Kroken RA, Loberg EM, et al
    Association between C-reactive protein levels and antipsychotic treatment during 12 months follow-up period after acute psychosis.
    Schizophr Res. 2022;241:174-183.
    PubMed     Abstract available

    What can genetics tell us about the schizophrenia construct?
    Schizophr Res. 2022 Feb 3. pii: S0920-9964(21)00492.

  613. JAVITT DC, Kantrowitz JT
    The glutamate/N-methyl-d-aspartate receptor (NMDAR) model of schizophrenia at 35: On the path from syndrome to disease.
    Schizophr Res. 2022 Feb 3. pii: S0920-9964(22)00023.
    PubMed     Abstract available

  614. DAZZAN P
    Is our mistake trying to identify a "homogeneous" schizophrenia construct?
    Schizophr Res. 2022 Feb 3. pii: S0920-9964(22)00067.

  615. GIORDANO GM, Palumbo D, Mucci A, Ventura J, et al
    The Cognitive Assessment Interview (CAI): Association with neuropsychological scores and real-life functioning in a large sample of Italian subjects with schizophrenia.
    Schizophr Res. 2022;241:161-170.
    PubMed     Abstract available

  616. O'DONOGHUE B, Polari A, McGorry P, Nelson B, et al
    Young migrants to Australia identified as being at ultra-high risk for psychosis: Pathways to care and clinical characteristics.
    Schizophr Res. 2022;241:156-160.
    PubMed     Abstract available

  617. TAMMINGA CA, Pearlson G, Gershon E, Keedy S, et al
    Using psychosis biotypes and the Framingham model for parsing psychosis biology.
    Schizophr Res. 2022 Feb 2. pii: S0920-9964(22)00028.
    PubMed     Abstract available

  618. KAHN RS
    Retroverting schizophrenia.
    Schizophr Res. 2022 Feb 2. pii: S0920-9964(22)00050.

  619. HUMPHREY C, Berry K, Degnan A, Bucci S, et al
    Childhood interpersonal trauma and paranoia in psychosis: The role of disorganised attachment and negative schema.
    Schizophr Res. 2022;241:142-148.
    PubMed     Abstract available

  620. DIAZ E, Estric C, Schandrin A, Lopez-Castroman J, et al
    Neurocognitive functioning and impulsivity in first-episode psychosis with suicidal ideation and behavior: A systematic review.
    Schizophr Res. 2022;241:130-139.
    PubMed     Abstract available

  621. KESHAVAN MS, Ongur D, Srihari VH
    Toward an expanded and personalized approach to coordinated specialty care in early course psychoses.
    Schizophr Res. 2022;241:119-121.

  622. KUSUDO K, Ochi R, Nakajima S, Suzuki T, et al
    Decision tree classification of cognitive functions with D2 receptor occupancy and illness severity in late-life schizophrenia.
    Schizophr Res. 2022;241:113-115.

  623. CAQUEO-URIZAR A, Mena-Chamorro P, Urzua A, Peroza E, et al
    Psychotic symptomatology and medication adherence in patients with schizophrenia: The mediating effect of awareness of mental disorder.
    Schizophr Res. 2022;241:110-112.

  624. SAGUE-VILAVELLA M, Lopez-Pelayo H, Arbelo N, Camara M, et al
    Clozapine toxicity and coronavirus disease 2019: A case report.
    Schizophr Res. 2022;240:184-185.

  625. ANDRADE C, Suhas S
    Scrutinizing the increased mortality risk associated with the use of typical oral antipsychotics.
    Schizophr Res. 2022;240:204.

  626. BA MB, Curtis L, Pellizzer G
    Viewer and object mental rotation in young adults with psychotic disorders.
    Schizophr Res. 2022;240:92-102.
    PubMed     Abstract available

  627. HOWELLS FM, Hsieh JH, Temmingh HS, Baldwin DS, et al
    Capacity for cortical excitation is reduced in psychotic disorders: An investigation of the TMS-EMG cortical silent period.
    Schizophr Res. 2022;240:73-77.

    January 2022
  628. VAN DER HEIJDEN HS, Schirmbeck F, Berry L, Simons CJP, et al
    Impact of coping styles on substance use in persons with psychosis, siblings, and controls.
    Schizophr Res. 2022;241:102-109.
    PubMed     Abstract available

  629. BURKE T, Thompson A, Mifsud N, Yung AR, et al
    Proportion and characteristics of young people in a first-episode psychosis clinic who first attended an at-risk mental state service or other specialist youth mental health service.
    Schizophr Res. 2022;241:94-101.
    PubMed     Abstract available

  630. TREVISAN N, Miola A, Cattarinussi G, Kubera KM, et al
    Cortical folding complexity is distinctively altered in schizophrenia and bipolar disorder.
    Schizophr Res. 2022;241:92-93.

  631. BILGRAMI ZR, Sarac C, Srivastava A, Herrera SN, et al
    Construct validity for computational linguistic metrics in individuals at clinical risk for psychosis: Associations with clinical ratings.
    Schizophr Res. 2022 Jan 27. pii: S0920-9964(22)00029.
    PubMed     Abstract available

  632. BRIDGWATER MA, Horton LE, Haas GL
    Premorbid adjustment in childhood is associated with later emotion management in first-episode schizophrenia.
    Schizophr Res. 2022;240:233-238.
    PubMed     Abstract available

  633. RIKANDI E, Mantyla T, Lindgren M, Kieseppa T, et al
    Functional network connectivity and topology during naturalistic stimulus is altered in first-episode psychosis.
    Schizophr Res. 2022;241:83-91.
    PubMed     Abstract available

  634. YATES K, Lang U, Peters EM, Wigman JTW, et al
    Sexual assault and psychosis in two large general population samples: Is childhood and adolescence a developmental window of sensitivity?
    Schizophr Res. 2022;241:78-82.
    PubMed     Abstract available

  635. MERCHANT JT, Moran EK, Barch DM
    Negative and depressive symptoms differentially relate to real-world anticipatory and consummatory pleasure in schizophrenia.
    Schizophr Res. 2022;241:72-77.
    PubMed     Abstract available

  636. MOTOYAMA M, Yamada H, Maebayashi K, Yoshimura C, et al
    Efficacy of a gluten-restricted diet in treatment-resistant schizophrenia patients with immunological gluten sensitivity: A case report.
    Schizophr Res. 2022;241:68-69.

  637. KISHI T, Nakamura H, Matsuura A, Iwata N, et al
    Early improvement as a predictor of response to blonanserin transdermal patch in patients with schizophrenia.
    Schizophr Res. 2022;240:231-232.

  638. WALKER EF, Goldsmith DR
    Schizophrenia: A scientific graveyard or a pragmatically useful diagnostic construct?
    Schizophr Res. 2022 Jan 25. pii: S0920-9964(22)00032.

  639. RANGASWAMY T, Arunachalam P, Raghavan V, John S, et al
    Schizophrenia construct: Quandaries and conundrums in India and LAMIC.
    Schizophr Res. 2022 Jan 25. pii: S0920-9964(22)00024.
    PubMed     Abstract available

    Schizophrenia as a categorical diagnosis: A view from the neural risk architecture.
    Schizophr Res. 2022 Jan 24. pii: S0920-9964(22)00031.
    PubMed     Abstract available

  641. THIRTHALLI J, Mehta UM, Keshav Kumar JK, Tyagi V, et al
    Randomized, sham-controlled trial of transcranial magnetic stimulation augmentation of cognitive remediation in schizophrenia.
    Schizophr Res. 2022;241:63-65.

  642. COLIJN MA, Torres IJ, Menon M, Howard A, et al
    Progressive neurocognitive decline in schizophrenia: A diagnostic dilemma for clinicians.
    Schizophr Res. 2022;241:59-62.

  643. AZZALI S, Pelizza L, Scazza I, Paterlini F, et al
    Examining subjective experience of aberrant salience in young individuals at ultra-high risk (UHR) of psychosis: A 1-year longitudinal study.
    Schizophr Res. 2022;241:52-58.
    PubMed     Abstract available

  644. TSUKAHARA M, So R, Nomura N, Kitagawa K, et al
    Association between subjective distress and symptom domains in patients with treatment-resistant schizophrenia receiving clozapine.
    Schizophr Res. 2022;240:228-230.

  645. GROVER S, Rani S, Kohat K, Kathiravan S, et al
    First episode psychosis following receipt of first dose of COVID-19 vaccine: A case report.
    Schizophr Res. 2022;241:70-71.

  646. NOGOVITSYN N, Metzak PD, Casseb RF, Souza R, et al
    Cerebello-limbic functional connectivity patterns in youth at clinical high risk for psychosis.
    Schizophr Res. 2022;240:220-227.
    PubMed     Abstract available

  647. TOUFEILI A, Cohen E, Ray JG, Wilton AS, et al
    Complex chronic conditions among children born to women with schizophrenia.
    Schizophr Res. 2022;241:24-35.
    PubMed     Abstract available

  648. PIGONI A, Delvecchio G, Dusi N, Schiena G, et al
    Insula volumes in first-episode and chronic psychosis: A longitudinal MRI study.
    Schizophr Res. 2022;241:14-23.
    PubMed     Abstract available

  649. TANDON R
    Agreement on the contours of schizophrenia: The first order of business.
    Schizophr Res. 2022 Jan 20. pii: S0920-9964(22)00003.

  650. KELLY DL, Buchanan RW
    Can the current schizophrenia construct endure?
    Schizophr Res. 2022 Jan 20. pii: S0920-9964(21)00512.

  651. ZICK JL, Staglin B, Vinogradov S
    Eliminate schizophrenia.
    Schizophr Res. 2022 Jan 20. pii: S0920-9964(22)00004.
    PubMed     Abstract available

  652. SUHAS S, Sreeraj VS, Amrutha C, Desai G, et al
    Is allopurinol a marvel in the endgame of ultra-resistant schizophrenia?
    Schizophr Res. 2022;241:12-13.

  653. BROGNA P, Brogna C, Santomassimo C, Romeo D, et al
    Shades of shame: Embarrassment as a covert marker of self-stigma in a sample case study of patients with schizophrenia.
    Schizophr Res. 2022;241:10-11.

  654. SIZER H, Brown E, Geros H, Yung A, et al
    Outcomes for first-episode psychosis after entry via an at-risk mental state clinic compared to direct entry to a first episode of psychosis service: A systematic review and meta-analysis.
    Schizophr Res. 2022;240:214-219.
    PubMed     Abstract available

  655. CORRELL CU, Tocco M, Pikalov A, Hsu J, et al
    Long-term safety and effectiveness of open-label lurasidone in antipsychotic-Naive versus previously treated adolescents with Schizophrenia: A post-hoc analysis.
    Schizophr Res. 2022;240:205-213.
    PubMed     Abstract available

  656. ANTONUCCI LA, Fazio L, Pergola G, Blasi G, et al
    Joint structural-functional magnetic resonance imaging features are associated with diagnosis and real-world functioning in patients with schizophrenia.
    Schizophr Res. 2022;240:193-203.
    PubMed     Abstract available

  657. VAN GOOL KCA, Collin G, Bauer CCC, Molokotos E, et al
    Altered working memory-related brain activity in children at familial high risk for psychosis: A preliminary study.
    Schizophr Res. 2022;240:186-192.
    PubMed     Abstract available

  658. GAEBEL W, Salveridou-Hof E
    Reinventing schizophrenia: Updating the construct - Primary schizophrenia 2021 - The road ahead.
    Schizophr Res. 2022 Jan 12. pii: S0920-9964(21)00505.
    PubMed     Abstract available

  659. GUR RE
    Considering alternatives to the schizophrenia construct.
    Schizophr Res. 2022 Jan 12. pii: S0920-9964(21)00511.

  660. CHU MH, Lau B, Leung J, Chan SC, et al
    Positive psychotherapy for psychosis in Hong Kong: A randomized controlled trial.
    Schizophr Res. 2022;240:175-183.
    PubMed     Abstract available

  661. JIAO X, Hu Q, Tang Y, Qian Z, et al
    Test-retest reliability of mismatch negativity and gamma-band auditory steady-state response in patients with schizophrenia.
    Schizophr Res. 2022;240:165-174.
    PubMed     Abstract available

  662. GREEN MF, Jimenez AM
    Clinical observations and neuroscientific evidence tell a similar story: Schizophrenia is a disorder of the self-other boundary.
    Schizophr Res. 2022 Jan 10. pii: S0920-9964(21)00516.

  663. VON MALACHOWSKI A, Schlier B, Austin SF, Frost M, et al
    IMPACHS: Feasibility and acceptability of an m-health solution integrated into routine clinical treatment for psychosis.
    Schizophr Res. 2022;240:150-152.

  664. ZHU R, Wang D, Tian Y, Du Y, et al
    Sex difference in association between insomnia and cognitive impairment in patients with chronic schizophrenia.
    Schizophr Res. 2022;240:143-149.
    PubMed     Abstract available

  665. BARTOLOMEO LA, Raugh IM, Strauss GP
    Deconstructing emotion regulation in schizophrenia: The nature and consequences of abnormalities in monitoring dynamics.
    Schizophr Res. 2022;240:135-142.
    PubMed     Abstract available

  666. CHOI S, Kim M, Park H, Kim T, et al
    Volume deficits in hippocampal subfields in unaffected relatives of schizophrenia patients with high genetic loading but without any psychiatric symptoms.
    Schizophr Res. 2022;240:125-131.
    PubMed     Abstract available

  667. MCCUTCHEON RA, McGuire P
    Reinventing schizophrenia: The rules of the game.
    Schizophr Res. 2022 Jan 5. pii: S0920-9964(21)00493.

  668. PARK S, Baxter T
    Schizophrenia in the flesh: Revisiting schizophrenia as a disorder of the bodily self.
    Schizophr Res. 2022 Jan 4. pii: S0920-9964(21)00515.

  669. RUDOLPH A, Liepelt R, Kaffes M, Hofmann-Shen C, et al
    Motor cognition in schizophrenia: Control of automatic imitation and mapping of action context are reduced.
    Schizophr Res. 2022;240:116-124.
    PubMed     Abstract available

  670. VAN OS J, Guloksuz S
    Schizophrenia as a symptom of psychiatry's reluctance to enter the moral era of medicine.
    Schizophr Res. 2022 Jan 3. pii: S0920-9964(21)00501.
    PubMed     Abstract available

  671. SAWA A, Yang K, Cascella NG
    Paradigm shift on the concept of schizophrenia that matches with both academic and clinical needs.
    Schizophr Res. 2022 Jan 3. pii: S0920-9964(21)00506.

  672. REICHENBERG A, Akbarian S
    Towards DSM 10: A bio-classification of developmental schizophrenia?
    Schizophr Res. 2022 Jan 3. pii: S0920-9964(21)00490.

  673. JIMENEZ-LOPEZ E, Villanueva-Romero CM, Sanchez-Morla EM, Martinez-Vizcaino V, et al
    Neurocognition, functional outcome, and quality of life in remitted and non-remitted schizophrenia: A comparison with euthymic bipolar I disorder and a control group.
    Schizophr Res. 2022;240:81-91.
    PubMed     Abstract available

  674. SCHANDRIN A, Picot MC, Marin G, Andre M, et al
    Video self-confrontation as a therapeutic tool in schizophrenia: A randomized parallel-arm single-blind trial.
    Schizophr Res. 2022;240:103-112.
    PubMed     Abstract available

  675. DE WINTER L, Couwenbergh C, van Weeghel J, Hasson-Ohayon I, et al
    Changes in social functioning over the course of psychotic disorders-A meta-analysis.
    Schizophr Res. 2022;239:55-82.
    PubMed     Abstract available

  676. FOTIA F, Van Dam L, Sykes JJ, Ambrosini E, et al
    Body structural representation in schizotypy.
    Schizophr Res. 2022;239:1-10.
    PubMed     Abstract available

    December 2021
  677. KEANE BP, Erlikhman G, Serody M, Silverstein SM, et al
    A brief psychometric test reveals robust shape completion deficits in schizophrenia that are less severe in bipolar disorder.
    Schizophr Res. 2021;240:78-80.

    Schizophrenia: A view of immediate future.
    Schizophr Res. 2021 Dec 27. pii: S0920-9964(21)00488.

  679. MARTINEZ-ALES G, Susser ES
    A useful construct to improve the lives of people with schizophrenia.
    Schizophr Res. 2021 Dec 27. pii: S0920-9964(21)00494.

  680. GUO C, Li J, Guo M, Bai R, et al
    Aberrant expressions of MIAT and PVT1 in serum exosomes of schizophrenia patients.
    Schizophr Res. 2021;240:71-72.

  681. FRANGOU S
    Schizophrenia: More data, less debate.
    Schizophr Res. 2021 Dec 22. pii: S0920-9964(21)00498.

  682. MURRAY RM, Quattrone D
    The Kraepelian concept of schizophrenia: Dying but not yet dead.
    Schizophr Res. 2021 Dec 21. pii: S0920-9964(21)00489.

  683. RAHMAN T, Purves-Tyson T, Geddes AE, Huang XF, et al
    N-Methyl-d-Aspartate receptor and inflammation in dorsolateral prefrontal cortex in schizophrenia.
    Schizophr Res. 2021;240:61-70.
    PubMed     Abstract available

  684. HERNIMAN SE, Wood SJ, Cotton SM, Allott KA, et al
    The specific phenotype of depression in recent onset schizophrenia spectrum disorders: A symptom profile and network comparison to recent onset major depressive disorder without psychotic features.
    Schizophr Res. 2021;240:52-60.
    PubMed     Abstract available

  685. GALDERISI S, Giordano GM
    We are not ready to abandon the current schizophrenia construct, but should be prepared to do so.
    Schizophr Res. 2021 Dec 16. pii: S0920-9964(21)00491.
    PubMed     Abstract available

  686. RAKHSHAN ROUHAKHTAR P, Roemer C, Reeves G, Schiffman J, et al
    The associations between attenuated psychosis symptoms and functioning in Black and White youth at clinical high-risk for psychosis.
    Schizophr Res. 2021 Dec 15. pii: S0920-9964(21)00453.
    PubMed     Abstract available

  687. CANNON TD
    Psychosis, schizophrenia, and states vs. traits.
    Schizophr Res. 2021 Dec 14. pii: S0920-9964(21)00485.
    PubMed     Abstract available

  688. PORTER L, Jones C, Fox A
    Reliability of the Calgary depression scale for schizophrenia: A meta-analysis.
    Schizophr Res. 2021;240:32-45.
    PubMed     Abstract available

  689. ZHOU D, Xie C, Li X, Song N, et al
    Rare presence of autoantibodies targeting to NMDA and GABAA receptors in schizophrenia patients.
    Schizophr Res. 2021 Dec 13. pii: S0920-9964(21)00486.
    PubMed     Abstract available

    The term "psychosis" is archaic.
    Schizophr Res. 2021;240:31.

  691. XENAKI LA, Stefanatou P, Ralli E, Hatzimanolis A, et al
    The relationship between early symptom severity, improvement and remission in first episode psychosis with jumping to conclusions.
    Schizophr Res. 2021;240:24-30.
    PubMed     Abstract available

  692. TANDON R
    Putting the cart before the horse. Schizophrenia does need a name change, but the time is not right.
    Schizophr Res. 2021;240:22-23.

  693. PRASAD K, Rubin J, Mitra A, Lewis M, et al
    Structural covariance networks in schizophrenia: A systematic review Part I.
    Schizophr Res. 2021;240:1-21.
    PubMed     Abstract available

    Psychosis and fever revisited.
    Schizophr Res. 2021 Dec 10. pii: S0920-9964(21)00445.

  695. FRUTH S, Brieden A, Leucht S, Heres S, et al
    New insight into the CATIE study by constrained confidence partitioning. An innovative technique towards personalized antipsychotic drug therapy in schizophrenia treatment.
    Schizophr Res. 2021;239:192-199.
    PubMed     Abstract available

  696. PRASAD K, Rubin J, Mitra A, Lewis M, et al
    Structural covariance networks in schizophrenia: A systematic review Part II.
    Schizophr Res. 2021;239:176-191.
    PubMed     Abstract available

  697. YU Y, Shen M, Niu L, Liu YE, et al
    The relationship between clinical recovery and personal recovery among people living with schizophrenia: A serial mediation model and the role of disability and quality of life.
    Schizophr Res. 2021;239:168-175.
    PubMed     Abstract available

  698. RAJJI TK, Mamo DC, Holden J, Granholm E, et al
    Cognitive-Behavioral Social Skills Training for patients with late-life schizophrenia and the moderating effect of executive dysfunction.
    Schizophr Res. 2021;239:160-167.
    PubMed     Abstract available

  699. TORREGROSSA LJ, Amedy A, Roig J, Prada A, et al
    Interoceptive functioning in schizophrenia and schizotypy.
    Schizophr Res. 2021;239:151-159.
    PubMed     Abstract available

  700. BARCH DM, Karcher N, Moran E
    Reinventing schizophrenia - Embracing complexity and complication.
    Schizophr Res. 2021 Dec 7. pii: S0920-9964(21)00468.
    PubMed     Abstract available

  701. NAVALON P, Sahuquillo-Leal R, Moreno-Gimenez A, Salmeron L, et al
    Attentional engagement and inhibitory control according to positive and negative symptoms in schizophrenia: An emotional antisaccade task.
    Schizophr Res. 2021;239:142-150.
    PubMed     Abstract available

  702. BERNARDIN F, Schwitzer T, Schwan R, Angioi-Duprez K, et al
    Altered central vision and amacrine cells dysfunction as marker of hypodopaminergic activity in treated patients with schizophrenia.
    Schizophr Res. 2021;239:134-141.
    PubMed     Abstract available

  703. RUBIN LH, Han J, Coughlin JM, Hill SK, et al
    Real-time facial emotion recognition deficits across the psychosis spectrum: A B-SNIP Study.
    Schizophr Res. 2021 Dec 6. pii: S0920-9964(21)00448.
    PubMed     Abstract available

  704. KISELY S, Strathearn L, Najman JM
    A comparison of psychosis-like symptoms following self-reported and agency-notified child abuse in a population-based birth cohort at 30-year-follow-up.
    Schizophr Res. 2021;239:116-122.
    PubMed     Abstract available

  705. KONG L, Lui SSY, Wang Y, Hung KSY, et al
    Structural network alterations and their association with neurological soft signs in schizophrenia: Evidence from clinical patients and unaffected siblings.
    Schizophr Res. 2021 Dec 4. pii: S0920-9964(21)00475.
    PubMed     Abstract available

  706. GOTRA MY, Keedy SK, Hill SK
    Interactive effects of maintenance decay and interference on working memory updating in schizophrenia.
    Schizophr Res. 2021;239:103-110.
    PubMed     Abstract available

  707. DELISI LE
    Redefining schizophrenia through genetics: A commentary on 50 years searching for biological causes.
    Schizophr Res. 2021 Dec 3. pii: S0920-9964(21)00437.
    PubMed     Abstract available

  708. LUDTKE T, Moritz S, Westermann S, Pfuhl G, et al
    Aberrant salience predicts fluctuations of paranoia two weeks in advance during a 1-year experience sampling method study in people with psychosis.
    Schizophr Res. 2021 Dec 3. pii: S0920-9964(21)00430.

  709. VAN DER TUIN S, Balafas SE, Oldehinkel AJ, Wit EC, et al
    Dynamic symptom networks across different at-risk stages for psychosis: An individual and transdiagnostic perspective.
    Schizophr Res. 2021;239:95-102.
    PubMed     Abstract available

  710. KENDLER KS, Heckers S
    The schizophrenia concept (for schizophrenia research special issue).
    Schizophr Res. 2021 Dec 2. pii: S0920-9964(21)00454.

  711. KESHAVAN MS, Davis B, Friedman-Yakoobian M, Mesholam-Gately RI, et al
    What is my diagnosis, Doc?: Discussing psychosis diagnosis with patients and families.
    Schizophr Res. 2021;239:92-94.

  712. DONALDSON KR, Larsen EM, Jonas K, Tramazzo S, et al
    Mismatch negativity amplitude in first-degree relatives of individuals with psychotic disorders: Links with cognition and schizotypy.
    Schizophr Res. 2021;238:161-169.
    PubMed     Abstract available

  713. QUIDE Y, Tonini E, Watkeys OJ, Carr VJ, et al
    Schizotypy, childhood trauma and brain morphometry.
    Schizophr Res. 2021;238:73-81.
    PubMed     Abstract available

    November 2021
  714. FILTS Y, Litman RE, Martinez J, Anta L, et al
    Long-term efficacy and safety of once-monthly Risperidone ISM(R) in the treatment of schizophrenia: Results from a 12-month open-label extension study.
    Schizophr Res. 2021;239:83-91.
    PubMed     Abstract available

  715. LEWIS DA, Dienel SJ, Chung DW
    Searching for the "final proof" of schizophrenia.
    Schizophr Res. 2021 Nov 26. pii: S0920-9964(21)00446.

  716. ZHU X, Fan H, Zou Y, Tan Y, et al
    Computerized or manual? Long term effects of cognitive remediation on schizophrenia.
    Schizophr Res. 2021;239:47-54.
    PubMed     Abstract available

  717. JOHNSON KA, Shrier LA, Eiduson R, Parsa N, et al
    Depressive symptom screening and endorsement of psychosis risk-related experiences in a diverse adolescent and young adult outpatient clinic in the US.
    Schizophr Res. 2021 Nov 25. pii: S0920-9964(21)00447.
    PubMed     Abstract available

  718. CARPINIELLO B, Pinna F, Manchia M, Tusconi M, et al
    Sustained symptomatic remission in schizophrenia: Course and predictors from a two-year prospective study.
    Schizophr Res. 2021;239:34-41.
    PubMed     Abstract available

  719. MILLER BJ, McEvoy JP, McCall WV, Harris RA, et al
    Insomnia and triglycerides in schizophrenia.
    Schizophr Res. 2021;239:42-43.

  720. SUHAS S, Rao NP
    Personal protective equipment in the emergency room and schizophrenia - Implications beyond safety.
    Schizophr Res. 2021;239:32-33.

  721. OLUWOYE O, Stokes B
    The unique pathways to coordinate specialty care for Black families navigating early psychosis: A preliminary report.
    Schizophr Res. 2021 Nov 22. pii: S0920-9964(21)00425.
    PubMed     Abstract available

  722. LI Z, Zhang T, Xu L, Wei Y, et al
    Plasma metabolic alterations and potential biomarkers in individuals at clinical high risk for psychosis.
    Schizophr Res. 2021;239:19-28.
    PubMed     Abstract available

  723. CERNIS E, Molodynski A, Ehlers A, Freeman D, et al
    Dissociation in patients with non-affective psychosis: Prevalence, symptom associations, and maintenance factors.
    Schizophr Res. 2021;239:11-18.
    PubMed     Abstract available

    To change the label of schizophrenia, first revise the construct.
    Schizophr Res. 2021;238:201-202.

  725. SANDOVAL LR, Stone L, Guimond S, Lawler A, et al
    Encapsulating psychosis with a second language: A clinical case.
    Schizophr Res. 2021 Nov 17. pii: S0920-9964(21)00422.
    PubMed     Abstract available

  726. MOTA NB
    Commentary on "Investigating the diagnostic utility of speech patterns in schizophrenia and their symptom associations": The current need for the harmonization of speech elicitation protocols in basic and applied science.
    Schizophr Res. 2021;238:199-200.

    Re-inventing the schizophrenia syndrome: The elusive "theory of everything".
    Schizophr Res. 2021 Nov 16. pii: S0920-9964(21)00427.

  728. WADDINGTON JL, Nkire N, Russell V
    Schizophrenia vis-a-vis dimensional-spectrum concepts of psychotic illness: Has an answer been 'hiding in plain sight'?
    Schizophr Res. 2021 Nov 16. pii: S0920-9964(21)00433.

  729. JOHNSON MC, Baum ML, Lizano P
    Falling through the cracks: Missed opportunities for diagnosing and treating lupus in schizophrenia.
    Schizophr Res. 2021;238:185-187.

    October 2021
  730. OWEN MJ, Legge SE
    The nature of schizophrenia: As broad as it is long.
    Schizophr Res. 2021 Oct 28. pii: S0920-9964(21)00409.

  731. SEABURY RD, Bearden CE, Ventura J, Subotnik KL, et al
    Confident memory errors and disrupted reality testing in early psychosis.
    Schizophr Res. 2021;238:170-177.
    PubMed     Abstract available

  732. MESHOLAM-GATELY RI, Varca N, Spitzer C, Parrish EM, et al
    Are we ready for a name change for schizophrenia? A survey of multiple stakeholders.
    Schizophr Res. 2021;238:152-160.
    PubMed     Abstract available

  733. LEATHEM LD, Currin DL, Montoya AK, Karlsgodt KH, et al
    Socioemotional mechanisms of loneliness in subclinical psychosis.
    Schizophr Res. 2021;238:145-151.
    PubMed     Abstract available

  734. KU BS, Addington J, Bearden CE, Cadenhead KS, et al
    Association between residential instability at individual and area levels and future psychosis in adolescents at clinical high risk from the North American Prodrome Longitudinal Study (NAPLS) consortium.
    Schizophr Res. 2021;238:137-144.
    PubMed     Abstract available

  735. CATALANO LT, Wynn JK, Lee J, Green MF, et al
    A comparison of stages of attention for social and nonsocial stimuli in schizophrenia: An ERP study.
    Schizophr Res. 2021;238:128-136.
    PubMed     Abstract available

  736. VOGEL JS, Bruins J, de Jong S, Knegtering H, et al
    Satisfaction with social connectedness as a predictor for positive and negative symptoms of psychosis: A PHAMOUS study.
    Schizophr Res. 2021;238:121-127.
    PubMed     Abstract available

  737. BASAVARAJU R, Ithal D, Thanki MV, Ramalingaiah AH, et al
    Intermittent theta burst stimulation of cerebellar vermis enhances fronto-cerebellar resting state functional connectivity in schizophrenia with predominant negative symptoms: A randomized controlled trial.
    Schizophr Res. 2021;238:108-120.
    PubMed     Abstract available

  738. NARITA Z, Yang K, Kuga H, Piancharoen P, et al
    Face processing of social cognition in patients with first episode psychosis: Its deficits and association with the right subcallosal anterior cingulate cortex.
    Schizophr Res. 2021;238:99-107.
    PubMed     Abstract available

  739. TAN EJ, Meyer D, Neill E, Rossell SL, et al
    Investigating the diagnostic utility of speech patterns in schizophrenia and their symptom associations.
    Schizophr Res. 2021;238:91-98.
    PubMed     Abstract available

  740. NORRA C, Ueberberg B, Juckel G
    A new electronically based clinical pathway for schizophrenia inpatients: A longitudinal pilot study.
    Schizophr Res. 2021;238:82-90.
    PubMed     Abstract available

  741. MCGRATH JJ, Wray NR
    Seven short reflections on the notion of schizophrenia.
    Schizophr Res. 2021 Oct 8. pii: S0920-9964(21)00396.

  742. JOE P, Clemente JC, Piras E, Wallach DS, et al
    An integrative study of the microbiome gut-brain-axis and hippocampal inflammation in psychosis: Persistent effects from mode of birth.
    Schizophr Res. 2021 Oct 5. pii: S0920-9964(21)00389.
    PubMed     Abstract available

  743. PUTHOTA J, Alatorre A, Walsh S, Clemente JC, et al
    Prenatal ambient temperature and risk for schizophrenia.
    Schizophr Res. 2021 Oct 4. pii: S0920-9964(21)00390.
    PubMed     Abstract available

  744. FELDMAN J, Hamlyn A, Rice T
    Social media in screening and monitoring for early intervention in psychosis.
    Schizophr Res. 2021;238:70-72.

  745. GOLAY P, Ramain J, Jenni R, Klauser P, et al
    Six months functional response to early psychosis intervention program best predicts outcome after three years.
    Schizophr Res. 2021;238:62-69.
    PubMed     Abstract available

  746. ESKRIDGE CLM, Hochberger WC, Kaseda ET, Lencer R, et al
    Deficits in generalized cognitive ability, visual sensorimotor function, and inhibitory control represent discrete domains of neurobehavioral deficit in psychotic disorders.
    Schizophr Res. 2021;236:54-60.
    PubMed     Abstract available

  747. KALIUZHNA M, Kirschner M, Carruzzo F, Hartmann-Riemer MN, et al
    How far to go in deconstructing negative symptoms? Behavioural and neural level evidence for the amotivation domain.
    Schizophr Res. 2021;236:41-47.
    PubMed     Abstract available

    September 2021
  748. KOSUGI N, Oshiyama C, Kodama N, Niwa SI, et al
    Predictability of a favorable outcome in schizophrenia associated with positive effects of "music therapy incorporated into cognitive remediation".
    Schizophr Res. 2021;238:52-53.

  749. WOODBERRY KA, Powers KS, Bryant C, Downing D, et al
    Emotional and stigma-related experiences relative to being told one is at risk for psychosis.
    Schizophr Res. 2021;238:44-51.
    PubMed     Abstract available

  750. CHESNEY E, Robson D, Patel R, Shetty H, et al
    The impact of cigarette smoking on life expectancy in schizophrenia, schizoaffective disorder and bipolar affective disorder: An electronic case register cohort study.
    Schizophr Res. 2021;238:29-35.
    PubMed     Abstract available

  751. PAVITHRA A, Durairaj J, Raghavan V
    No association between advanced paternal age and age of onset of illness among patients with schizophrenia: A cross-sectional study from South India.
    Schizophr Res. 2021;238:27-28.

  752. HAHN S, Moritz S, Elmers J, Scheunemann J, et al
    Do you like cliff-hangers? Objective versus subjective need for closure in the schizophrenia spectrum.
    Schizophr Res. 2021;238:20-26.
    PubMed     Abstract available

  753. TAKEUCHI H, Sanches M, Borlido C, Agid O, et al
    Antipsychotic nonadherence measured by electronic adherence monitoring in stabilized chronic schizophrenia: Clinical implications.
    Schizophr Res. 2021;237:202-207.
    PubMed     Abstract available

  754. LEE YJ, Huang SY, Lin CP, Tsai SJ, et al
    Alteration of power law scaling of spontaneous brain activity in schizophrenia.
    Schizophr Res. 2021;238:10-19.
    PubMed     Abstract available

  755. ROSEN C, Harrow M, Tong L, Jobe TH, et al
    A word is worth a thousand pictures: A 20-year comparative analysis of aberrant abstraction in schizophrenia, affective psychosis, and non-psychotic depression.
    Schizophr Res. 2021;238:1-9.
    PubMed     Abstract available

  756. OSPINA LH, Beck-Felts K, Ifrah C, Shagalow S, et al
    Relationships among inflammation, social cognition, and social functioning in schizophrenia.
    Schizophr Res. 2021 Sep 22. pii: S0920-9964(21)00362.

  757. KRISTENSEN TD, Glenthoj LB, Ragahava JM, Syeda W, et al
    Changes in negative symptoms are linked to white matter changes in superior longitudinal fasciculus in individuals at ultra-high risk for psychosis.
    Schizophr Res. 2021;237:192-201.
    PubMed     Abstract available

  758. ESCOLA-GASCON A, Wright AC
    Psychotic behaviors during COVID-19: Should conspiracist ideation be included within the continuum model of psychosis?
    Schizophr Res. 2021;237:190-191.

  759. SENGUTTA M, Karow A, Gaweda L
    Anomalous self-experiences (ASE) in relation to clinical high risk for psychosis (CHRP), childhood trauma and general psychopathology among adolescent and young adult help seekers.
    Schizophr Res. 2021;237:182-189.
    PubMed     Abstract available

  760. TAKAHASHI T, Sasabayashi D, Takayanagi Y, Furuichi A, et al
    Altered Heschl's gyrus duplication pattern in first-episode schizophrenia.
    Schizophr Res. 2021;237:174-181.
    PubMed     Abstract available

  761. CHEN YM, Chen HK, Wu BJ, Chen IC, et al
    Systemic lupus erythematosus and autoimmune features in chronic hospitalized patients with schizophrenia.
    Schizophr Res. 2021;237:166-173.
    PubMed     Abstract available

  762. MEHTA UM, Ibrahim FA, Sharma MS, Venkatasubramanian G, et al
    Resting-state functional connectivity predictors of treatment response in schizophrenia - A systematic review and meta-analysis.
    Schizophr Res. 2021;237:153-165.
    PubMed     Abstract available

  763. FOX V, Sheffield JM, Woodward ND
    Attention-deficit/hyperactivity disorder in youth with psychosis spectrum symptoms.
    Schizophr Res. 2021;237:141-147.
    PubMed     Abstract available

  764. SUETANI S, Honarparvar F, Siskind D, Hindley G, et al
    Increased rates of respiratory disease in schizophrenia: A systematic review and meta-analysis including 619,214 individuals with schizophrenia and 52,159,551 controls.
    Schizophr Res. 2021;237:131-140.
    PubMed     Abstract available

  765. CUESTA MJ, Gil-Berrozpe GJ, Sanchez-Torres AM, Lorente-Omenaca R, et al
    A network analysis and empirical validation of executive deficits in patients with psychosis and their healthy siblings.
    Schizophr Res. 2021;237:122-130.
    PubMed     Abstract available

  766. ROKITA KI, Dauvermann MR, Mothersill D, Holleran L, et al
    Current psychosocial stress, childhood trauma and cognition in patients with schizophrenia and healthy participants.
    Schizophr Res. 2021;237:115-121.
    PubMed     Abstract available

  767. TAO TJ, Hui CLM, Lam BST, Ho ECN, et al
    Mindfulness meditation for Chinese patients with psychosis: A systematic review and meta-analysis.
    Schizophr Res. 2021;237:103-114.
    PubMed     Abstract available

  768. PAREDES R, Ferri F, Series P
    Influence of E/I balance and pruning in peri-personal space differences in schizophrenia: A computational approach.
    Schizophr Res. 2021 Sep 8. pii: S0920-9964(21)00238.
    PubMed     Abstract available

  769. SHIMOMURA Y, Kikuchi Y, Suzuki T, Uchida H, et al
    Antipsychotic treatment strategies for acute phase and treatment resistance in schizophrenia: A systematic review of the guidelines and algorithms.
    Schizophr Res. 2021;236:142-155.
    PubMed     Abstract available

  770. POLARI A, Street R, Conus P, Finkelstein A, et al
    Patients', carers' and clinicians' attitudes towards alternative terms to describe the at-risk for psychosis state.
    Schizophr Res. 2021;237:69-75.
    PubMed     Abstract available

  771. LURIE I, Shoval G, Hoshen M, Balicer R, et al
    The association of medical resource utilization with physical morbidity and premature mortality among patients with schizophrenia: An historical prospective population cohort study.
    Schizophr Res. 2021;237:62-68.
    PubMed     Abstract available

  772. O'DRISCOLL C, Shaikh M, Finamore C, Platt B, et al
    Profiles and trajectories of mental health service utilisation during early intervention in psychosis.
    Schizophr Res. 2021;237:47-53.
    PubMed     Abstract available

  773. MOLINA JL, Joshi YB, Nungaray JA, Thomas ML, et al
    Central auditory processing deficits in schizophrenia: Effects of auditory-based cognitive training.
    Schizophr Res. 2021;236:135-141.
    PubMed     Abstract available

  774. SEPPALA A, Pylvanainen J, Lehtiniemi H, Hirvonen N, et al
    Predictors of response to pharmacological treatments in treatment-resistant schizophrenia - A systematic review and meta-analysis.
    Schizophr Res. 2021;236:123-134.
    PubMed     Abstract available

  775. VAN DUIN D, de Winter L, Kroon H, Veling W, et al
    Effects of IPS plus cognitive remediation in early psychosis: 18-month functioning outcomes of a randomized controlled trial.
    Schizophr Res. 2021;236:115-122.
    PubMed     Abstract available

  776. GUPTA L, Hoffman KW
    Exploring the intersection of the microbiome and the developing brain: Impacts on schizophrenia risk.
    Schizophr Res. 2021 Sep 2. pii: S0920-9964(21)00325.
    PubMed     Abstract available

  777. ROSA PGP, Zugman A, Cerqueira CT, Serpa MH, et al
    Cortical surface abnormalities are different depending on the stage of schizophrenia: A cross-sectional vertexwise mega-analysis of thickness, area and gyrification.
    Schizophr Res. 2021;236:104-114.
    PubMed     Abstract available

  778. AMORETTI S, Rabelo-da-Ponte FD, Rosa AR, Mezquida G, et al
    Cognitive clusters in first-episode psychosis.
    Schizophr Res. 2021;237:31-39.
    PubMed     Abstract available

  779. PATIL AN, Kasudhan KS, Naveen M, Batra GK, et al
    Precise pharmacogenetic pharmacometabolomic (PPP) guided clozapine therapy in treatment resistant schizophrenia: Insights from one ethnicity experiment.
    Schizophr Res. 2021;237:26-28.

  780. ZHU Y, Zhang C, Siafis S, Zhuo K, et al
    Prolactin levels influenced by antipsychotic drugs in schizophrenia: A systematic review and network meta-analysis.
    Schizophr Res. 2021;237:20-25.
    PubMed     Abstract available

  781. MAGUIRE PA, Reay RE, Looi JCL
    H1N109 pandemic research in people with schizophrenia providing insights into COVID-19 clinical care.
    Schizophr Res. 2021;237:101-102.

    August 2021
  782. TANG CH, Ramcharran D, Yang CW, Chang CC, et al
    A nationwide study of the risk of all-cause, sudden death, and cardiovascular mortality among antipsychotic-treated patients with schizophrenia in Taiwan.
    Schizophr Res. 2021;237:9-19.
    PubMed     Abstract available

  783. GIN K, Stewart C, Abbott C, Banerjea P, et al
    Psychosocial predictors of distressing unusual experiences in adolescence: Testing the fit of an adult cognitive model of psychosis.
    Schizophr Res. 2021;237:1-8.
    PubMed     Abstract available

  784. GIRARD JM, Vail AK, Liebenthal E, Brown K, et al
    Computational analysis of spoken language in acute psychosis and mania.
    Schizophr Res. 2021 Aug 26. pii: S0920-9964(21)00252.
    PubMed     Abstract available

  785. DE JAGER J, Topper M, Nugter A, van Os J, et al
    The impact of childhood sexual trauma on intimacy and sexuality needs among people with non-affective psychosis.
    Schizophr Res. 2021;236:97-103.
    PubMed     Abstract available

  786. IHLER HM, Lagerberg TV, Lyngstad SH, Melle I, et al
    Exploring the relationship between recency and frequency of cannabis use and diminished expression and apathy as two dimensions of negative symptoms in first episode psychosis. A one-year follow-up study.
    Schizophr Res. 2021;236:89-96.
    PubMed     Abstract available

  787. SANTESTEBAN-ECHARRI O, Liu L, Cadenhead KS, Tsuang MT, et al
    Anxiety in youth at clinical high-risk for psychosis: A two-year follow-up.
    Schizophr Res. 2021;236:87-88.

  788. MILLER ML, Strassnig MT, Bromet E, Depp CA, et al
    Performance-based assessment of social skills in a large sample of participants with schizophrenia, bipolar disorder and healthy controls: Correlates of social competence and social appropriateness.
    Schizophr Res. 2021;236:80-86.
    PubMed     Abstract available

  789. FERRARO L, La Cascia C, La Barbera D, Sanchez-Gutierrez T, et al
    The relationship of symptom dimensions with premorbid adjustment and cognitive characteristics at first episode psychosis: Findings from the EU-GEI study.
    Schizophr Res. 2021;236:69-79.
    PubMed     Abstract available

  790. ERICKSON MA, Hahn B, Kiat JE, Alliende LM, et al
    Neural basis of the visual working memory deficit in schizophrenia: Merging evidence from fMRI and EEG.
    Schizophr Res. 2021;236:61-68.
    PubMed     Abstract available

  791. VAN DER HEIJDEN HS, Schirmbeck F, McGuire P, Valmaggia LR, et al
    Association between tobacco use and symptomatology in individuals at ultra-high risk to develop a psychosis: A longitudinal study.
    Schizophr Res. 2021;236:48-53.
    PubMed     Abstract available

  792. GROVER S, Kathiravan S, Suman A, Naskar C, et al
    Incidence and outcome of COVID-19 in patients with schizophrenia: A Study from India.
    Schizophr Res. 2021;236:38-40.

  793. WANG Y, Jiang Y, Collin G, Liu D, et al
    The effects of antipsychotics on interactions of dynamic functional connectivity in the triple-network in first episode schizophrenia.
    Schizophr Res. 2021;236:29-37.
    PubMed     Abstract available

  794. GONZALEZ-BLANCO L, Garcia-Portilla MP, Gutierrez M, Mezquida G, et al
    Impact of previous tobacco use with or without cannabis on first psychotic experiences in patients with first-episode psychosis.
    Schizophr Res. 2021;236:19-28.
    PubMed     Abstract available

  795. LUNSFORD-AVERY JR, Pelletier-Baldelli A, Korenic SA, Schiffman J, et al
    Eveningness chronotype preference among individuals at clinical high risk for psychosis.
    Schizophr Res. 2021;236:3-8.
    PubMed     Abstract available

  796. DESTE G, Vita A, Nibbio G, Barlati S, et al
    Autistic symptoms in people with schizophrenia: Neurocognitive, socio-cognitive, clinical and real-world functional characteristics of individuals without autistic features.
    Schizophr Res. 2021;236:12-18.
    PubMed     Abstract available

  797. KLEIN-PETERSEN AW, Kohler-Forsberg O, Benros ME
    Infections, antibiotic treatment and the Microbiome in relation to schizophrenia.
    Schizophr Res. 2021;234:71-77.
    PubMed     Abstract available

  798. NGUYEN TT, Hathaway H, Kosciolek T, Knight R, et al
    Gut microbiome in serious mental illnesses: A systematic review and critical evaluation.
    Schizophr Res. 2021;234:24-40.
    PubMed     Abstract available

    July 2021
  799. DEL RE EC, Tan EJ
    Let's talk about researchers: A SIRS roundtable on mental health among schizophrenia researchers.
    Schizophr Res. 2021;235:63-64.

  800. IRURETAGOYENA B, Castaneda CP, Mena C, Diaz C, et al
    Predictors of clozapine discontinuation at 2years in treatment-resistant schizophrenia.
    Schizophr Res. 2021;235:102-108.
    PubMed     Abstract available

  801. MACDONALD KI, Spilka MJ, Bartolomeo LA, Raugh IM, et al
    Adherence to recommended health and social distancing precautions during the COVID-19 pandemic in individuals with schizophrenia and youth at clinical high-risk for psychosis.
    Schizophr Res. 2021 Jul 29. pii: S0920-9964(21)00283.

  802. HALVERSON TF, Meyer-Kalos PS, Perkins DO, Gaylord SA, et al
    Enhancing stress reactivity and wellbeing in early schizophrenia: A randomized controlled trial of Integrated Coping Awareness Therapy (I-CAT).
    Schizophr Res. 2021;235:91-101.
    PubMed     Abstract available

  803. LINKE M, Jankowski KS
    Chronotype in individuals with schizophrenia: A meta-analysis.
    Schizophr Res. 2021;235:74-79.
    PubMed     Abstract available

  804. SANTO-ANGLES A, Salvador R, Gomar JJ, Guerrero-Pedraza A, et al
    Interindividual variability of functional connectome in schizophrenia.
    Schizophr Res. 2021;235:65-73.
    PubMed     Abstract available

  805. GROVER S, Keshavan MS, Lizano PL, Reinhart RMG, et al
    Proximate markers of cognitive dysfunction in schizophrenia.
    Schizophr Res. 2021 Jul 26. pii: S0920-9964(21)00272.

  806. HANSEN MC, Lynch DA, Stefancic A, Medalia A, et al
    Metamotivation in people diagnosed with schizophrenia: A conceptual introduction and qualitative study.
    Schizophr Res. 2021 Jul 26. pii: S0920-9964(21)00215.
    PubMed     Abstract available

  807. PRASAD KM
    Infectious agents as risk factors for psychosis - A time to reconsider and reinvigorate investigations.
    Schizophr Res. 2021 Jul 26. pii: S0920-9964(21)00259.

  808. WANG YC, Chen CH, Chen SJ, Cheng FY, et al
    Identification of ultra-rare missense mutations associated with familial schizophrenia by whole-exome sequencing.
    Schizophr Res. 2021;235:60-62.

  809. HIGUCHI CH, Cogo-Moreira H, Fonseca L, Ortiz BB, et al
    Identifying strategies to improve PANSS based dimensional models in schizophrenia: Accounting for multilevel structure, Bayesian model and clinical staging.
    Schizophr Res. 2021 Jul 22. pii: S0920-9964(21)00249.
    PubMed     Abstract available

  810. BULUBAS L, Goerigk S, Gomes JS, Brem AK, et al
    Cognitive outcomes after tDCS in schizophrenia patients with prominent negative symptoms: Results from the placebo-controlled STARTS trial.
    Schizophr Res. 2021;235:44-51.
    PubMed     Abstract available

  811. DLAGNEKOVA A, van Staden W, Masenge A
    Validity and reliability of the Vigour Assessment Scale in avolitional schizophrenia outpatients.
    Schizophr Res. 2021;235:36-43.
    PubMed     Abstract available

  812. GROVER S, Naskar C, Sahoo S, Mehra A, et al
    Starting clozapine in patients with schizophrenia during the ongoing pandemic.
    Schizophr Res. 2021 Jul 21. pii: S0920-9964(21)00257.

  813. STROMME MF, Mellesdal LS, Bartz-Johannesen C, Kroken RA, et al
    Mortality and non-use of antipsychotic drugs after acute admission in schizophrenia: A prospective total-cohort study.
    Schizophr Res. 2021;235:29-35.
    PubMed     Abstract available

  814. SHIMADA T, Ito S, Makabe A, Yamanushi A, et al
    Aerobic exercise and cognitive functioning in schizophrenia: Findings of dose-response analysis from a pilot randomized controlled trial.
    Schizophr Res. 2021 Jul 20. pii: S0920-9964(21)00268.

  815. TENDILLA-BELTRAN H, Coatl-Cuaya H, Meneses-Prado S, Vazquez-Roque RA, et al
    Neuroplasticity and inflammatory alterations in the nucleus accumbens are corrected after risperidone treatment in a schizophrenia-related developmental model in rats.
    Schizophr Res. 2021;235:17-28.
    PubMed     Abstract available

  816. ZHAO Y, Wen SW, Qin Y, Liu Y, et al
    Association between valproate treatment for acute phase schizophrenia and risk of new onset hypothyroidism.
    Schizophr Res. 2021;235:12-16.
    PubMed     Abstract available

  817. YANG K, Hua J, Etyemez S, Paez A, et al
    Volumetric alteration of olfactory bulb and immune-related molecular changes in olfactory epithelium in first episode psychosis patients.
    Schizophr Res. 2021;235:9-11.

  818. CARRION RE, Auther AM, McLaughlin D, Cornblatt BA, et al
    The immediate impact of the COVID-19 pandemic on attenuated positive symptoms and functioning in individuals at clinical high risk for psychosis: A pilot study.
    Schizophr Res. 2021;236:9-11.

  819. KREIS I, Zhang L, Moritz S, Pfuhl G, et al
    Spared performance but increased uncertainty in schizophrenia: Evidence from a probabilistic decision-making task.
    Schizophr Res. 2021 Jul 13. pii: S0920-9964(21)00246.
    PubMed     Abstract available

  820. KOHLER-FORSBERG O, Madsen T, Behrendt-Moller I, Nordentoft M, et al
    The 10-year trajectories of auditory hallucinations among 496 patients with a first schizophrenia-spectrum disorder: Findings from the OPUS cohort.
    Schizophr Res. 2021 Jul 13. pii: S0920-9964(21)00245.
    PubMed     Abstract available

  821. YOON JH, Maddock RJ, Laufer J, Minzenberg MJ, et al
    Absence of altered in vivo concentration of dorsolateral prefrontal cortex GABA in recent onset schizophrenia.
    Schizophr Res. 2021 Jul 9. pii: S0920-9964(21)00230.

  822. BROWNE J, Mohamed S
    Evaluation of disparities in impact of mental health intensive case management on 6-month symptoms, functioning, and quality of life between black and white veterans diagnosed with schizophrenia.
    Schizophr Res. 2021 Jul 8. pii: S0920-9964(21)00255.
    PubMed     Abstract available

  823. ALBINANA C, Boelt SG, Cohen AS, Zhu Z, et al
    Developmental exposure to vitamin D deficiency and subsequent risk of schizophrenia.
    Schizophr Res. 2021 Jul 8. pii: S0920-9964(21)00216.
    PubMed     Abstract available

  824. XI YB, Guo F, Liu WM, Fu YF, et al
    Triple network hypothesis-related disrupted connections in schizophrenia: A spectral dynamic causal modeling analysis with functional magnetic resonance imaging.
    Schizophr Res. 2021;233:89-96.
    PubMed     Abstract available

  825. DE CATES AN, Catone G, Marwaha S, Bebbington P, et al
    Self-harm, suicidal ideation, and the positive symptoms of psychosis: Cross-sectional and prospective data from a national household survey.
    Schizophr Res. 2021;233:80-88.
    PubMed     Abstract available

  826. KHACHADOURIAN V, Zaks N, Lin E, Reichenberg A, et al
    Advanced paternal age and risk of schizophrenia in offspring - Review of epidemiological findings and potential mechanisms.
    Schizophr Res. 2021;233:72-79.
    PubMed     Abstract available

  827. POOLE-WRIGHT K, Gaughran F, Murray R, Chalder T, et al
    Fatigue in psychosis.
    Schizophr Res. 2021 Jul 6. pii: S0920-9964(21)00244.

  828. GROSSMAN MJ, Bowie CR
    Money talks: The influence of extrinsic motivators on social cognition in early episode psychosis.
    Schizophr Res. 2021;233:52-59.
    PubMed     Abstract available

  829. HOY KE, Coyle H, Gainsford K, Hill AT, et al
    Investigating neurophysiological markers of impaired cognition in schizophrenia.
    Schizophr Res. 2021;233:34-43.
    PubMed     Abstract available

  830. O'DONOGHUE B, Castagnini E, Langstone A, Mifsud N, et al
    Sedentary behaviour in young people presenting with a first episode of psychosis before and during the covid-19 pandemic restrictions.
    Schizophr Res. 2021;233:31-33.

  831. BURKHARDT E, Berger M, Yolken RH, Lin A, et al
    Toxoplasma gondii, Herpesviridae and long-term risk of transition to first-episode psychosis in an ultra high-risk sample.
    Schizophr Res. 2021;233:24-30.
    PubMed     Abstract available

  832. SALGADO-PINEDA P, Fuentes-Claramonte P, Spanlang B, Pomes A, et al
    Neural correlates of disturbance in the sense of agency in schizophrenia: An fMRI study using the 'enfacement' paradigm.
    Schizophr Res. 2021 Jul 1. pii: S0920-9964(21)00243.
    PubMed     Abstract available

  833. IGATA R, Tesen H, Konishi Y, Ikenouchi A, et al
    Prisoner's dilemma game in recovered schizophrenia patients, compared with healthy controls: Preliminary findings.
    Schizophr Res. 2021 Jul 1. pii: S0920-9964(21)00253.

  834. BRAR PS, Sass L, Kalarchian MA
    Advancing research on delusions: Fostering dialogue between cognitive and phenomenological researchers.
    Schizophr Res. 2021;233:62-63.

    June 2021
  835. XIE Y, Xi Y, Cui LB, Li C, et al
    Altered functional connectivity of the dentate nuclei in patients with schizophrenia.
    Schizophr Res. 2021;233:16-23.
    PubMed     Abstract available

  836. BONFILS KA, Luther L, Lysaker PH
    Metacognition & social cognition differentially influence experiential & expressive negative symptoms in schizophrenia.
    Schizophr Res. 2021;233:13-15.

  837. FUSAR-POLI P, Salazar de Pablo G
    Antipsychotics and Attenuated Psychosis Syndrome: Transdiagnostic assessment and discontinuation strategies.
    Schizophr Res. 2021 Jun 30. pii: S0920-9964(21)00242.

  838. BANEA OC, Bandeira Dos Santos LG, Marcu S, Stefannson SB, et al
    Network signatures of rTMS treatment in patients with schizophrenia and auditory verbal hallucination during an auditory-motor task using HD-EEG.
    Schizophr Res. 2021 Jun 30. pii: S0920-9964(21)00214.

  839. GAO Y, Li M, Huang AS, Anderson AW, et al
    Lower functional connectivity of white matter during rest and working memory tasks is associated with cognitive impairments in schizophrenia.
    Schizophr Res. 2021 Jun 29. pii: S0920-9964(21)00225.
    PubMed     Abstract available

  840. HU M, Qian X, Liu S, Koh AJ, et al
    Structural and diffusion MRI based schizophrenia classification using 2D pretrained and 3D naive Convolutional Neural Networks.
    Schizophr Res. 2021 Jun 28. pii: S0920-9964(21)00223.
    PubMed     Abstract available

  841. BHATTACHARYYA U, Bhatia T, Deshpande SN, Thelma BK, et al
    Association of g-quadruplex variants with schizophrenia symptoms.
    Schizophr Res. 2021 Jun 26. pii: S0920-9964(21)00220.

  842. HU Y, Xu L, Gan R, Wu G, et al
    A potential objective marker in first-episode schizophrenia based on abnormal niacin response.
    Schizophr Res. 2021 Jun 26. pii: S0920-9964(21)00240.
    PubMed     Abstract available

  843. CLAYSON PE, Joshi YB, Thomas ML, Tarasenko M, et al
    The viability of the frequency following response characteristics for use as biomarkers of cognitive therapeutics in schizophrenia.
    Schizophr Res. 2021 Jun 26. pii: S0920-9964(21)00234.
    PubMed     Abstract available

  844. RUBIO JM, Lencz T, Barber A, Moyett A, et al
    Striatal functional connectivity in psychosis relapse: A hypothesis generating study.
    Schizophr Res. 2021 Jun 25. pii: S0920-9964(21)00222.
    PubMed     Abstract available

  845. BARLATI S, Morena D, Nibbio G, Cacciani P, et al
    Internalized stigma among people with schizophrenia: Relationship with socio-demographic, clinical and medication-related features.
    Schizophr Res. 2021 Jun 25. pii: S0920-9964(21)00219.
    PubMed     Abstract available

  846. KRONICK J, Sabesan P, Burhan AM, Palaniyappan L, et al
    Assessment of treatment resistance criteria in non-invasive brain stimulation studies of schizophrenia.
    Schizophr Res. 2021 Jun 25. pii: S0920-9964(21)00221.
    PubMed     Abstract available

  847. YESILKAYA UH, Sen M, Karamustafalioglu N
    New variants and new symptoms in COVID-19: First episode psychosis and Cotard's Syndrome two months after infection with the B.1.1.7 variant of coronavirus.
    Schizophr Res. 2021 Jun 16. pii: S0920-9964(21)00213.

  848. METZAK PD, Farris MS, Placsko T, Braun A, et al
    Social functioning and brain imaging in individuals at clinical high-risk for psychosis: A systematic review.
    Schizophr Res. 2021;233:3-12.
    PubMed     Abstract available

  849. CORTES-BRIONES JA, Tapia-Rivas NI, D'Souza DC, Estevez PA, et al
    Going deep into schizophrenia with artificial intelligence.
    Schizophr Res. 2021 Jun 5. pii: S0920-9964(21)00179.
    PubMed     Abstract available

  850. BOMMERSBACH TJ, Rhee TG, Stefanovics EA, Rosenheck RA, et al
    Comparison of Black and white individuals who report diagnoses of schizophrenia in a national sample of US adults: Discrimination and service use.
    Schizophr Res. 2021 Jun 1. pii: S0920-9964(21)00178.
    PubMed     Abstract available

    May 2021
  851. LISOWAY AJ, Chen CC, Zai CC, Tiwari AK, et al
    Toward personalized medicine in schizophrenia: Genetics and epigenetics of antipsychotic treatment.
    Schizophr Res. 2021;232:112-124.
    PubMed     Abstract available

  852. ZHANG YJ, Pu CC, Wang YM, Zhang RT, et al
    Social brain network correlates with real-life social network in individuals with schizophrenia and social anhedonia.
    Schizophr Res. 2021;232:77-84.
    PubMed     Abstract available

  853. SENGUTTA M, Karow A, Moritz S
    Deconstruction of a screening questionnaire for prodromal psychosis to reduce false positive responses.
    Schizophr Res. 2021;232:107-108.

  854. FORTEA A, Batalla A, Radua J, van Eijndhoven P, et al
    Cortical gray matter reduction precedes transition to psychosis in individuals at clinical high-risk for psychosis: A voxel-based meta-analysis.
    Schizophr Res. 2021;232:98-106.
    PubMed     Abstract available

  855. WANG D, Zhuo K, Sun Y, Xiang Q, et al
    Middle temporal corpus callosum impairment as a predictor of eight-week treatment outcome of drug-naive first-episode psychosis patients: A pilot longitudinal study.
    Schizophr Res. 2021;232:95-97.

  856. HEGELSTAD WTV, Berg AO, Bjornestad J, Gismervik K, et al
    Childhood interpersonal trauma and premorbid social adjustment as predictors of symptom remission in first episode psychosis.
    Schizophr Res. 2021;232:87-94.
    PubMed     Abstract available

  857. WELLESLEY WESLEY E, Patel I, Kadra-Scalzo G, Pritchard M, et al
    Gender disparities in clozapine prescription in a cohort of treatment-resistant schizophrenia in the South London and Maudsley case register.
    Schizophr Res. 2021;232:68-76.
    PubMed     Abstract available

  858. MOXAM AB, McClellan EJ, Cagande C, Calkins ME, et al
    Few primary care pediatricians screen for psychosis but many are willing.
    Schizophr Res. 2021;232:65-67.

    Prenatal infection and schizophrenia: A decade of further progress.
    Schizophr Res. 2021 May 17. pii: S0920-9964(21)00174.
    PubMed     Abstract available

  860. DEL RE EC
    The 2020 World Congress of Psychiatric Genetics: Schizophrenia highlights with an eye on sex differences.
    Schizophr Res. 2021;232:63-64.

  861. BARTOLI F, Cioni RM, Callovini T, Cavaleri D, et al
    The kynurenine pathway in schizophrenia and other mental disorders: Insight from meta-analyses on the peripheral blood levels of tryptophan and related metabolites.
    Schizophr Res. 2021;232:61-62.

  862. TARGUM SD, Pendergrass JC, Murphy C
    Audio-digital recordings to assess ratings reliability in clinical trials of schizophrenia.
    Schizophr Res. 2021;232:54-60.
    PubMed     Abstract available

  863. KAHN RS, Silverman BL, DiPetrillo L, Graham C, et al
    A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension.
    Schizophr Res. 2021;232:45-53.
    PubMed     Abstract available

  864. TIIHONEN J, Koskuvi M, Lahteenvuo M, Trontti K, et al
    Molecular signaling pathways underlying schizophrenia.
    Schizophr Res. 2021;232:33-41.
    PubMed     Abstract available

  865. SEVERANCE EG, Yolken RH
    Binning bugs and beyond: The state of the schizophrenia microbiome.
    Schizophr Res. 2021 May 15. pii: S0920-9964(21)00162.

  866. VANES LD, Murray RM, Nosarti C
    Adult outcome of preterm birth: Implications for neurodevelopmental theories of psychosis.
    Schizophr Res. 2021 May 15. pii: S0920-9964(21)00152.
    PubMed     Abstract available

  867. SARRE A, Abdel-Ahad P, Meilland A, Renard U, et al
    Verbal hallucinations in deaf schizophrenia patients.
    Schizophr Res. 2021;232:31-32.

  868. MAYORAL-VAN SON J, Juncal-Ruiz M, Ortiz-Garcia de la Foz V, Vazquez-Bourgon J, et al
    Long-term clinical and functional outcome after antipsychotic discontinuation in early phases of non-affective psychosis: Results from the PAFIP-10 cohort.
    Schizophr Res. 2021;232:28-30.

  869. WRIGHT AC, Browne J, Skiest H, Bhiku K, et al
    The relationship between conventional clinical assessments and momentary assessments of symptoms and functioning in schizophrenia spectrum disorders: A systematic review.
    Schizophr Res. 2021;232:11-27.
    PubMed     Abstract available

  870. GEBICKE-HAERTER PJ, Leonardi-Essmann F, Haerter JO, Rossner MJ, et al
    Differential gene regulation in the anterior cingulate cortex and superior temporal cortex in schizophrenia: A molecular network approach.
    Schizophr Res. 2021;232:1-10.
    PubMed     Abstract available

  871. NASKAR C
    Understanding the effect of various factors on clozapine serum levels in Indian population.
    Schizophr Res. 2021;231:178.

  872. OREPIC P, Rognini G, Kannape OA, Faivre N, et al
    Sensorimotor conflicts induce somatic passivity and louden quiet voices in healthy listeners.
    Schizophr Res. 2021;231:170-177.
    PubMed     Abstract available

  873. MISAWA F, Okumura Y, Takeuchi Y, Fujii Y, et al
    Neuroleptic malignant syndrome associated with long-acting injectable versus oral second-generation antipsychotics: Analyses based on a spontaneous reporting system database in Japan.
    Schizophr Res. 2021;231:42-46.
    PubMed     Abstract available

    April 2021
  874. KIDD SA, Mutschler C, Lichtenstein S, Yan S, et al
    Randomized trial of a brief peer support intervention for individuals with schizophrenia transitioning from hospital to community.
    Schizophr Res. 2021;231:214-220.
    PubMed     Abstract available

  875. RUNGE K, Fiebich BL, Kuzior H, Saliba SW, et al
    An observational study investigating cytokine levels in the cerebrospinal fluid of patients with schizophrenia spectrum disorders.
    Schizophr Res. 2021;231:205-213.
    PubMed     Abstract available

  876. TEEUW J, Ori APS, Brouwer RM, de Zwarte SMC, et al
    Accelerated aging in the brain, epigenetic aging in blood, and polygenic risk for schizophrenia.
    Schizophr Res. 2021;231:189-197.
    PubMed     Abstract available

  877. WANG C, Oughourlian T, Tishler TA, Anwar F, et al
    Cortical morphometric correlational networks associated with cognitive deficits in first episode schizophrenia.
    Schizophr Res. 2021;231:179-188.
    PubMed     Abstract available

  878. BROWNE J, Wright AC, Berry K, Mueser KT, et al
    The alliance-outcome relationship in individual psychosocial treatment for schizophrenia and early psychosis: A meta-analysis.
    Schizophr Res. 2021;231:154-163.
    PubMed     Abstract available

  879. MEKORI-DOMACHEVSKY E, Taler M, Weinberger R, Guri Y, et al
    Neutrophils to lymphocytes ratio and psychosis in 22q11.2 deletion syndrome - Clinical and scientific implications.
    Schizophr Res. 2021;231:164-169.
    PubMed     Abstract available

  880. PINHO S, Rocha V, Vieira-Coelho MA
    Effectiveness of multimodal interventions focused on smoking cessation in patients with schizophrenia: A systematic review.
    Schizophr Res. 2021;231:145-153.
    PubMed     Abstract available

  881. DICKERSON F, Origoni A, Katsafanas E, Squire A, et al
    Randomized controlled trial of an adjunctive sulforaphane nutraceutical in schizophrenia.
    Schizophr Res. 2021;231:142-144.

  882. HOGERZEIL SJ, Hoek HW, van Hemert AM
    The impact of study design on schizophrenia incidence estimates: A systematic review of Northern European studies 2008-2019.
    Schizophr Res. 2021;231:134-141.
    PubMed     Abstract available

  883. AJNAKINA O, Stubbs B, Francis E, Gaughran F, et al
    Employment and relationship outcomes in first-episode psychosis: A systematic review and meta-analysis of longitudinal studies.
    Schizophr Res. 2021;231:122-133.
    PubMed     Abstract available

  884. FRAGUAS D, Diaz-Caneja CM, Pina-Camacho L, Winter van Rossum I, et al
    The role of depression in the prediction of a "late" remission in first-episode psychosis: An analysis of the OPTiMiSE study.
    Schizophr Res. 2021;231:100-107.
    PubMed     Abstract available

  885. TAO B, Xiao Y, Yang B, Zeng J, et al
    Morphological alterations of the corpus callosum in antipsychotic-naive first-episode schizophrenia before and 1-year after treatment.
    Schizophr Res. 2021;231:115-121.
    PubMed     Abstract available

  886. FREEDMAN R, Hunter SK, Law AJ, Clark AM, et al
    Choline, folic acid, Vitamin D, and fetal brain development in the psychosis spectrum.
    Schizophr Res. 2021 Apr 7. pii: S0920-9964(21)00128.
    PubMed     Abstract available

  887. GIBBONS RD, Chattopadhyay I, Meltzer H, Kane JM, et al
    Development of a computerized adaptive diagnostic screening tool for psychosis.
    Schizophr Res. 2021 Apr 6. pii: S0920-9964(21)00140.
    PubMed     Abstract available

  888. SOUSA AE, Ryan JD, Lepage M
    A feasibility pilot study on using unitization to circumvent relational memory impairments in schizophrenia.
    Schizophr Res. 2021;231:98-99.

  889. RAO NP, Ramachandran P, Jacob A, Joseph A, et al
    Add on yoga treatment for negative symptoms of schizophrenia: A multi-centric, randomized controlled trial.
    Schizophr Res. 2021;231:90-97.
    PubMed     Abstract available

  890. MAITRA R, Pollak TA, Pritchard M, Shergill S, et al
    Stem cell transplant in psychotic disorders: Immunological cause or cure?
    Schizophr Res. 2021;230:50-52.

    The only difference between a jail and a psychiatric hospital is a pillow.
    Schizophr Res. 2021;230:100.
    PubMed     Abstract available

    March 2021
  892. PRUESSNER M, King S, Veru F, Schalinski I, et al
    Impact of childhood trauma on positive and negative symptom remission in first episode psychosis.
    Schizophr Res. 2021;231:82-89.
    PubMed     Abstract available

  893. YAEGASHI H, Misawa F, Noda H, Fujii Y, et al
    Risk of withdrawal of consent for treatment with long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled trials.
    Schizophr Res. 2021;229:94-101.
    PubMed     Abstract available

    February 2021
  894. KEEFE RSE
    Where do we cut the bell-shaped curve of CIAS?
    Schizophr Res. 2021;228:633-634.

  895. KOLBAEK P, Dines D, Hansen J, Opler M, et al
    Standardized training in the rating of the six-item Positive And Negative Syndrome Scale (PANSS-6).
    Schizophr Res. 2021;228:438-446.
    PubMed     Abstract available

  896. LAHTEENVUO M, Taipale H, Tanskanen A, Mittendorfer-Rutz E, et al
    Effectiveness of pharmacotherapies for delusional disorder in a Swedish national cohort of 9076 patients.
    Schizophr Res. 2021;228:367-372.
    PubMed     Abstract available

  897. DAS D, Peng X, Lam AN, Bader JS, et al
    Transcriptome analysis of human induced excitatory neurons supports a strong effect of clozapine on cholesterol biosynthesis.
    Schizophr Res. 2021;228:324-326.
    PubMed     Abstract available

  898. SUMNER PJ, Rossell SL, Tan EJ
    On the assessment of subjective formal thought disorder.
    Schizophr Res. 2021;228:58-59.

  899. SUHAS S, Nagpal M, Rao NP, Kumar V, et al
    Echo of reading - The forgotten psychopathology: A case report.
    Schizophr Res. 2021;228:602-603.

  900. RABINOWITZ J, Opler M, Rabinowitz AA, Negash S, et al
    Consistency checks to improve measurement with the Personal and Social Performance Scale (PSP).
    Schizophr Res. 2021;228:529-533.
    PubMed     Abstract available

    January 2021
  901. MALHI GS, Bell E, Hamilton A, Morris G, et al
    Early intervention for risk syndromes: What are the real risks?
    Schizophr Res. 2021;227:4-9.

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge.